Prepared and filed by St Ives Burrups

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, I32Gm/7IbSE6rX+1s9wRLqtcqXUSkbtoAj5Lx0lTuoJQKx2mTYB12h7y6wIjBYG5 +xzSlylmk+/Xul2TFPgfZw== 0001125282-06-004975.txt : 20060814 0001125282-06-004975.hdr.sgml : 20060814 20060814131030 ACCESSION NUMBER: 0001125282-06-004975 CONFORMED SUBMISSION TYPE: SC TO-I PUBLIC DOCUMENT COUNT: 13 FILED AS OF DATE: 20060814 DATE AS OF CHANGE: 20060814 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SAVIENT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000722104 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133033811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-I SEC ACT: 1934 Act SEC FILE NUMBER: 005-34455 FILM NUMBER: 061028490 BUSINESS ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 BUSINESS PHONE: 7324189300 MAIL ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 FORMER COMPANY: FORMER CONFORMED NAME: BIO TECHNOLOGY GENERAL CORP DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: SAVIENT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000722104 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133033811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-I BUSINESS ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 BUSINESS PHONE: 7324189300 MAIL ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 FORMER COMPANY: FORMER CONFORMED NAME: BIO TECHNOLOGY GENERAL CORP DATE OF NAME CHANGE: 19920703 SC TO-I 1 b414446_sctoi.htm SC TO-I Prepared and filed by St Ives Burrups

Back to Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE TO
Tender Offer Statement Under Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934

SAVIENT PHARMACEUTICALS, INC.
(Name of Subject Company (Issuer))

SAVIENT PHARMACEUTICALS, INC.
(Name of Filing Person (Issuer))

Common Stock, Par Value $0.01 Per Share
(including the associated Preferred Share Purchase Rights)
(Title of Class of Securities)

80517Q100
(CUSIP Number of Class of Securities)

Philip K. Yachmetz
Executive Vice President
Chief Business Officer
Savient Pharmaceuticals, Inc.
One Tower Center
East Brunswick, New Jersey 08816
(732) 418-9300
(Name, address and telephone number of person authorized to receive notices
and communications on behalf of Filing Persons)

With a copy to:

David E. Redlick
Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
(617) 526-6000

CALCULATION OF FILING FEE

Transaction Valuation*
$68,000,000

Amount of Filing Fee**
$7,276


*	Estimated for purposes of calculating the amount of the filing fee only, this amount is based on the purchase of 10,000,000 shares of common stock at the maximum tender offer price of $6.80 per share.


**	The amount of the filing fee, calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, and Fee Advisory #5 for Fiscal Year 2006 issued by the Securities and Exchange Commission, equals $107 per million of the value of the transaction.


	Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.


Amount Previously Paid: N/A	Filing Party: N/A


Form or Registration No.: N/A	Date Filed: N/A


Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transaction to which the statement relates:

third party tender offer subject to Rule 14d-1.


	issuer tender offer subject to Rule 13e-4.


	going private transaction subject to Rule 13e-3.


	amendment to Schedule 13D under Rule 13-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:

Back to Contents

INTRODUCTION

This Tender Offer Statement on Schedule TO relates to the offer by Savient Pharmaceuticals, Inc., a Delaware corporation (the “Company”), to purchase up to 10,000,000 shares of its common stock, par value $0.01 per share, including the associated preferred share purchase rights (the “rights”) issued under the Rights Agreement dated as of October 7, 1998, between the Company and American Stock Transfer & Trust Company, as Rights Agent, as amended, at a price not greater than $6.80 nor less than $5.80 per share, net to the seller in cash, less any applicable withholding taxes and without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase dated August 14, 2006 (the “Offer to Purchase”), a copy of which is attached hereto as Exhibit (a)(1)(A), and in the related Letter of Transmittal (the “Letter of Transmittal”), a copy of which is attached hereto as Exhibit (a)(1)(B). This Tender Offer Statement on Schedule TO is intended to satisfy the reporting requirements of Rule 13e-4(c)(2) of the Securities Exchange Act of 1934, as amended. The information contained in the Offer to Purchase and the related Letter of Transmittal is incorporated herein by reference in response to all of the items of this Schedule TO, as more particularly described below.

Item 1. Summary Term Sheet.

The information set forth under “Summary Term Sheet” in the Offer to Purchase is incorporated herein by reference.

Item 2. Subject Company Information.

(a) The name of the issuer is Savient Pharmaceuticals, Inc., a Delaware corporation, and the address of its principal executive office is One Tower Center, East Brunswick, New Jersey 08816. The telephone number of its principal executive office is (732) 418-9300.

(b) The information set forth under “Introduction” in the Offer to Purchase is incorporated herein by reference.

(c) The information set forth in the Offer to Purchase under Section 8 (“Price Range of the Shares”) is incorporated herein by reference.

Item 3. Identity and Background of Filing Person.

(a) The Company is the filing person. The Company’s address and telephone number are set forth in Item 2 above. The information set forth in the Offer to Purchase under Section 11 (“Interest of Directors and Executive Officers; Transactions and Arrangements Concerning the Shares”) is incorporated herein by reference.

Item 4. Terms of the Transaction.

(a) The following sections of the Offer to Purchase contain a description of the material terms of the transaction and are incorporated herein by reference:

•

“Summary Term Sheet”;


	•	“Introduction”;


	•	Section 1 (“Terms of the Tender Offer”);


	•	Section 2 (“Purpose of the Tender Offer; Certain Effects of the Tender Offer; Other Plans”);


	•	Section 3 (“Procedures for Tendering Shares”);


	•	Section 4 (“Withdrawal Rights”);


	•	Section 5 (“Purchase of Shares and Payment of Purchase Price”);

•

Section 6 (“Conditional Tender of Shares”);

Back to Contents

•

Section 7 (“Conditions of the Tender Offer”);


	•	Section 9 (“Source and Amount of Funds”);


	•	Section 10 (“Information About Savient Pharmaceuticals, Inc.”);


	•	Section 11 (“Interest of Directors and Executive Officers; Transactions and Arrangements Concerning the Shares”);


	•	Section 14 (“United States Federal Income Tax Consequences”); and


	•	Section 15 (“Extension of the Tender Offer; Termination; Amendment”).

(b) The information in the “Introduction” to the Offer to Purchase and in Section 11 of the Offer to Purchase (“Interest of Directors and Executive Officers; Transactions and Arrangements Concerning the Shares”) is incorporated herein by reference.

Item 5. Past Contacts, Transactions, Negotiations and Agreements.

(e) The information set forth in the Offer to Purchase under Section 11 (“Interest of Directors and Executive Officers; Transactions and Arrangements Concerning the Shares”) is incorporated herein by reference.

Item 6. Purposes of the Transaction and Plans or Proposals.

(a), (b) and (c) The information set forth in the Offer to Purchase under Section 2 (“Purpose of the Tender Offer; Certain Effects of the Tender Offer; Other Plans”) is incorporated herein by reference.

Item 7. Source and Amount of Funds or Other Consideration.

(a) The information set forth in the Offer to Purchase under Section 9 (“Source and Amount of Funds”) is incorporated herein by reference.

(b) Not applicable.

(d) Not applicable.

Item 8. Interest in Securities of the Subject Company.

(a) and (b) The information set forth in the Offer to Purchase under Section 11 (“Interest of Directors and Executive Officers; Transactions and Arrangements Concerning the Shares”) is incorporated herein by reference.

Item 9. Persons/Assets, Retained, Employed, Compensated or Used.

(a) The information set forth in the Offer to Purchase under Section 16 (“Fees and Expenses”) is incorporated herein by reference.

Item 10. Financial Statements.

Not applicable. In accordance with the instructions to Item 10 of Schedule TO, the financial statements are not considered material because: (1) the consideration offered consists solely of cash; (2) the offer is not subject to any financing condition; and (3) the offeror is a public reporting company under Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, that files reports electronically on EDGAR.

Item 11. Additional Information.

(a) The information set forth in the Offer to Purchase under Section 10 (“Information about Savient Pharmaceuticals, Inc.”), Section 11 (“Interest of Directors and Executive Officers; Transactions and Arrangements Concerning the Shares”), Section 12 (“Effects of the Tender Offer on the Market for Shares; Registration under the Exchange Act”) and Section 13 (“Legal Matters; Regulatory Approvals”) is

Back to Contents

incorporated herein by reference. To the knowledge of the Company, no material legal proceedings relating to the tender offer are pending.

(b) The information set forth in the Offer to Purchase and the related Letter of Transmittal, copies of which are filed as Exhibits (a)(1)(A) and (a)(1)(B) hereto, respectively, as each may be amended or supplemented from time to time, is incorporated herein by reference.

Item 12. Exhibits.

(a)(1)(A)*		Offer to Purchase, dated August 14, 2006.
(a)(1)(B)*		Letter of Transmittal including Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9.
(a)(1)(C)*		Notice of Guaranteed Delivery.
(a)(1)(D)*		Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees, dated August 14, 2006.
(a)(1)(E)*		Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees, dated August 14, 2006.
(a)(1)(F)*		Press Release, dated August 14, 2006.
(a)(1)(G)*		Form of Summary Advertisement, dated August 14, 2006.
(a)(2)		Not Applicable.
(a)(3)		Not Applicable.
(a)(4)		Not Applicable.
(a)(5)		Not Applicable.
(b)		Not Applicable.
(d)(1)		Rights Agreement, dated as of October 7, 1998, by and between Bio-Technology General Corp. and American Stock Transfer & Trust Company, as Rights Agent, which includes the form of Certificate of Designations setting forth the terms of the Series A Junior Participating Cumulative Preferred Stock, par value $0.01 per share, as Exhibit A, the form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C. (Incorporated by reference to the Company’s Current Report on Form 8-K, dated October 9, 1998 (File No. 000- 15313).)
(d)(2)		Amendment to Rights Agreement, dated as of March 22, 2006 between the Registrant and American Stock Transfer & Trust Company. (Incorporated by reference to the Company’s Current Report on Form 8-K dated March 28, 2006 (File No. 000-15313).)
(d)(3)		Savient Pharmaceuticals, Inc. 2004 Incentive Plan. (Incorporated by reference to the Company’s Proxy Statement on Schedule 14A dated April 12, 2006 (File No. 000-15313).)
(d)(4)		Bio-Technology General Corp. Stock Option Plan for New Directors, as amended. (Incorporated by reference to the Company’s Annual Report on Form 10-K for the year ended December 31, 1991 (File No. 000-15313).)
(d)(5)		Bio-Technology General Corp. 1992 Stock Option Plan, as amended. (Incorporated by reference to the Company’s Annual Report on Form 10-K for the year ended December 31, 1997 (File No. 000-15313).)
(d)(6)		Bio-Technology General Corp. 1997 Stock Option Plan for Non-Employee Directors. (Incorporated by reference to the Company’s Annual Report on Form 10-K for the year ended December 31, 1997 (File No. 000-15313).)
(d)(7)		Bio-Technology General Corp. 1998 Employee Stock Purchase Plan. (Incorporated by reference to the Company’s Registration Statement on Form S-8 (File No. 333-64541), dated September 29, 1998.)
(d)(8)		Bio-Technology General Corp. 2001 Stock Option Plan. (Incorporated by reference to the Company’s Annual Report on Form 10-K for the year ended December 31, 2001 (File No. 000-15313).)
(g)		Not Applicable.
(h)		Not Applicable.

* Filed herewith.

Back to Contents

Item 13. Information Required by Schedule 13E-3.

Not Applicable.

Back to Contents

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: August 14, 2006	SAVIENT PHARMACEUTICALS, INC.

	By:	/s/ Christopher G. Clement Name: Christopher G. Clement Title: Chief Executive Officer

Back to Contents

Exhibit Index

(a)(1)(A)*		Offer to Purchase, dated August 14, 2006.
(a)(1)(B)*		Letter of Transmittal including Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9.
(a)(1)(C)*		Notice of Guaranteed Delivery.
(a)(1)(D)*		Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees, dated August 14, 2006.
(a)(1)(E)*		Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees, dated August 14, 2006.
(a)(1)(F)*		Press Release, dated August 14, 2006.
(a)(1)(G)*		Form of Summary Advertisement, dated August 14, 2006.
(a)(2)		Not Applicable.
(a)(3)		Not Applicable.
(a)(4)		Not Applicable.
(a)(5)		Not Applicable.
(b)		Not Applicable.
(d)(1)		Rights Agreement, dated as of October 7, 1998, by and between Bio-Technology General Corp. and American Stock Transfer & Trust Company, as Rights Agent, which includes the form of Certificate of Designations setting forth the terms of the Series A Junior Participating Cumulative Preferred Stock, par value $0.01 per share, as Exhibit A, the form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C. (Incorporated by reference to the Company’s Current Report on Form 8-K, dated October 9, 1998 (File No. 000- 15313).)
(d)(2)		Amendment to Rights Agreement, dated as of March 22, 2006 between the Registrant and American Stock Transfer & Trust Company. (Incorporated by reference to the Company’s Current Report on Form 8-K dated March 28, 2006 (File No. 000-15313).)
(d)(3)		Savient Pharmaceuticals, Inc. 2004 Incentive Plan. (Incorporated by reference to the Company’s Proxy Statement on Schedule 14A dated April 12, 2006 (File No. 000-15313).)
(d)(4)		Bio-Technology General Corp. Stock Option Plan for New Directors, as amended. (Incorporated by reference to the Company’s Annual Report on Form 10-K for the year ended December 31, 1991 (File No. 000-15313).)
(d)(5)		Bio-Technology General Corp. 1992 Stock Option Plan, as amended. (Incorporated by reference to the Company’s Annual Report on Form 10-K for the year ended December 31, 1997 (File No. 000-15313).)
(d)(6)		Bio-Technology General Corp. 1997 Stock Option Plan for Non-Employee Directors. (Incorporated by reference to the Company’s Annual Report on Form 10-K for the year ended December 31, 1997 (File No. 000-15313).)
(d)(7)		Bio-Technology General Corp. 1998 Employee Stock Purchase Plan. (Incorporated by reference to the Company’s Registration Statement on Form S-8 (File No. 333-64541), dated September 29, 1998.)
(d)(8)		Bio-Technology General Corp. 2001 Stock Option Plan. (Incorporated by reference to the Company’s Annual Report on Form 10-K for the year ended December 31, 2001 (File No. 000-15313).)
(g)		Not Applicable.
(h)		Not Applicable.

* Filed herewith.

GRAPHIC 2 emptybox.gif GRAPHIC begin 644 emptybox.gif M1TE&.#EA#``,`/?^``````$!`0("`@,#`P0$!`4%!08&!@<'!P@("`D)"0H* M"@L+"PP,#`T-#0X.#@\/#Q`0$!$1$1(2$A,3$Q04%!45%186%A<7%Q@8&!D9 M&1H:&AL;&QP<'!T='1X>'A\?'R`@("$A(2(B(B,C(R0D)"4E)28F)B7IZ>GM[>WQ\?'U]?7Y^?G]_?X"`@(&!@8*" M@H.#@X2$A(6%A8:&AH>'AXB(B(F)B8J*BHN+BXR,C(V-C8Z.CH^/CY"0D)&1 MD9*2DI.3DY24E)65E9:6EI>7EYB8F)F9F9J:FIN;FYRGI^?GZ"@ MH*&AH:*BHJ.CHZ2DI*6EI::FIJ>GIZBHJ*FIJ:JJJJNKJZRLK*VMK:ZNKJ^O MK["PL+&QL;*RLK.SL[2TM+6UM;:VMK>WM[BXN+FYN;JZNKN[N[R\O+V]O;Z^ MOK^_O\#`P,'!P<+"PL/#P\3$Q,7%Q<;&QL?'Q\C(R,G)RWM_?W^#@X.'AX>+BXN/CX^3DY.7EY>;FYN?GY^CHZ.GIZ>KJZNOK MZ^SL[.WM[>[N[N_O[_#P\/'Q\?+R\O/S\_3T]/7U]?;V]O?W]_CX^/GY^?KZ M^OO[^_S\_/W]_?[^_O___R'Y!`$``/X`+``````,``P`!P@Z`/\)'$APX)L? M"!,J_/<#F;B'$!\:8"BNX,`#%"T*Q/BCHD:.'BV"U/AOY,>,)SN2Y&C@@,N7 &+@$$!``[ ` end GRAPHIC 3 tickedbox.gif GRAPHIC begin 644 tickedbox.gif M1TE&.#EA#``,`/?^``````$!`0("`@,#`P0$!`4%!08&!@<'!P@("`D)"0H* M"@L+"PP,#`T-#0X.#@\/#Q`0$!$1$1(2$A,3$Q04%!45%186%A<7%Q@8&!D9 M&1H:&AL;&QP<'!T='1X>'A\?'R`@("$A(2(B(B,C(R0D)"4E)28F)B7IZ>GM[>WQ\?'U]?7Y^?G]_?X"`@(&!@8*" M@H.#@X2$A(6%A8:&AH>'AXB(B(F)B8J*BHN+BXR,C(V-C8Z.CH^/CY"0D)&1 MD9*2DI.3DY24E)65E9:6EI>7EYB8F)F9F9J:FIN;FYRGI^?GZ"@ MH*&AH:*BHJ.CHZ2DI*6EI::FIJ>GIZBHJ*FIJ:JJJJNKJZRLK*VMK:ZNKJ^O MK["PL+&QL;*RLK.SL[2TM+6UM;:VMK>WM[BXN+FYN;JZNKN[N[R\O+V]O;Z^ MOK^_O\#`P,'!P<+"PL/#P\3$Q,7%Q<;&QL?'Q\C(R,G)RWM_?W^#@X.'AX>+BXN/CX^3DY.7EY>;FYN?GY^CHZ.GIZ>KJZNOK MZ^SL[.WM[>[N[N_O[_#P\/'Q\?+R\O/S\_3T]/7U]?;V]O?W]_CX^/GY^?KZ M^OO[^_S\_/W]_?[^_O___R'Y!`$``/X`+``````,``P`!PA>`/]%8T:PH,%_ M&0`H7,@0(3UF_R)&C*8N`T)P"O1(1"4@F$6+UB@0^H=*P2V$*/]94\!$P$F4 J%B/^`1!%XL>('#-EC'BSY,F0(S]& EX-99.A(1A) 4 b414446_exa1a.htm EXHIBIT (A)(1)(A) Prepared and filed by St Ives Burrups

Back to Contents

Exhibit (a)(1)(A)

Offer to Purchase for Cash
Up to 10,000,000 Shares of its Common Stock
(including the Associated Preferred Share Purchase Rights)
at a Purchase Price Not Greater Than $6.80 nor Less Than $5.80 Per Share

THE TENDER OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL
EXPIRE AT 9:00 A.M., NEW YORK CITY TIME, ON SEPTEMBER 12, 2006,
UNLESS THE TENDER OFFER IS EXTENDED

Savient Pharmaceuticals, Inc., a Delaware corporation (the “Company,” “we,” or “us”), is offering to purchase for cash up to 10,000,000 shares of its common stock, par value $0.01 per share (the “common stock”), including the associated preferred share purchase rights (the “rights”) issued under the Rights Agreement dated as of October 7, 1998, between the Company and American Stock Transfer & Trust Company, as Rights Agent, as amended, at a price not greater than $6.80 nor less than $5.80 per share, net to the seller in cash, less any applicable withholding taxes and without interest, upon the terms and subject to the conditions described in this Offer to Purchase and the related Letter of Transmittal (which together, as they may be amended and supplemented from time to time, constitute the “Tender Offer”). Unless the context otherwise requires, all references to the shares shall refer to the common stock of the Company and shall include the rights, and unless the rights are redeemed prior to the expiration of the Tender Offer, a tender of the shares will constitute a tender of the rights.

We are offering to purchase up to 10,000,000 shares in the Tender Offer. On the terms and subject to the conditions of the Tender Offer, we will determine a single per share price, not greater than $6.80 nor less than $5.80 per share, net to the seller in cash, less any applicable withholding taxes and without interest, that we will pay for shares properly tendered and not properly withdrawn in the Tender Offer, taking into account the total number of shares tendered and the prices specified by tendering stockholders. After the Tender Offer expires, we will look at the prices chosen by stockholders for all of the shares properly tendered and not properly withdrawn. We will then select the lowest purchase price (in multiples of $0.10) within the price range specified above that will allow us to buy 10,000,000 shares, subject to our right to increase the total number of shares purchased to the extent permitted by applicable law. If fewer shares are properly tendered and not properly withdrawn, we will select the lowest price that will allow us to buy all the shares that are properly tendered and not properly withdrawn. All shares we acquire in the Tender Offer will be acquired at the same purchase price regardless of whether the stockholder tendered at a lower price. We will purchase only shares properly tendered at prices at or below the purchase price we determine. However, because of the “odd lot” priority, proration and conditional tender provisions described in this Offer to Purchase, we may not purchase all of the shares tendered, even if stockholders tendered at or below the purchase price, if more than the number of shares we seek are properly tendered and not properly withdrawn. We will return shares tendered at prices in excess of the purchase price that we determine and shares that we do not purchase because of the “odd lot” priority, proration and conditional tender provisions to the tendering stockholders at our expense promptly after the Tender Offer expires. See Section 3.

Subject to applicable law, we reserve the right to accept for payment, according to the terms and conditions of the Tender Offer, up to an additional 2% of our outstanding shares (or approximately 1,200,000 shares). See Sections 1 and 15.

The Tender Offer is not conditioned upon any minimum number of shares being tendered. The Tender Offer is, however, subject to certain conditions. See Section 7.

Questions and requests for assistance may be directed to MacKenzie Partners, Inc. (the “Information Agent”), or to Citigroup Global Markets Inc. (the “Dealer Manager”), at their respective addresses and telephone numbers set forth on the back cover of this Offer to Purchase. Requests for additional copies of this Offer to Purchase, the Letter of Transmittal or the Notice of Guaranteed Delivery should be directed to the Information Agent.

The Dealer Manager for the Tender Offer is:

August 14, 2006

Back to Contents

The shares are listed and traded on The NASDAQ Global Market (“NASDAQ”) under the symbol “SVNT”. On August 11, 2006, the last full trading day before we commenced our Tender Offer, the closing price of the shares as reported on NASDAQ was $5.59 per share. Stockholders are urged to obtain current market quotations for the shares. See Section 8.

Our directors and executive officers have each advised us that they do not intend to tender any of their shares in the Tender Offer. See Section 11.

Our Board of Directors has approved the Tender Offer. However, neither we nor our Board of Directors nor the Dealer Manager, the Depositary nor the Information Agent are making any recommendation to you as to whether to tender or refrain from tendering your shares or as to the price or prices at which you may choose to tender your shares. You must decide as to whether to tender your shares and, if so, how many shares to tender and the price or prices at which you will tender them. In doing so, you should read carefully the information in this Offer to Purchase and in the related Letter of Transmittal, and should consult your own tax and investment advisors.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of this transaction or passed upon the merits or fairness of such transaction or passed upon the adequacy or accuracy of the information contained in this Offer to Purchase. Any representation to the contrary is a criminal offense.

Back to Contents

IMPORTANT

If you want to tender all or part of your shares, you must do one of the following before the Tender Offer expires:

•

if your shares are registered in the name of a broker, dealer, commercial bank, trust company or other nominee, contact the nominee and have the nominee tender your shares for you;


	•	if you hold certificates in your own name, complete and sign a Letter of Transmittal according to its instructions and deliver it, together with any required signature guarantees, the certificates for your shares and any other documents required by the Letter of Transmittal, to American Stock Transfer & Trust Company, the Depositary for the Tender Offer (the “Depositary”) at its address shown on the Letter of Transmittal;


	•	if you are an institution participating in The Depository Trust Company, tender your shares according to the procedure for book-entry transfer described in Section 3 of this Offer to Purchase; or


	•	if you are a holder of vested options, you may exercise your vested options and tender any of the shares issued upon exercise.

If you wish to tender shares in the Tender Offer and your certificates for shares are not immediately available or the procedures for book-entry transfer cannot be completed on a timely basis or time will not permit all required documents to reach the Depositary prior to the expiration of the Tender Offer, you can still tender your shares if you comply with the guaranteed delivery procedures described in Section 3.

If you wish to maximize the chance that your shares will be purchased in the Tender Offer, you should check the box in the section of the Letter of Transmittal captioned “Shares Tendered at Price Determined in the Tender Offer.” If you agree to accept the purchase price determined in the Tender Offer, your shares will be deemed to be tendered at the minimum price of $5.80 per share. You should understand that this election may lower the purchase price paid for all shares in the Tender Offer and could result in your shares being purchased at the minimum price of $5.80 per share.

We are not making the Tender Offer to, and will not accept any tendered shares from, stockholders in any jurisdiction where it would be illegal to do so. If we become aware of any jurisdiction where the making of the Tender Offer or the acceptance of shares pursuant thereto is not in compliance with applicable law, we will make a good faith effort to comply with the applicable law where practicable. If, after such good faith effort, we cannot comply with the applicable law, the Tender Offer will not be made to (nor will tenders be accepted from or on behalf of) the holders of shares in such jurisdiction.

If you have any questions regarding the Tender Offer, please contact MacKenzie Partners, Inc., the Information Agent for the Tender Offer, at (212) 929-5500 (collect) or (800) 322-2885 (toll free), or Citigroup Global Markets Inc., the Dealer Manager for the Tender Offer, at (877) 531-8365 (toll free) or (212) 723-7236 (collect).

We have not authorized any person to make any recommendation on our behalf as to whether you should tender or refrain from tendering your shares or as to the purchase price or purchase prices at which you may choose to tender your shares in the Tender Offer. You should rely only on the information contained in this Offer to Purchase or to which we have referred you. We have not authorized anyone to provide you with information or to make any representation in connection with the Tender Offer other than those contained in this Offer to Purchase or in the related Letter of Transmittal. If anyone makes any recommendation or gives any information or representation, you must not rely upon that recommendation, information or representation as having been authorized by us, the Dealer Manager, the Depositary or the Information Agent.

iii

Back to Contents

TABLE OF CONTENTS

Section		Page

SUMMARY TERM SHEET		1
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS		8
INTRODUCTION		9
THE TENDER OFFER		10
1.	Terms of the Tender Offer	10
2.	Purpose of the Tender Offer; Certain Effects of the Tender Offer; Other Plans	13
3.	Procedures for Tendering Shares	15
4.	Withdrawal Rights	19
5.	Purchase of Shares and Payment of Purchase Price	20
6.	Conditional Tender of Shares	21
7.	Conditions of the Tender Offer	22
8.	Price Range of the Shares	24
9.	Source and Amount of Funds	24
10.	Information About Savient Pharmaceuticals, Inc.	24
11.	Interest of Directors and Executive Officers; Transactions and Arrangements Concerning the Shares	26
12.	Effects of the Tender Offer on the Market for Shares; Registration under the Exchange Act	30
13.	Legal Matters; Regulatory Approvals	30
14.	United States Federal Income Tax Consequences	31
15.	Extension of the Tender Offer; Termination; Amendment	33
16.	Fees and Expenses	34
17	Miscellaneous	35

Back to Contents

SUMMARY TERM SHEET

We are providing this summary term sheet for your convenience. The Company is at times referred to as “we,” “our” or “us.” We refer to the shares of our common stock, including the rights, as the “shares.” This summary term sheet highlights the material information in this Offer to Purchase, but you should realize that it does not describe all of the details of the Tender Offer to the same extent described in this Offer to Purchase. We urge you to read the entire Offer to Purchase and the related Letter of Transmittal because they contain the full details of the Tender Offer. We have included references to the sections of this Offer to Purchase where you will find a more complete discussion where helpful.

Who is offering to purchase my shares?

Savient Pharmaceuticals, Inc.

What will be the purchase price for the shares and what will be the form of payment?

We are conducting the Tender Offer through a procedure commonly called a “modified Dutch Auction.”

This procedure allows you to select the price within a price range specified by us at which you are willing to sell your shares. The lowest price that may be specified is $5.80. The prices that may be specified increase in increments of $0.10 and the highest price that may be specified is $6.80.

After the Tender Offer expires, we will look at the prices chosen by stockholders for all of the shares properly tendered and not properly withdrawn. We will then select the lowest purchase price that will allow us to buy 10,000,000 shares, subject to our right to increase the total number of shares purchased to the extent permitted by applicable law. If fewer shares are properly tendered and not properly withdrawn, we will select the lowest price that will allow us to buy all the shares that are properly tendered and not properly withdrawn.

All shares we purchase will be purchased at the same price, even if you have selected a lower price, but we will not purchase any shares above the purchase price determined in the Tender Offer.

If you wish to maximize the chance that your shares will be purchased in the Tender Offer, you should check the box in the section of the Letter of Transmittal captioned “Shares Tendered at Price Determined in the Tender Offer” indicating that you will accept the purchase price we determine. If you agree to accept the purchase price determined in the Tender Offer, your shares will be deemed to be tendered at the minimum price of $5.80 per share. You should understand that this election may lower the purchase price paid for all shares in the Tender Offer and could result in your shares being purchased at the minimum price of $5.80 per share.

If your shares are purchased in the Tender Offer, we will pay you the purchase price in cash, less any applicable withholding taxes and without interest, promptly after the Tender Offer expires. See Sections 1 and 5. Under no circumstances will we pay interest on the purchase price, even if there is a delay in making payment.

How many shares is the Company offering to purchase in the Tender Offer?

We are offering to purchase up to 10,000,000 shares of our common stock, par value $0.01 per share, including the rights. The 10,000,000 shares represent approximately 16.2% of our issued and outstanding common stock as of August 9, 2006. See Section 1. If fewer shares are properly tendered and not properly withdrawn, we will purchase all shares that are properly tendered and not properly withdrawn. If more than 10,000,000 shares are properly tendered and not properly withdrawn, we will purchase all shares tendered and not properly withdrawn at or below the purchase price on a pro rata basis, except for “odd lots” (lots of less than 100 shares), which we will purchase on a priority basis, and except for each conditional tender whose condition was not met, which we will not purchase (except as described in Section 6). Each share is coupled with an associated preferred share purchase right that we will acquire with the shares of common stock we purchase. No additional consideration will be paid for the rights. Subject to applicable law, we reserve the right to accept for payment, according to the terms and conditions of the Tender Offer, up to an additional

Back to Contents

2% of our outstanding shares (or approximately 1,200,000 shares). In exercising the right to accept for payment up to an additional 2% of our outstanding shares, we may increase the purchase price to allow us to purchase such additional shares. The Tender Offer is not conditioned on any minimum number of shares being tendered.

What are the “rights”?

Each time we issue a share of common stock, we issue to the holder of the share one preferred share purchase right pursuant to the Rights Agreement dated as of October 7, 1998, between the American Stock Transfer & Trust Company, as Rights Agent, as amended, which agreement is incorporated herein by reference and is an exhibit to our Issuer Tender Offer Statement on Schedule TO filed with the Securities and Exchange Commission in connection with the Tender Offer. These rights are not represented by separate certificates. Instead, they are evidenced by certificates of shares of common stock, and they automatically trade with the associated shares of common stock. Unless the context otherwise requires, all references in this Offer to Purchase to the “shares” shall refer to the common stock of the Company and shall include the rights. Unless the rights are redeemed prior to the expiration of the Tender Offer, a tender of the shares will constitute a tender of the rights.

How will the Company pay for the shares?

Assuming that 10,000,000 shares are tendered in the Tender Offer at the maximum purchase price of $6.80 per share, the aggregate purchase price will be $68,000,000. We anticipate that we will pay for the shares tendered in the Tender Offer as well as paying related fees and expenses, from our cash and short-term investments. See Section 9.

How long do I have to tender my shares? Can the Tender Offer be extended, amended or terminated?

You may tender your shares until the Tender Offer expires. The Tender Offer will expire at 9:00 a.m., New York City time, on September 12, 2006, which we refer to as the “Expiration Time,” unless we extend it. See Section 1. If a broker, dealer, commercial bank, trust company or other nominee holds your shares, it is likely the nominee has established an earlier deadline for you to act to instruct the nominee to accept the Tender Offer on your behalf. We urge you to contact the broker, dealer, commercial bank, trust company or other nominee to find out the nominee’s deadline. See Section 3.

We may choose to extend the Tender Offer at any time and for any reason, subject to applicable laws. See Section 15. We cannot assure you that we will extend the Tender Offer or indicate the length of any extension that we may provide. If we extend the Tender Offer, we will delay the acceptance of any shares that have been tendered. We can also amend the Tender Offer in our sole discretion or terminate the Tender Offer under certain circumstances. See Sections 7 and 15.

How will I be notified if the Company extends the Tender Offer or amends the terms of the Tender Offer?

If we extend the Tender Offer, we will issue a press release announcing the extension and the new Expiration Time by 9:00 a.m., New York City time, on the next business day after the previously scheduled Expiration Time. We will announce any amendment to the Tender Offer by making a public announcement of the amendment. See Section 15.

What is the purpose of the Tender Offer?

Back to Contents

sales. In addition, if we complete the Tender Offer, stockholders who do not participate in the Tender Offer will automatically increase their relative percentage ownership interest in us and our future operations at no additional cost to them. As a result, our Board of Directors believes that investing in our own shares in this manner is an attractive use of capital and an efficient means to provide value to our stockholders.

The Tender Offer also provides our stockholders with an efficient way to sell their shares without incurring brokers’ fees or commissions. Where shares are tendered by the registered owner of those shares directly to the Depositary, the sale of those shares in the Tender Offer will permit the seller to avoid the usual transaction costs associated with open market sales. Furthermore, Odd Lot Holders who hold shares registered in their names and tender their shares directly to the Depositary and whose shares are purchased in the Tender Offer will avoid any applicable odd lot discounts that might be payable on sales of their shares. See Section 2.

What are the significant conditions to the Tender Offer?

Our obligation to accept and pay for your tendered shares depends upon a number of conditions that must be satisfied or waived prior to the Expiration Time, including, but not limited to:

•

no legal action shall have been threatened, instituted, or been pending that challenges the Tender Offer or seeks to impose limitations on our ability to acquire or hold or to exercise full rights of ownership of the shares;


	•	no changes in the general political, market, economic or financial conditions in the United States or abroad that are reasonably likely to materially adversely affect our business or the trading in the shares shall have occurred;


	•	no person or entity shall have commenced a tender or exchange offer (other than the Tender Offer) for our shares, and no merger, acquisition, business combination or other similar transaction with or involving us or any subsidiary has been proposed, announced or made by any person;


	•	no person or entity (including a group) shall have acquired, or announced its proposal to acquire, beneficial ownership of more than 5% of the outstanding shares (other than anyone who publicly disclosed such ownership in a filing with the Securities and Exchange Commission (the “SEC”) on or before August 11, 2006), and no person or entity (including a group) which has made such a filing on or before August 11, 2006 has acquired or proposed to acquire an additional 1% or more of our outstanding shares;


	•	no material adverse change in our business, properties, assets, liabilities, capitalization, stockholders’ equity, financial condition, operations, licenses, results of operations or prospects of us or any of our subsidiaries, shall have occurred or is reasonably likely to occur; and


	•	we shall not have determined that as a result of the consummation of the Tender Offer and the purchase of shares that there will be a reasonable likelihood that the shares will be delisted from NASDAQ or be eligible for deregistration under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

The Tender Offer is subject to a number of other conditions described in greater detail in Section 7.

Following the Tender Offer, will the Company continue as a public company?

Yes. The completion of the Tender Offer in accordance with its terms and conditions will not cause the Company to be delisted from NASDAQ or to stop being subject to the periodic reporting requirements of the Exchange Act. It is a condition of our obligation to purchase shares pursuant to the Tender Offer that there will not be a reasonable likelihood that such purchase will cause the shares not to continue to be eligible for listing on NASDAQ or not to continue to be eligible for registration under the Exchange Act. See Section 7.

Back to Contents

How do I tender my shares?

If you want to tender all or part of your shares, you must do one of the following before 9:00 a.m., New York City time, on September 12, 2006, or any later time and date to which the Tender Offer may be extended or earlier as your broker or other nominee may require:

•

if your shares are registered in the name of a broker, dealer, commercial bank, trust company or other nominee, contact the nominee and have the nominee tender your shares for you;


	•	if you hold certificates in your own name, complete and sign a Letter of Transmittal according to its instructions and deliver it, together with any required signature guarantees, the certificates for your shares and any other documents required by the Letter of Transmittal, to the Depositary at its address shown on the Letter of Transmittal;


	•	if you are an institution participating in The Depository Trust Company, tender your shares according to the procedure for book-entry transfer described in Section 3 of this Offer to Purchase; or


	•	if you are a holder of vested options to purchase shares under our equity compensation plans, you may exercise your vested options and tender any of the shares issued upon exercise.

If you want to tender your shares, but:

•

your certificates for your shares are not immediately available or cannot be delivered to the Depositary by the expiration of the Tender Offer;


	•	you cannot comply with the procedure for book-entry transfer by the expiration of the Tender Offer; or


	•	your other required documents cannot be delivered to the Depositary by the expiration of the Tender Offer;

you can still tender your shares if you comply with the guaranteed delivery procedure described in Section 3.

You may contact the Information Agent or the Dealer Manager for assistance. The contact information for the Information Agent and the Dealer Manager appears on the back cover of this Offer to Purchase. See Section 3 and the Instructions to the Letter of Transmittal.

How do participants in our employee stock purchase plan participate in the Tender Offer?

Participants in our 1998 Employee Stock Purchase Plan (the “Stock Purchase Plan”) have their shares registered in the name of Deutsche Bank Alex. Brown, a broker, and should follow the instructions applicable to stockholders with shares registered in the name of brokers and other nominees. Please contact the Information Agent at (212) 929-5500 (collect) or (800) 322-2885 (toll free) with any questions regarding tendering shares acquired in the Stock Purchase Plan. See Section 3.

How do holders of vested stock options participate in the Tender Offer?

If you hold vested but unexercised options to purchase shares, you may exercise such options in accordance with the terms of the applicable stock option plan or plans and tender the shares received upon such exercise in accordance with the Tender Offer. An exercise of an option cannot be revoked even if shares received upon the exercise thereof and tendered in the Tender Offer are not purchased in the Tender Offer for any reason. See Section 3. Holders of unvested stock awards or other restricted equity interests may not tender shares or shares represented by such interests unless they are fully vested.

What happens if more than 10,000,000 shares are tendered at or below the purchase price?

If more than 10,000,000 shares (or such greater number of shares as we may elect to accept for payment, subject to applicable law) are properly tendered at or below the purchase price we determine and not properly withdrawn prior to the Expiration Time, we will purchase shares as follows:

Back to Contents

•

first, all “odd lots” of less than 100 shares from holders who properly tender all of their shares at or below the purchase price determined in the Tender Offer and do not properly withdraw them before the Expiration Time;


	•	second, from all other stockholders who properly tender shares at or below the purchase price determined in the Tender Offer and who do not properly withdraw them before the Expiration Time, on a pro rata basis (except for stockholders who tendered shares conditionally for which the condition was not initially satisfied); and


	•	third, only if necessary to permit us to purchase 10,000,000 shares (or such greater number of shares as we may elect to accept for payment, subject to applicable law), from holders who have tendered shares at or below the purchase price determined in the Tender Offer conditionally (for which the condition was not initially satisfied) by random lot, to the extent feasible. To be eligible for purchase by random lot, stockholders whose shares are conditionally tendered must have tendered all of their shares.

Because of the “odd lot” priority, proration and conditional tender provisions described above, we may not purchase all of the shares that you tender even if you tender them at or below the purchase price. See Section 1.

If I own fewer than 100 shares and I tender all of my shares, will I be subject to proration?

If you own beneficially or of record fewer than 100 shares in the aggregate, you properly tender all of these shares at or below the purchase price and do not properly withdraw them before the Expiration Time, and you complete the section entitled “Odd Lots” in the Letter of Transmittal and, if applicable, in the Notice of Guarantee Delivery, we will purchase all of your shares without subjecting them to the proration procedure. See Section 1.

Once I have tendered shares in the Tender Offer, can I withdraw my tender?

Yes. You may withdraw any shares you have tendered at any time before 9:00 a.m., New York City time, on September 12, 2006, unless we extend the Tender Offer, in which case you can withdraw your shares until the expiration of the Tender Offer as extended. If we have not accepted for payment the shares you have tendered to us, you may also withdraw your shares at any time after October 10, 2006. See Section 4.

How do I withdraw shares I previously tendered?

To withdraw shares, you must deliver a written notice of withdrawal with the required information to the Depositary while you still have the right to withdraw the shares. If you have used more than one Letter of Transmittal or have otherwise tendered shares in more than one group of shares, you may withdraw shares using either separate notices of withdrawal or a combined notice of withdrawal, so long as the required information is included. Your notice of withdrawal must specify your name, the number of shares to be withdrawn and the name of the registered holder of these shares. Some additional requirements apply if the share certificates to be withdrawn have been delivered to the Depositary or if your shares have been tendered under the procedure for book-entry transfer described in Section 3. See Section 4. If you have tendered your shares by giving instructions to a broker, dealer, commercial bank, trust company or other nominee, you must instruct the nominee to arrange for the withdrawal of your shares.

Has the Company or its Board of Directors adopted a position on the Tender Offer?

Back to Contents

the information in this Offer to Purchase and in the related Letter of Transmittal, and should consult your own tax and investment advisors. See Section 2.

Do the directors and executive officers of the Company intend to tender their shares in the Tender Offer?

Our directors and executive officers have each advised us that they do not intend to tender any of their shares in the Tender Offer. Accordingly, if we complete the Tender Offer, the proportional holdings of our directors and executive officers will increase. After completion of the Tender Offer, our directors and executive officers may, in compliance with applicable law, sell their shares in open market or other transactions at prices that may or may not be more favorable than the purchase price to be paid to our stockholders in the Tender Offer. See Section 11.

If I decide not to tender, how will the Tender Offer affect my shares?

Stockholders who choose not to tender their shares will own a greater percentage interest in our outstanding common stock following the consummation of the Tender Offer. See Section 2.

What is the recent market price of my shares?

On August 11, 2006, the last full trading day before we commenced the Tender Offer, the closing price of the shares as reported on NASDAQ was $5.59 per share. You are urged to obtain current market quotations for the shares before deciding whether and at what price or prices to tender your shares. See Section 8.

When will the Company pay for the shares I tender?

We will pay the purchase price, net to the seller in cash, less any applicable withholding tax and without interest, for the shares we purchase promptly after the expiration of the Tender Offer. We do not expect, however, to announce the results of proration and begin paying for tendered shares until up to five business days after the expiration of the Tender Offer. See Section 5.

Will I have to pay brokerage commissions if I tender my shares?

If you are the record owner of your shares and you tender your shares directly to the Depositary, you will not have to pay brokerage fees or similar expenses. If you own your shares through a broker, dealer, commercial bank, trust company or other nominee and the nominee tenders your shares on your behalf, the nominee may charge you a fee for doing so. You should consult with your broker, dealer, commercial bank, trust company or other nominee to determine whether any charges will apply. See Section 3.

What are the United States federal income tax consequences if I tender my shares?

Generally, if you are a U.S. Holder (as defined in Section 14), you will be subject to United States federal income taxation when you receive cash from the Company in exchange for the shares you tender in the Tender Offer. Depending on your particular circumstances, you will be treated as either (1) recognizing capital gain or loss from the disposition of your shares or (2) receiving a dividend distribution from the Company. See Section 14. If you are a foreign stockholder (as defined in Section 14), you may be subject to withholding at a rate of 30% on payments received pursuant to the Tender Offer. You may also be subject to tax in other jurisdictions on the disposal of shares. See Sections 3 and 14.

If you are a U.S. Holder, you should complete the Substitute Form W-9 included in your Letter of Transmittal. Any tendering stockholder or other payee that fails to complete, sign and return to the Depositary the Substitute Form W-9 included in the Letter of Transmittal (or such other Internal Revenue Service (“IRS”) form as may be applicable) may be subject to United States backup withholding. Such withholding would be equal to 28% of the gross proceeds paid to the stockholder or other payee pursuant to the Tender Offer. Different rules on filings in respect of withholding of tax apply to foreign stockholders. See Sections 3 and 14. We recommend that you consult with your tax advisor with respect to your particular situation.

Back to Contents

Will I have to pay stock transfer taxes if I tender my shares?

We will pay all stock transfer taxes unless payment is made to, or if shares not tendered or accepted for payment are to be registered in the name of, someone other than the registered holder, or tendered certificates are registered in the name of someone other than the person signing the Letter of Transmittal. See Section 5.

Whom can I talk to if I have questions?

Back to Contents

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS

This Offer to Purchase, and the documents incorporated herein by reference, contain “forward-looking statements” which are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in the forward-looking statements. Such risks, trends and uncertainties are in some instances beyond the Company’s control.

•

our stock price and market conditions;


	•	delay or failure in developing Puricase^® (PEG-uricase) and other product candidates;


	•	difficulties of expanding our product portfolio through in-licensing;


	•	introduction of generic competition for Oxandrin^®;


	•	fluctuations in buying patterns of wholesalers;


	•	potential future returns of Oxandrin or other products;


	•	our continuing to incur substantial net losses for the foreseeable future;


	•	difficulties in obtaining financing;


	•	potential development of alternative technologies or more effective products by competitors;


	•	reliance on third-parties to manufacture, market and distribute many of our products;


	•	economic, political and other risks associated with foreign operations;


	•	risks of maintaining protection for our intellectual property;


	•	risks of an adverse determination in on-going or future intellectual property litigation; and


	•	risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries.

These risks and uncertainties include risks related to our businesses as well as the factors relating to the transactions discussed in this Offer to Purchase. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. You should not place undue reliance on the forward-looking statements, which speak only as to the date of this Offer to Purchase or the date of documents incorporated by reference. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. Except as required by law, we do not assume any obligation to update any forward-looking statements.

In addition, please refer to our Current Reports on Form 8-K filed on July 11, 2006 (two reports), August 10, 2006 and August 11, 2006, our Quarterly Reports on Form 10-Q for the quarterly periods ended June 30, 2006 and March 31, 2006, and our Annual Report on Form 10-K for the fiscal year ended December 31, 2005, in each case as filed with the SEC, each of which is incorporated by reference herein, for additional information on risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements or that may otherwise impact our Company and business. See Section 10.

Notwithstanding anything in this Offer to Purchase, the Letter of Transmittal or any document incorporated by reference into this Offer to Purchase, the safe harbor protections of the Private Securities Litigation Reform Act of 1995 do not apply to statements made in connection with a tender offer.

Back to Contents

INTRODUCTION

To the Holders of our Common Stock:

We invite our stockholders to tender shares of our common stock, par value $0.01 per share (the “common stock”), including the rights, for purchase by us. Upon the terms and subject to the conditions of this Offer to Purchase and the related Letter of Transmittal, we are offering to purchase up to 10,000,000 shares at a price not greater than $6.80 nor less than $5.80 per share, net to the seller in cash, less applicable withholding taxes and without interest. Unless the context otherwise requires, all references to shares shall refer to the common stock of the Company and shall include the rights, and a tender of the shares will constitute a tender of the rights. We will not pay any additional consideration for the rights.

The Tender Offer will expire at 9:00 a.m., New York City time, on September 12, 2006, unless extended as described in Section 15.

After the Expiration Time, we will look at the prices chosen by stockholders for all of the shares properly tendered and not properly withdrawn. We will then select the lowest purchase price within the price range specified above that will allow us to buy 10,000,000 shares, subject to our right to increase the total number of shares purchased to the extent permitted by applicable law. If fewer shares are properly tendered and not properly withdrawn, we will select the lowest price that will allow us to buy all the shares that are properly tendered and not properly withdrawn. All shares we acquire in the Tender Offer will be acquired at the same purchase price regardless of whether the stockholder tendered at a lower price.

We will purchase only shares properly tendered at prices at or below the purchase price we determine. However, because of the “odd lot” priority, proration and conditional tender provisions described in this Offer to Purchase, we may not purchase all of the shares tendered, even if stockholders tendered at or below the purchase price, if more than the number of shares we seek are properly tendered and not properly withdrawn. We will return shares tendered at prices in excess of the purchase price that we determine and shares that we do not purchase because of the “odd lot” priority, proration or conditional tender provisions to the tendering stockholders at our expense promptly following the Expiration Time. See Section 1.

Tendering stockholders whose shares are registered in their own names and who tender directly to American Stock Transfer & Trust Company, the Depositary for the Tender Offer, will not be obligated to pay brokerage fees or commissions or, except as described in Section 5, stock transfer taxes on the purchase of shares by us in the Tender Offer. If you own your shares through a broker, dealer, commercial bank, trust company or other nominee and the nominee tenders your shares on your behalf, the nominee may charge you a fee for doing so. You should consult your broker, dealer, commercial bank, trust company or other nominee to determine whether any charges will apply.

Holders of vested but unexercised options to purchase shares outstanding under the Bio-Technology General Corp. Stock Option Plan for New Directors, Bio-Technology General Corp. 1992 Stock Option Plan, Bio-Technology General Corp. 1997 Stock Option Plan, Bio-Technology General Corp. 1998 Employee Stock Option Plan, Bio-Technology General Corp. 2001 Stock Option Plan or the Savient Pharmaceuticals, Inc. 2004 Incentive Plan (collectively, the “Stock Option Plans”) may exercise such options and tender some or all of the shares issued upon such exercise. Holders of restricted stock and restricted stock units may not tender those shares or the shares represented by such units unless such restrictions have lapsed.

The Tender Offer is not conditioned upon any minimum number of shares being tendered. Our obligation to accept, and pay for, shares validly tendered pursuant to the Tender Offer is conditioned upon satisfaction or waiver of the conditions described in Section 7.

Back to Contents

price or prices at which you may choose to tender your shares. You must decide as to whether to tender your shares and, if so, how many shares to tender and the price or prices at which you will tender them. In doing so, you should read carefully the information in this Offer to Purchase and in the related Letter of Transmittal, and should consult your own tax and investment advisors. See Section 2.

Any tendering stockholder or other payee that fails to complete, sign and return to the Depositary the Substitute Form W-9 included in the Letter of Transmittal (or such other IRS form as may be applicable) may be subject to United States backup withholding at a rate equal to 28% of the gross proceeds paid to the holder or other payee pursuant to the Tender Offer, unless such holder establishes that it is exempt from backup withholding. See Section 3. Also see Section 14 of this Offer to Purchase regarding certain United States federal income tax consequences of a sale of shares pursuant to the Tender Offer.

As of August 9, 2006, there were approximately 61,870,000 shares of our common stock issued and outstanding. The 10,000,000 shares that we are offering to purchase hereunder represent approximately 16.2% of the total number of issued and outstanding shares of our common stock as of August 9, 2006. The shares are listed and traded on NASDAQ under the symbol “SVNT”. On August 11, 2006, the last full trading day before we commenced the Tender Offer, the closing price of the shares as reported on NASDAQ was $5.59 per share. Stockholders are urged to obtain current market quotations for the shares before deciding whether and at what price or prices to tender their shares. See Section 8.

THE TENDER OFFER

1.	Terms of the Tender Offer

General. Upon the terms and subject to the conditions of the Tender Offer, we will purchase 10,000,000 shares of our common stock or, if fewer shares are properly tendered, all shares that are properly tendered and not properly withdrawn in accordance with Section 4, at a price not greater than $6.80 nor less than $5.80 per share, net to the seller in cash, less any applicable withholding tax and without interest.

The term “Expiration Time” means 9:00 a.m., New York City time, on September 12, 2006, unless we, in our sole discretion, extend the period of time during which the Tender Offer will remain open, in which event the term “Expiration Time” shall refer to the latest time and date at which the Tender Offer, as so extended by us, shall expire. See Section 15 for a description of our right to extend, delay, terminate or amend the Tender Offer. Subject to applicable law, we reserve the right to accept for payment, according to the terms and conditions of the Tender Offer, up to an additional 2% of our outstanding shares (or approximately 1,200,000 shares). See Section 15.

If the Tender Offer is over-subscribed as described below, shares tendered at or below the purchase price we determine and not properly withdrawn will be subject to proration, except for “odd lots.” The proration period and, except as described herein, withdrawal rights expire at the Expiration Time.

If we:

•

increase the price to be paid for shares above $6.80 per share or decrease the price to be paid for shares below $5.80 per share;


	•	increase the number of shares being sought in the Tender Offer and such increase in the number of shares being sought exceeds 2% of our outstanding shares (or approximately 1,200,000 shares); or


	•	decrease the number of shares being sought in the Tender Offer; and

Back to Contents

the Tender Offer is scheduled to expire at any time earlier than the expiration of a period ending at 12:00 midnight, New York City time, on the tenth business day (as defined below) from, and including, the date that notice of any such increase or decrease is first published, sent or given in the manner specified in Section 15, then the Tender Offer will be extended until the expiration of such ten business day period. For the purposes of the Tender Offer, a “business day” means any day other than a Saturday, Sunday or United States federal holiday and consists of the time period from 12:01 a.m. to 12:00 midnight, New York City time.

The Tender Offer is not conditioned on any minimum number of shares being tendered.

In accordance with Instruction 5 to the Letter of Transmittal, stockholders desiring to tender shares must specify the price or prices, not in excess of $6.80 nor less than $5.80 per share, at which they are willing to sell their shares to us in the Tender Offer. The prices that may be specified begin at $5.80, and increase in $0.10 increments up to a maximum price of $6.80. Alternatively, stockholders desiring to tender shares can choose not to specify a price and, instead, can elect to tender their shares at the purchase price ultimately paid for shares properly tendered and not properly withdrawn in the Tender Offer, which could result in the tendering stockholder receiving the minimum price of $5.80 per share. See Section 8 for recent market prices for the shares.

Promptly following the Expiration Time, we will look at the prices chosen by stockholders for all of the shares properly tendered and not properly withdrawn and will determine the purchase price within the price range specified above that will allow us to buy 10,000,000 shares, subject to our right to increase the total number of shares purchased to the extent permitted by applicable law. If fewer shares are properly tendered and not properly withdrawn, we will select the lowest price that will allow us to buy all the shares that are properly tendered and not properly withdrawn. Once the purchase price has been determined, we intend to promptly disclose such price in a manner calculated to inform stockholders of this information, which will include a press release through PR Newswire or another comparable service.

All shares we acquire in the Tender Offer will be acquired at the same purchase price regardless of whether the stockholder tendered at a lower price. We will purchase only shares properly tendered at prices at or below the purchase price we determine. However, because of the “odd lot” priority, proration and conditional tender provisions described in this Offer to Purchase, we may not purchase all of the shares tendered, even if stockholders tendered at or below the purchase price, if more than the number of shares we seek to purchase are properly tendered and not properly withdrawn. We will return shares tendered at prices in excess of the purchase price that we determine and shares that we do not purchase because of the “odd lot” priority, proration or conditional tender provisions to the tendering stockholders at our expense promptly after the Expiration Time. Stockholders can specify one minimum price for a specified portion of their shares and a different minimum price for other specified shares, but a separate Letter of Transmittal must be submitted for shares tendered at each price. See Instruction 5 to the Letter of Transmittal.

Stockholders also can specify the order in which we will purchase the specified portions in the event that, as a result of the proration provisions or otherwise, we purchase some but not all of the tendered shares pursuant to the Tender Offer. In the event a stockholder does not designate the order and fewer than all shares are purchased due to proration, the Depositary will select the order of shares purchased.

If the number of shares properly tendered at or below the purchase price determined in the Tender Offer and not properly withdrawn prior to the Expiration Time is less than or equal to 10,000,000 shares, or such greater number of shares as we may elect to accept for payment, we will, subject to applicable law and upon the terms and subject to the conditions of the Tender Offer, purchase all shares so tendered at the purchase price we determine.

Priority of Purchases. Upon the terms and subject to the conditions of the Tender Offer, if more than 10,000,000 shares, or such greater number of shares as we may elect to accept for payment, have been properly tendered at prices at or below the purchase price determined by us and not properly withdrawn prior to the Expiration Time, we will, subject to applicable law, purchase properly tendered shares on the basis described below:

Back to Contents

•

First, we will purchase all shares tendered by any Odd Lot Holder (as defined below) who:


		•	tenders all shares owned beneficially and of record by the Odd Lot Holder at a price at or below the purchase price determined in the Tender Offer (tenders of less than all of the shares owned by an Odd Lot Holder will not qualify for this priority); and


		•	completes the section entitled “Odd Lots” in the Letter of Transmittal and, if applicable, in the Notice of Guaranteed Delivery.


	•	Second, subject to the conditional tender provisions described in Section 6, we will purchase all other shares tendered at prices at or below the purchase price determined by us on a pro rata basis with appropriate adjustments to avoid purchases of fractional shares, as described below.


	•	Third, if necessary to permit us to purchase 10,000,000 shares (or such greater number of shares as we may elect to accept for payment), shares conditionally tendered (for which the condition requiring us to purchase a specified number of shares was not initially satisfied) at or below the purchase price determined by us and not properly withdrawn, will, to the extent feasible, be selected for purchase by random lot. To be eligible for purchase by random lot, stockholders whose shares are conditionally tendered must have tendered all of their shares.

As a result of the foregoing priorities applicable to the purchase of shares tendered, it is possible that all of the shares that a stockholder tenders in the Tender Offer may not be purchased even if they are tendered at prices at or below the purchase price. In addition, if a tender is conditioned upon the purchase of a specified number of shares, it is possible that none of those shares will be purchased even though those shares were tendered at prices at or below the purchase price we determine.

Odd Lots. The term “odd lots” means all shares properly tendered prior to the Expiration Time at prices at or below the purchase price determined by us and not properly withdrawn by any person (an “Odd Lot Holder”) who owned beneficially or of record a total of fewer than 100 shares in the aggregate and so certified in the appropriate place on the Letter of Transmittal and, if applicable, on the Notice of Guaranteed Delivery.

To qualify for this priority, an Odd Lot Holder must tender all shares owned by the Odd Lot Holder in accordance with the procedures described in Section 3. Odd Lots will be accepted for payment before any proration of the purchase of other tendered shares. This priority is not available to partial tenders or to beneficial or record holders of an aggregate of 100 or more shares, even if these holders have separate accounts or certificates representing fewer than 100 shares. By tendering in the Tender Offer, an Odd Lot Holder who holds shares in its name and tenders its shares directly to the Depositary would not only avoid the payment of brokerage commissions, but also would avoid any applicable odd lot discounts in a sale of the holder’s shares. Any Odd Lot Holder wishing to tender all of its shares pursuant to the Tender Offer should complete the section entitled “Odd Lots” in the Letter of Transmittal and, if applicable, in the Notice of Guaranteed Delivery.

Proration. If proration of tendered shares is required, we will determine the proration factor promptly following the Expiration Time. Subject to adjustment to avoid the purchase of fractional shares and subject to the provisions governing conditional tenders described in Section 6, proration for each stockholder tendering shares, other than Odd Lot Holders, will be based on the ratio of the number of shares properly tendered and not properly withdrawn by the stockholder to the total number of shares properly tendered and not properly withdrawn by all stockholders, other than Odd Lot Holders, at or below the purchase price determined in the Tender Offer. Because of the difficulty in determining the number of shares properly tendered and not properly withdrawn, and because of the odd lot procedure described above and the conditional tender procedure described in Section 6, we expect that we will not be able to announce the final proration factor or commence payment for any shares purchased pursuant to the Tender Offer until up to five business days after the Expiration Time. The preliminary results of any proration will be announced by press release promptly after the Expiration Time. After the Expiration Time, stockholders may obtain preliminary proration information from the Information Agent and also may be able to obtain the information from their brokers.

Back to Contents

As described in Section 14, the number of shares that we will purchase from a stockholder in the Tender Offer may affect the United States federal income tax consequences to that stockholder and, therefore, may be relevant to a stockholder’s decision whether or not to tender shares and whether to condition any tender upon our purchase of a stated number of shares held by such stockholder.

This Offer to Purchase and the related Letter of Transmittal will be mailed to record holders of shares and will be furnished to brokers, dealers, commercial banks and trust companies whose names, or the names of whose nominees, appear on our stockholder list or, if applicable, who are listed as participants in a clearing agency’s security position listing for subsequent transmittal to beneficial owners of shares.

2.	Purpose of the Tender Offer; Certain Effects of the Tender Offer; Other Plans

Purpose of the Tender Offer. On August 4, 2006, we sold our Rosemont Pharmaceuticals Ltd. business to an entity affiliated with Close Brothers Private Equity for $176 million. The estimated net proceeds from this transaction after taxes and expenses were approximately $140 million. Including these net proceeds, we had cash, cash equivalents and short-term investments of $266 million as of August 10, 2006.

In considering whether to proceed with the Tender Offer, our Board of Directors reviewed our available cash resources in light of our anticipated cash flows from operations and our expected need for capital resources to fund operations. Among other factors, our Board of Directors considered the estimated cost of completing the full clinical development program for, and commercial launch of, our Puricase^® (PEG-uricase) drug candidate, and the possible timing and effect of the introduction of a generic version of our Oxandrin^® (oxandrolone) product. As a result of this review, our Board of Directors concluded that our available cash resources are sufficient to permit a significant repurchase of shares of our common stock. Our Board of Directors consulted with Citigroup Global Markets Inc. and determined that a “modified Dutch Auction” tender offer is the optimal mechanism for repurchasing these shares, and therefore unanimously approved the making of this Tender Offer. Our Board of Directors believes that the recent trading price range of our shares is not fully reflective of the value of our business and future prospects, and that consequently the repurchase of the shares represents an attractive investment and an appropriate and desirable use of available cash resources. However, actual experience may differ significantly from our expectations. See “Cautionary Note on Forward-Looking Statements.”

The purpose of the Tender Offer is to repurchase a portion of our outstanding shares. We believe that the “modified Dutch Auction” tender offer described herein represents a mechanism to provide all of our stockholders with the opportunity to tender all or a portion of their shares and, thereby, receive a return of some or all of their investment if they so elect. The Tender Offer also provides stockholders (particularly those who, because of the size of their holdings, might not be able to sell their shares without potential disruption to the share price) with an opportunity to obtain liquidity with respect to all or a portion of their shares, without potential disruption to the share price and the usual transaction costs associated with market sales. In addition, if we complete the Tender Offer, stockholders who do not participate in the Tender Offer will automatically increase their relative percentage ownership interest in us and our future operations at no additional cost to them. As a result, our Board of Directors believes that investing in our own shares in this manner is an attractive use of capital and an efficient means to provide value to our stockholders.

All shares purchased in the Tender Offer will be retired.

Back to Contents

tender your shares and, if so, how many shares to tender and the price or prices at which you will tender them. In doing so, you should read carefully the information in this Offer to Purchase and in the related Letter of Transmittal, and should consult your own tax and investment advisors.

Certain Effects of the Tender Offer. Stockholders who do not tender their shares pursuant to the Tender Offer and stockholders who otherwise retain an equity interest in the Company as a result of a partial tender of shares or proration will continue to be owners of the Company. As a result, if we complete the Tender Offer, those stockholders will realize a proportionate increase in their relative equity interest in the Company and, thus, in our future earnings and assets, if any, and will bear the attendant risks associated with owning our equity securities, including risks resulting from our purchase of shares. Stockholders may be able to sell non-tendered shares in the future on NASDAQ, or otherwise, at a net price significantly higher or lower than the purchase price in the Tender Offer. We can give no assurance, however, as to the price at which a stockholder may be able to sell his or her shares in the future.

The Tender Offer will reduce our “public float” (the number of shares owned by non-affiliate stockholders and available for trading in the securities markets), and may reduce the number of our stockholders. These reductions may result in reduced liquidity in the trading market for our common stock following completion of the Tender Offer.

Our shares are currently “margin securities” under the rules of the Federal Reserve Board. This has the effect, among other things, of allowing brokers to extend credit to their customers using the shares as collateral. We believe that, following the purchase of shares pursuant to the Tender Offer, the shares will continue to be “margin securities” for purposes of the Federal Reserve Board’s margin regulations.

Other Plans. Except for the foregoing and as otherwise disclosed in this Offer to Purchase or the documents incorporated by reference herein, we currently have no plans, proposals or negotiations underway that relate to or would result in:

•

any extraordinary transaction, such as a merger, reorganization or liquidation, involving us or any of our subsidiaries;


	•	any purchase, sale or transfer of an amount of our assets or any of our subsidiaries’ assets which is material to us and our subsidiaries, taken as a whole;


	•	any material change in our present dividend rate or policy, our indebtedness or capitalization, our corporate structure or our business;


	•	any change in our present Board of Directors or management or any plans or proposals to change the number or the term of directors or to fill any existing vacancies on the Board of Directors or to change any material term of the employment contract of any executive officer;


	•	our ceasing to be listed on NASDAQ;


	•	any class of our equity securities becoming eligible for termination of registration under Section 12(g) of the Exchange Act;


	•	the suspension of our obligation to file reports under Section 15(d) of the Exchange Act;


	•	the acquisition or disposition by any person of our securities; or


	•	any changes in our charter or by-laws or other actions that could impede the acquisition of control of us.

Back to Contents

Notwithstanding the foregoing, as part of our long-term corporate goal of increasing stockholder value, we have regularly considered alternatives to enhance stockholder value, including open market repurchases of our shares, payment of a dividend to our stockholders, strategic acquisitions, divestitures and business combinations, and we intend to continue to consider alternatives to enhance stockholder value. Except as otherwise disclosed in this Offer to Purchase, as of the date hereof, no agreements, understandings or decisions have been reached and there can be no assurance that we will decide to undertake any such alternatives. See Section 11.

3.	Procedures for Tendering Shares

Valid Tender. For a stockholder to make a valid tender of shares in the Tender Offer, the Depositary must receive, at one of its addresses set forth on the back cover of this Offer to Purchase and prior to the Expiration Time:

•

a Letter of Transmittal, properly completed and duly executed, together with any required signature guarantees, or, in the case of a book-entry transfer, an “agent’s message” (see “—Book-Entry Transfer” below), and any other required documents; and


	•	either certificates representing the tendered shares or, in the case of tendered shares delivered in accordance with the procedures for book-entry transfer we describe below, a book-entry confirmation of that delivery (see “—Book-Entry Transfer” below).

In the alternative, the tendering stockholder must, before the Expiration Time, comply with the guaranteed delivery procedures we describe below.

If a broker, dealer, commercial bank, trust company or other nominee holds your shares, it is likely the nominee has established an earlier deadline for you to act to instruct the nominee to accept the Tender Offer on your behalf. We urge you to contact your broker, dealer, commercial bank, trust company or other nominee to find out the nominee’s applicable deadline.

In accordance with Instruction 5 to the Letter of Transmittal, each stockholder desiring to tender shares pursuant to the Tender Offer must either (1) check the box in the section of the Letter of Transmittal captioned “Shares Tendered at Price Determined Pursuant to the Tender Offer,” in which case you will be deemed to have tendered your shares at the minimum price of $5.80 per share (YOU SHOULD UNDERSTAND THAT THIS ELECTION MAY LOWER THE PURCHASE PRICE PAID FOR ALL PURCHASED SHARES IN THE TENDER OFFER AND COULD RESULT IN THE TENDERED SHARES BEING PURCHASED AT THE MINIMUM PRICE OF $5.80 PER SHARE) or (2) check one, and only one, of the boxes corresponding to the price at which shares are being tendered in the section of the Letter of Transmittal captioned “Price (in Dollars) Per Share at Which Shares Are Being Tendered.” A tender of shares will be proper if one, and only one, of these boxes is checked on the Letter of Transmittal.

If tendering stockholders desire to maximize the chance that their shares will be purchased in the Tender Offer, they should check the box in the section of the Letter of Transmittal captioned “Shares Tendered at Price Determined Pursuant to the Tender Offer.” If tendering stockholders desire to indicate a specific price at which their shares are being tendered, they must check the applicable price box in the section of the Letter of Transmittal captioned “Price (in Dollars) per Share at Which Shares Are Being Tendered.” Tendering stockholders should be aware that this election could mean that none of their shares will be purchased if the price selected by the stockholder is higher than the purchase price we eventually determined after the Expiration Time.

A stockholder who desires to tender shares at more than one price must complete a separate Letter of Transmittal for each price at which shares are being tendered. The same shares cannot be tendered (unless previously properly withdrawn in accordance with the terms of the Tender Offer) at more than one price. In order to properly withdraw, stockholders who tendered at multiple prices pursuant to multiple Letters of Transmittal must comply with the procedures described in Section 4.

Back to Contents

We urge stockholders who hold shares through brokers or banks to consult the brokers or banks to determine whether transaction costs are applicable if they tender shares through the brokers or banks and not directly to the Depositary.

Odd Lot Holders who tender all their shares must also complete the section captioned “Odd Lots” in the Letter of Transmittal and, if applicable, in the Notice of Guaranteed Delivery, to qualify for the preferential treatment available to Odd Lot Holders as described in Section 1.

Book-Entry Transfer. For purposes of the Tender Offer, the Depositary will establish an account for the shares at The Depository Trust Company (the “book-entry transfer facility”) within two business days after the date of this Offer to Purchase. Any financial institution that is a participant in the book-entry transfer facility’s system may make book-entry delivery of shares by causing the book-entry transfer facility to transfer those shares into the Depositary’s account in accordance with the book-entry transfer facility’s procedures for that transfer. Although delivery of shares may be effected through book-entry transfer into the Depositary’s account at the book-entry transfer facility, the Letter of Transmittal, properly completed and duly executed, with any required signature guarantees, or an agent’s message, and any other required documents must, in any case, be transmitted to, and received by, the Depositary at one of its addresses set forth on the back cover of this Offer to Purchase prior to the Expiration Time, or the tendering stockholder must comply with the guaranteed delivery procedures we describe below.

The confirmation of a book-entry transfer of shares into the Depositary’s account at the book-entry transfer facility as we describe above is referred to herein as a “book-entry confirmation.” Delivery of documents to the book-entry transfer facility in accordance with the book-entry transfer facility’s procedures will not constitute delivery to the Depositary.

The term “agent’s message” means a message transmitted by the book-entry transfer facility to, and received by, the Depositary and forming a part of a book-entry confirmation, stating that the book-entry transfer facility has received an express acknowledgment from the participant tendering shares through the book-entry transfer facility that the participant has received and agrees to be bound by the terms of the Letter of Transmittal and that we may enforce that agreement against that participant.

Method of Delivery. The method of delivery of shares, the Letter of Transmittal and all other required documents, including delivery through the book-entry transfer facility, is at the sole election and risk of the tendering stockholder. Shares will be deemed delivered only when actually received by the Depositary (including, in the case of a book-entry transfer, by book-entry confirmation). If you plan to make delivery by mail, we recommend that you deliver by registered mail with return receipt requested and obtain proper insurance. In all cases, sufficient time should be allowed to ensure timely delivery.

Signature Guarantees. No signature guarantee will be required on a Letter of Transmittal for shares tendered thereby if:

•

the “registered holder(s)” of those shares signs the Letter of Transmittal and has not completed either the box entitled “Special Delivery Instructions” or the box entitled “Special Payment Instructions” in the Letter of Transmittal; or


	•	those shares are tendered for the account of an “eligible institution.”

A “registered holder” of tendered shares will include any participant in the book-entry transfer facility’s system whose name appears on a security position listing as the owner of those shares, and an “eligible institution” is a “financial institution,” which term includes most commercial banks, savings and loan associations and brokerage houses, that is a participant in any of the following: (1) the Securities Transfer Agents Medallion Program; (2) the New York Stock Exchange, Inc. Medallion Signature Program; or (3) the Stock Exchange Medallion Program.

Back to Contents

Except as described above, all signatures on any Letter of Transmittal for shares tendered thereby must be guaranteed by an eligible institution. See Instructions 1 and 6 to the Letter of Transmittal. If the certificates for shares are registered in the name of a person other than the signer of the Letter of Transmittal, or if payment is to be made or certificates for shares not tendered or not accepted for payment are to be returned to a person other than the registered holder of the certificates surrendered, then the tendered certificates must be endorsed or accompanied by appropriate stock powers, in either case signed exactly as the name or names of the registered holders or owners appear on the certificates, with the signatures on the certificates or stock powers guaranteed as aforesaid. See Instructions 1 and 6 to the Letter of Transmittal.

Guaranteed Delivery. If you wish to tender shares in the Tender Offer and your certificates for shares are not immediately available or the procedures for book-entry transfer cannot be completed on a timely basis or time will not permit all required documents to reach the Depositary prior to the Expiration Time, you can still tender your shares if you satisfy all of the following conditions:

•

your tender is made by or through an eligible institution;


	•	a properly completed and duly executed Notice of Guaranteed Delivery in the form we have provided is received by the Depositary, as provided below, prior to the Expiration Time; and


	•	the Depositary receives, at one of its addresses set forth on the back cover of this Offer to Purchase and within the period of three business days after the date of execution of that Notice of Guaranteed Delivery, either: (1) the certificates representing the shares being tendered, in the proper form for transfer, together with all other required documents and a Letter of Transmittal, which has been properly completed and duly executed and includes all signature guarantees required thereon; or (2) confirmation of book-entry transfer of the shares into the Depositary’s account at the book-entry transfer facility, together with all other required documents and either a Letter of Transmittal, which has been properly completed and duly executed and includes all signature guarantees required thereon or an agent’s message.

A Notice of Guaranteed Delivery must be delivered to the Depositary by hand, overnight courier, facsimile transmission or mail before the Expiration Time and must include a guarantee by an eligible institution in the form set forth in the Notice of Guaranteed Delivery.

Stock Option Plans; Restricted Stock. Holders of vested but unexercised options may exercise such options in accordance with the terms of the Stock Option Plans and tender the shares received upon such exercise in accordance with the Offer. See “Valid Tender” above. Your exercise of options will be irrevocable, regardless of whether your shares are purchased. Holders of vested but unexercised options should evaluate this Offer to Purchase carefully to determine if participation would be advantageous to them, based on their stock option exercise prices, the date of their stock option grants and the years left to exercise their options, the range of tender prices and the provisions for pro rata purchases by the Company described in Section 1. We strongly encourage those holders to discuss the Tender Offer with their tax and investment advisors. Holders of restricted stock or restricted stock units may not tender those shares or the shares represented by such units unless the restrictions imposed on such shares or the shares represented by such units by the relevant Stock Option Plan and award agreement have lapsed.

Stock Purchase Plan. Participants in the Stock Purchase Plan have their shares registered in the name of Deutsche Bank Alex. Brown, a broker, and should follow the instructions applicable to stockholders with shares registered in the name of brokers and other nominees. Please contact the Information Agent at (212) 929-5500 (collect) or (800) 322-2885 (toll free) with any questions regarding tendering shares acquired in the Stock Purchase Plan.

Return of Unpurchased Shares. The Depositary will return certificates for unpurchased shares promptly after the expiration or termination of the Tender Offer or the proper withdrawal of the shares, as applicable, or, in the case of shares tendered by book-entry transfer at the book-entry transfer facility, the Depositary will credit the shares to the appropriate account maintained by the tendering stockholder at the book-entry transfer facility, in each case without expense to the stockholder.

Back to Contents

Tendering Stockholders’ Representation and Warranty; Our Acceptance Constitutes an Agreement. It is a violation of Rule 14e-4 promulgated under the Exchange Act for a person acting alone or in concert with others, directly or indirectly, to tender shares for such person’s own account unless at the time of tender and at the Expiration Time such person has a “net long position” in (1) a number of shares that is equal to or greater than the amount tendered and will deliver or cause to be delivered such shares for the purpose of tendering to us within the period specified in the Tender Offer or (2) other securities immediately convertible into, exercisable for or exchangeable into a number of shares (“Equivalent Securities”) that is equal to or greater than the number of shares tendered and, upon the acceptance of such tender, will acquire such shares by conversion, exchange or exercise of such Equivalent Securities to the extent required by the terms of the Tender Offer and will deliver or cause to be delivered such shares so acquired for the purpose of tender to us within the period specified in the Tender Offer. Rule 14e-4 also provides a similar restriction applicable to the tender or guarantee of a tender on behalf of another person. A tender of shares made pursuant to any method of delivery described herein will constitute the tendering stockholder’s acceptance of the terms and conditions of the Tender Offer, as well as the tendering stockholder’s representation and warranty to us that (1) such stockholder has a “net long position” in a number of shares or Equivalent Securities at least equal to the shares being tendered within the meaning of Rule 14e-4, and (2) such tender of shares complies with Rule 14e-4.

Our acceptance for payment of shares tendered pursuant to the Tender Offer will constitute a binding agreement between the tendering stockholder and us upon the terms and subject to the conditions of the Tender Offer.

Determination of Validity; Rejection of Shares; Waiver of Defects; No Obligation to Give Notice of Defects. All questions as to the number of shares to be accepted, the price to be paid for shares to be accepted and the validity, form, eligibility (including time of receipt) and acceptance for payment of any tender of shares will be determined by us, in our sole discretion, and each such decision will be final and binding on all parties. We reserve the absolute right prior to the Expiration Time to reject any or all tenders we determine not to be in proper form or the acceptance for payment of or payment for which may, in the opinion of our counsel, be unlawful. We also reserve the absolute right subject to applicable law to waive any conditions of the Tender Offer with respect to all stockholders or any defect or irregularity in any tender with respect to any particular shares or any particular stockholder whether or not we waive similar defects or irregularities in the case of other stockholders. No tender of shares will be deemed to have been validly made until all defects or irregularities relating thereto have been cured or waived. None of us, the Dealer Manager, the Depositary, the Information Agent or any other person will be under any duty to give notification of any defects or irregularities in tenders or incur any liability for failure to give any such notification. Our reasonable interpretation of the terms of and conditions to the Tender Offer, including the Letter of Transmittal and the instructions thereto, will be final and binding on all parties. By tendering shares to us, you agree to accept all decisions we make concerning these matters and waive any right you might otherwise have to challenge those decisions.

Lost Certificates. If the share certificates which a registered holder wants to surrender have been lost, destroyed or stolen, the stockholder should promptly notify the Depositary at (877) 248-6417 (toll free). The Depositary will instruct the stockholder as to the steps that must be taken in order to replace the certificates. See Instruction 12 to the Letter of Transmittal.

United States Federal Backup Withholding. Under the current United States backup withholding rules, 28% of the gross proceeds payable to a stockholder or other payee pursuant to the Tender Offer must be withheld and remitted to the United States Treasury, unless the stockholder or other payee (1) provides its taxpayer identification number (i.e., its employer identification number or social security number) to the Depositary and certifies that such number is correct and that such stockholder is not subject to backup withholding, or (2) establishes that an exemption from withholding otherwise applies under applicable regulations. Therefore, unless an exemption exists and is proven in a manner satisfactory to the Depositary, each tendering stockholder that is a U.S. Holder (as defined in Section 14) should complete and sign the Substitute Form W-9 included as part of the Letter of Transmittal so as to provide the information and certification necessary to avoid backup withholding. Certain stockholders (including, among others, all corporations and certain foreign individuals) are not subject to these backup withholding and reporting

Back to Contents

requirements. In order for a foreign stockholder to qualify as an exempt recipient, that stockholder must submit a statement (generally, an applicable IRS Form W-8), signed under penalties of perjury, attesting to that stockholder’s exempt status. Such statements can be obtained from the Depositary. See Instruction 10 to the Letter of Transmittal. Amounts withheld, if any, under the backup withholding rules are generally not an additional tax and may be refunded or credited against the stockholder’s federal income tax liability, provided that the stockholder furnishes the required information to the Internal Revenue Service.

ANY TENDERING STOCKHOLDER OR OTHER PAYEE THAT FAILS TO COMPLETE FULLY AND SIGN THE SUBSTITUTE FORM W-9 INCLUDED IN THE LETTER OF TRANSMITTAL (OR SUCH OTHER IRS FORM AS MAY BE APPLICABLE) MAY BE SUBJECT TO REQUIRED UNITED STATES BACKUP WITHHOLDING AT A RATE EQUAL TO 28% OF THE GROSS PROCEEDS PAID TO SUCH STOCKHOLDER OR OTHER PAYEE PURSUANT TO THE TENDER OFFER.

Withholding on Payments to Foreign Stockholders. In addition, gross proceeds payable pursuant to the Tender Offer to a foreign stockholder or its agent will be subject to withholding of United States federal income tax at a rate of 30%, unless the Company determines that a reduced rate of withholding is applicable pursuant to a tax treaty or that an exemption from withholding is applicable because such gross proceeds are effectively connected with the conduct of a trade or business within the United States and, in either case, the foreign stockholder provides the appropriate certification, as described below. For this purpose, a foreign stockholder is any stockholder that is not for United States federal income tax purposes: (a) an individual citizen or resident of the United States, (b) a corporation, partnership, or other entity created or organized in or under the laws of the United States, any state thereof or the District of Columbia, (c) an estate the income of which is subject to United States federal income taxation regardless of its source, or (d) a trust the income from which is subject to United States federal income taxation regardless of source.

A foreign stockholder may be eligible to file for a refund of such tax or a portion of such tax withheld if such stockholder meets the “complete termination,” “substantially disproportionate” or “not essentially equivalent to a dividend” tests described in Section 14 or if such stockholder is entitled to a reduced rate of withholding pursuant to a tax treaty and we withheld at a higher rate. In order to obtain a reduced rate of withholding under a tax treaty, a foreign stockholder must deliver to the Depositary before payment a properly completed and executed IRS Form W-8BEN claiming such an exemption or reduction. Such forms can be obtained from the Depositary. In order to claim an exemption from withholding on the grounds that gross proceeds paid pursuant to the Tender Offer are effectively connected with the conduct of a trade or business within the United States, a foreign stockholder must deliver to the Depositary a properly completed and executed IRS Form W-8ECI claiming such exemption. Such forms can be obtained from the Information Agent. Backup withholding generally will not apply to amounts subject to the 30% or a treaty-reduced rate of withholding. Foreign stockholders are urged to consult their own tax advisors regarding the application of United States federal income tax withholding, including eligibility for a withholding tax reduction or exemption and the refund procedure.

For a discussion of material United States federal income tax consequences to tendering stockholders, see Section 14.

4.	Withdrawal Rights

Except as this Section 4 otherwise provides, tenders of shares are irrevocable. You may withdraw shares that you have previously tendered in the Tender Offer according to the procedures we describe below at any time prior to the Expiration Time. You may also withdraw your previously tendered shares at any time after October 10, 2006, unless such shares have been accepted for payment as provided in the Tender Offer.

For a withdrawal to be effective, a written notice of withdrawal must:

•

be received in a timely manner by the Depositary at one of its addresses set forth on the back cover of this Offer to Purchase; and

Back to Contents

•

specify the name of the person having tendered the shares to be withdrawn, the number of shares to be withdrawn and the name of the registered holder of the shares to be withdrawn, if different from the name of the person who tendered the shares.

If certificates for shares have been delivered or otherwise identified to the Depositary, then, prior to the physical release of those certificates, the serial numbers shown on those certificates must be submitted to the Depositary and, unless an eligible institution has tendered those shares, an eligible institution must guarantee the signatures on the notice of withdrawal.

If a stockholder has used more than one Letter of Transmittal or has otherwise tendered shares in more than one group of shares, the stockholder may withdraw shares using either separate notices of withdrawal or a combined notice of withdrawal, so long as the information specified above is included.

If shares have been delivered in accordance with the procedures for book-entry transfer described in Section 3, any notice of withdrawal must also specify the name and number of the account at the book-entry transfer facility to be credited with the withdrawn shares and otherwise comply with the book-entry transfer facility’s procedures.

Withdrawals of tenders of shares may not be rescinded, and any shares properly withdrawn will thereafter be deemed not validly tendered for purposes of the Tender Offer. Withdrawn shares may be retendered at any time prior to the Expiration Time by again following one of the procedures described in Section 3.

We will decide, in our sole discretion, all questions as to the form, validity and eligibility, including time of receipt, of notices of withdrawal, and each such decision will be final and binding on all parties. We also reserve the absolute right to waive any defect or irregularity in the withdrawal of shares by any stockholder, whether or not we waive similar defects or irregularities in the case of any other stockholder. None of us, the Dealer Manager, the Depositary, the Information Agent or any other person will be under any duty to give notification of any defects or irregularities in any notice of withdrawal or incur any liability for failure to give any such notification.

If we extend the Tender Offer, are delayed in our purchase of shares, or are unable to purchase shares in the Tender Offer as a result of a failure of a condition disclosed in Section 7, then, without prejudice to our rights in the Tender Offer, the Depositary may, subject to applicable law, retain tendered shares on our behalf, and such shares may not be withdrawn except to the extent tendering stockholders are entitled to withdrawal rights as described in this Section 4. Our reservation of the right to delay payment for shares which we have accepted for payment is limited by Rule 13e-4(f)(5) promulgated under the Exchange Act, which requires that we must pay the consideration offered or return the shares tendered promptly after termination or withdrawal of a tender offer.

5.	Purchase of Shares and Payment of Purchase Price

Upon the terms and subject to the conditions of the Tender Offer, promptly following the Expiration Time, we will (1) determine a single per share purchase price we will pay for the shares properly tendered and not properly withdrawn before the Expiration Time, taking into account the number of shares tendered and the prices specified by tendering stockholders, (2) accept for payment up to 10,000,000 shares properly tendered at prices at or below the purchase price, and not properly withdrawn before the Expiration Time, and (3) subject to applicable law and in our discretion, accept for payment up to an additional 2% of our outstanding shares (or approximately 1,200,000 shares), properly tendered at prices at or below the purchase price, and not properly withdrawn before the Expiration Time. In exercising the right to accept for payment up to an additional 2% of our outstanding shares, we may increase the purchase price (but not above the maximum price of $6.80) to allow us to purchase such additional shares.

For purposes of the Tender Offer, we will be deemed to have accepted for payment (and therefore purchased), subject to the “odd lot” priority, proration and conditional tender provisions of the Tender Offer, shares that are properly tendered at or below the purchase price determined by us and not properly withdrawn only when, as and if we give oral or written notice to the Depositary of our acceptance of the shares for payment pursuant to the Tender Offer.

Back to Contents

Upon the terms and subject to the conditions of the Tender Offer, we will accept for payment and pay the per share purchase price for all of the shares accepted for payment pursuant to the Tender Offer promptly after the Expiration Time. In all cases, payment for shares tendered and accepted for payment pursuant to the Tender Offer will be made promptly, subject to possible delay in the event of proration, but only after timely receipt by the Depositary of:

•

certificates for shares, or a timely book-entry confirmation of the deposit of shares into the Depositary’s account at the book-entry transfer facility;


	•	a properly completed and duly executed Letter of Transmittal, or, in the case of a book-entry transfer, an agent’s message; and


	•	any other required documents.

We will pay for shares purchased pursuant to the Tender Offer by depositing the aggregate purchase price for the shares with the Depositary, which will act as agent for tendering stockholders for the purpose of receiving payment from us and transmitting payment to the tendering stockholders.

In the event of proration, we will determine the proration factor and pay for those tendered shares accepted for payment promptly after the Expiration Time. However, we expect that we will not be able to announce the final results of any proration or commence payment for any shares purchased pursuant to the Tender Offer until up to five business days after the Expiration Time. Certificates for all shares tendered and not purchased, including all shares tendered at prices in excess of the purchase price and shares not purchased due to proration or conditional tender, will be returned or, in the case of shares tendered by book-entry transfer, will be credited to the account maintained with the book-entry transfer facility by the participant who delivered the shares, to the tendering stockholder at our expense promptly after the Expiration Time or termination of the Tender Offer.

Under no circumstances will we pay interest on the purchase price, including but not limited to, by reason of any delay in making payment. In addition, if certain events occur, we may not be obligated to purchase shares pursuant to the Tender Offer. See Section 7.

We will pay all stock transfer taxes, if any, payable on the transfer to us of shares purchased pursuant to the Tender Offer. If, however, payment of the purchase price is to be made to, or (in the circumstances permitted by the Tender Offer) if unpurchased shares are to be registered in the name of, any person other than the registered holder, or if tendered certificates are registered in the name of any person other than the person signing the Letter of Transmittal, the amount of all stock transfer taxes, if any (whether imposed on the registered holder or the other person), payable on account of the transfer to the person will be deducted from the purchase price unless satisfactory evidence of the payment of the stock transfer taxes, or exemption from payment of the stock transfer taxes, is submitted. See Instruction 7 to the Letter of Transmittal.

Any tendering stockholder or other payee that fails to complete fully, sign and return to the Depositary the Substitute Form W-9 included with the Letter of Transmittal (or such other IRS form as may be applicable) may be subject to required United States backup withholding at a rate equal to 28% of the gross proceeds paid to the stockholder or other payee pursuant to the Tender Offer. See Section 3. Also see Sections 3 and 14 regarding U.S. federal income tax consequences for foreign stockholders.

6.	Conditional Tender of Shares

Subject to the exception for Odd Lot Holders, in the event of an over-subscription of the Tender Offer, shares tendered at or below the purchase price prior to the Expiration Time will be subject to proration. See Section 1. As discussed in Section 14, the number of shares to be purchased from a particular stockholder may affect the tax treatment of the purchase to the stockholder and the stockholder’s decision whether to tender. Accordingly, a stockholder may tender shares subject to the condition that a specified minimum number of the stockholder’s shares tendered pursuant to a Letter of Transmittal must be purchased if any shares tendered are purchased. Any stockholder desiring to make a conditional tender must so indicate in the box entitled “Conditional Tender” in the Letter of Transmittal, and, if applicable, in the Notice of Guaranteed Delivery.

Back to Contents

Any tendering stockholder wishing to make a conditional tender must calculate and appropriately indicate the minimum number of shares that must be purchased if any are to be purchased. After the Expiration Time, if more than 10,000,000 shares (or such greater number of shares as we may elect to accept for payment, subject to applicable law) are properly tendered and not properly withdrawn, so that we must prorate our acceptance of and payment for tendered shares, we will calculate a preliminary proration percentage based upon all shares properly tendered, conditionally or unconditionally. If the effect of this preliminary proration would be to reduce the number of shares to be purchased from any stockholder below the minimum number specified, the tender will automatically be regarded as withdrawn (except as provided in the next paragraph). All shares tendered by a stockholder subject to a conditional tender and regarded as withdrawn as a result of proration will be returned at our expense, promptly after the Expiration Time.

After giving effect to these withdrawals, we will accept the remaining shares properly tendered, conditionally or unconditionally, on a pro rata basis, if necessary. If conditional tenders would otherwise be regarded as withdrawn and would cause the total number of shares to be purchased to fall below 10,000,000 (or such greater number of shares as we may elect to accept for payment, subject to applicable law) then, to the extent feasible, we will select enough of the conditional tenders that would otherwise have been withdrawn to permit us to purchase 10,000,000 shares (or such greater number of shares as we may elect to accept for payment, subject to applicable law). In selecting among the conditional tenders, we will select by random lot, treating all tenders by a particular taxpayer as a single lot, and will limit our purchase in each case to the designated minimum number of shares to be purchased. To be eligible for purchase by random lot, stockholders whose shares are conditionally tendered must have tendered all of their shares.

7.	Conditions of the Tender Offer

Notwithstanding any other provision of the Tender Offer, we will not be required to accept for payment, purchase or pay for any shares tendered, and may terminate or amend the Tender Offer or may postpone the acceptance for payment of, or the purchase of and the payment for shares tendered, subject to Rule 13e-4(f)(5) under the Exchange Act (which requires that the issuer making the tender offer shall either pay the consideration offered or return tendered securities promptly after the termination or withdrawal of the tender offer), if at any time prior to the Expiration Time any of the following events has occurred (or shall have been reasonably determined by us to have occurred) that, in our reasonable judgment and regardless of the circumstances giving rise to the event or events (other than any such event or events that are proximately caused by our action or failure to act), make it inadvisable to proceed with the Tender Offer or with acceptance for payment:

•

there has occurred any change in the general political, market, economic or financial conditions in the United States or abroad that is reasonably likely to materially and adversely affect our business or the trading in the shares, including, but not limited to, the following:


		•	any general suspension of, or general limitation on prices for, or trading in, securities on any national securities exchange in the United States or in the over-the-counter market;


		•	a declaration of a banking moratorium or any suspension of payments in respect of banks in the United States or any limitation (whether or not mandatory) by any governmental agency or authority on, or any other event that, in our reasonable judgment, could reasonably be expected to adversely affect, the extension of credit by banks or other financial institutions in the United States;


		•	the commencement or escalation of a war, armed hostilities or other similar national or international calamity directly or indirectly involving the United States;


		•	a decrease in excess of 10% in the market price for the shares or in the Dow Jones Industrial Average, the NASDAQ Composite Index or the S&P 500 Composite Index; or


		•	legislation amending the Code (as defined in Section 14) has been passed by either the U.S. House of Representatives or the Senate or becomes pending before the U.S. House of Representatives or the Senate or any committee thereof, the effect of which, in our reasonable judgment, would be to change the tax consequences of the transaction contemplated by the Tender Offer in any manner that would adversely affect us;

Back to Contents

•

there has been threatened, instituted, or pending any action, proceeding, application or counterclaim by or before any court or governmental, administrative or regulatory agency or authority, domestic or foreign, or any other person or tribunal, domestic or foreign, which:


		•	challenges or seeks to challenge, restrain, prohibit or delay the making of the Tender Offer, the acquisition by us of the shares in the Tender Offer, or any other matter relating to the Tender Offer, or seeks to obtain any material damages or otherwise relating to the transactions contemplated by the Tender Offer;


		•	seeks to make the purchase of, or payment for, some or all of the shares pursuant to the Tender Offer illegal or results in a delay in our ability to accept for payment or pay for some or all of the shares; or


		•	seeks to impose limitations on our ability to acquire or hold or to exercise full rights of ownership of the shares or otherwise could reasonably be expected to materially adversely affect the business, properties, assets, liabilities, capitalization, stockholders’ equity, financial condition, operations, licenses, results of operations or prospects of us or any of our subsidiaries, taken as a whole, or the value of the shares;


	•	any action has been taken or any statute, rule, regulation, judgment, decree, injunction or order (preliminary, permanent or otherwise) has been proposed, sought, enacted, entered, promulgated, enforced or deemed to be applicable to the Tender Offer or us or any of our subsidiaries by any court, government or governmental agency or other regulatory or administrative authority, domestic or foreign, which, in our reasonable judgment:


		•	indicates that any approval or other action of any such court, agency or authority may be required in connection with the Tender Offer or the purchase of shares thereunder;


		•	could reasonably be expected to prohibit, restrict or delay consummation of the Tender Offer; or


		•	otherwise could reasonably be expected to materially adversely affect the business, properties, assets, liabilities, capitalization, stockholders’ equity, financial condition, operations, licenses, results of operations or prospects of us or any of our subsidiaries, taken as a whole;


	•	a tender or exchange offer for any or all of our outstanding shares (other than the Tender Offer), or any merger, acquisition, business combination or other similar transaction with or involving us or any subsidiary, has been proposed, announced or made by any person or entity;


	•	we learn that:


		•	any entity, “group” (as that term is used in Section 13(d)(3) of the Exchange Act) or person has acquired or proposes to acquire beneficial ownership of more than 5% of our outstanding shares, whether through the acquisition of stock, the formation of a group, the grant of any option or right, or otherwise (other than as and to the extent disclosed in a Schedule 13D or Schedule 13G filed with the SEC on or before August 11, 2006); or


		•	any entity, group or person who has filed a Schedule 13D or Schedule 13G with the SEC on or before August 11, 2006 has acquired or proposes to acquire, whether through the acquisition of stock, the formation of a group, the grant of any option or right, or otherwise, beneficial ownership of an additional 1% or more of our outstanding shares;


	•	any approval, permit, authorization, favorable review or consent of any governmental entity required to be obtained in connection with the Tender Offer has not been obtained on terms satisfactory to us in our reasonable discretion;


	•	any change (or condition, event or development involving a prospective change) has occurred in the business, properties, assets, liabilities, capitalization, stockholders’ equity, financial condition, operations, licenses, results of operations or prospects of us or any of our subsidiaries, taken as a whole, that, in our reasonable judgment, does or is reasonably likely to have a materially adverse effect on us or any of our subsidiaries, taken as a whole, or we have become aware of any fact that, in our reasonable judgment, does or is reasonably likely to have a material adverse effect on the value of the shares; or

Back to Contents

•

we determine that the consummation of the Tender Offer and the purchase of the shares is reasonably likely to cause the shares to be delisted from NASDAQ or to be eligible for deregistration under the Exchange Act.

The conditions referred to above are for our sole benefit and may be asserted by us regardless of the circumstances giving rise to any of these conditions (other than conditions that are proximately caused by our action or failure to act), and may be waived by us, in whole or in part, at any time and from time to time in our reasonable discretion before the Expiration Time. Our failure at any time to exercise any of the foregoing rights will not be deemed a waiver of any right, and each such right will be deemed an ongoing right that may be asserted at any time and from time to time prior to the Expiration Time. Any determination by us concerning the events described above will be final and binding on all parties.

8.	Price Range of the Shares

The shares are traded on NASDAQ under the symbol “SVNT”. The following table sets forth, for each of the periods indicated, the high and low sales prices per share as reported by NASDAQ based on published financial sources.

	High		Low

Year Ending December 31, 2006:
First Quarter	$	5.35	$	3.58
Second Quarter	$	6.13	$	4.90
Third Quarter (through August 11, 2006)	$	5.99	$	5.07

Year Ended December 31, 2005:
First Quarter	$	3.38	$	2.25
Second Quarter	$	4.47	$	2.53
Third Quarter	$	4.79	$	3.38
Fourth Quarter	$	3.99	$	3.00

Year Ended December 31, 2004:
First Quarter	$	5.60	$	3.55
Second Quarter	$	4.19	$	2.20
Third Quarter	$	2.85	$	2.00
Fourth Quarter	$	3.18	$	1.77

On August 11, 2006, the last full trading day before we commenced the Tender Offer, the last reported sales price of the shares reported by NASDAQ was $5.59 per share. We urge stockholders to obtain a current market price for the shares before deciding whether and at what price or prices to tender their shares.

9.	Source and Amount of Funds

Assuming that 10,000,000 shares are purchased in the Tender Offer at the maximum purchase price of $6.80 per share, the aggregate purchase price will be $68,000,000, and the total amount of funds required to purchase such shares and to pay the fees and expenses relating to the Offer is estimated to be $69,366,000.

We anticipate that we will pay for the shares tendered in the Tender Offer, as well as paying related fees and expenses, from our cash and short-term investments.

10.

Information About Savient Pharmaceuticals, Inc.

We are a specialty pharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical products that address unmet medical needs in both niche and wider markets. We currently market one product in the United States, Oxandrin^®, used to promote weight gain following involuntary weight loss. We also have one product in clinical development, Puricase^® (PEG-uricase), intended for treatment-failure gout, which has received “orphan drug” designation by the FDA. We have repositioned our company to focus on our specialty pharmaceutical assets, and particularly on the development of Puricase

Back to Contents

(PEG-uricase), our product candidate for the control of hyperuricemia in patients with treatment-failure gout in whom conventional treatment is contraindicated or shown to be ineffective.

Recent Developments. On August 4, 2006, we sold our wholly-owned subsidiary, Rosemont Pharmaceuticals Ltd, to an entity affiliated with Close Brothers Private Equity for $176 million. The net proceeds from this transaction after taxes and expenses were approximately $140 million.

Where You Can Find More Information. We are subject to the informational filing requirements of the Exchange Act, and, accordingly, are obligated to file reports, statements and other information with the SEC relating to our business, financial condition and other matters. Information, as of particular dates, concerning directors and officers, their remuneration, options granted to them, the principal holders of our securities and any material interest of these persons in transactions with us is required to be disclosed in proxy statements distributed to our stockholders and filed with the SEC. We also have filed an Issuer Tender Offer Statement on Schedule TO with the SEC that includes additional information relating to the Tender Offer.

These reports, statements and other information can be inspected and copied at the public reference facilities maintained by the SEC at 100 F Street, N.E., Room 1580, Washington, D.C. 20549 and at the library of NASDAQ at One Liberty Plaza, 165 Broadway, New York, N.Y. 10006. Copies of this material may also be obtained by mail, upon payment of the SEC’s customary charges, from the Public Reference Section of the SEC at 100 F Street, N.E., Washington, D.C. 20549. The SEC also maintains a web site on the Internet at http:// www.sec.gov that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC.

Incorporation by Reference. The rules of the SEC allow us to “incorporate by reference” information into this Offer to Purchase, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The Tender Offer incorporates by reference the documents listed below, including the financial statements and the notes related thereto contained in those documents that have been previously filed with the SEC. These documents contain important information about us.

SEC Filing (File No. 000-15313)			Period or Date Filed
Annual Report on Form 10-K			Fiscal Year Ended December 31, 2005, filed March 28, 2006

Quarterly Report on Form 10-Q			Fiscal quarter ended June 30, 2006, filed August 9, 2006

			Fiscal Quarter Ended March 31, 2006, filed May 10, 2006

Current Report on Form 8-K			July 11, 2006

			July 11, 2006

			August 10, 2006

			August 11, 2006

You can obtain any of the documents incorporated by reference in this Offer to Purchase from us or from the SEC’s web site at the address described above. Documents incorporated by reference are available from us without charge, excluding any exhibits to those documents. You may request a copy of these filings at no cost, by writing or telephoning us at: Savient Pharmaceuticals, Inc., Attention: Investor Relations Department, One Tower Center, East Brunswick, New Jersey 08816, Telephone: (732) 418-9300. Please be sure to include your complete name and address in your request. If you request any incorporated documents, we will mail them to you by first class mail, or another equally prompt means, within one business day after we receive your request. You can also find copies of our filings with the SEC by visiting our website at: http://www.savientpharma.com. Information contained on our website is not part of, and is not incorporated into, the Tender Offer.

Back to Contents

11.

Interest of Directors and Executive Officers; Transactions and Arrangements Concerning the Shares

As of August 9, 2006, there were approximately 61,870,000 shares of our common stock issued and outstanding. The 10,000,000 shares we are offering to purchase in the Tender Offer represent approximately 16.2% of the total number of issued and outstanding shares as of August 9, 2006.

As of August 9, 2006, our directors and executive officers as a group (14 persons) beneficially owned an aggregate of approximately 1,485,000 shares, representing approximately 2.4% of the total number of outstanding shares. Our directors and executive officers have each advised us that they do not intend to tender any of their shares in the Tender Offer. Accordingly, if we complete the Tender Offer, the proportional holdings of our directors and executive officers will increase to approximately 2.8%, assuming we repurchase 10,000,000 shares. After completion of the Tender Offer, our directors and executive officers may, in compliance with applicable law, sell their shares in open market or other transactions at prices that may or may not be more favorable than the purchase price to be paid to our stockholders in the Tender Offer.

As of August 9, 2006, the aggregate number and percentage of shares of our common stock that were beneficially owned by our current directors, current executive officers and each person who owns (to our knowledge) 5% or more of our outstanding shares were as appears in the second and third columns of the table below. Assuming we purchase an aggregate of 10,000,000 shares in the Tender Offer, and no director, executive officer or any person who owns (to our knowledge based on our review of available Schedule 13D and 13G filings with the SEC) 5% or more of our outstanding shares of common stock tenders any shares in the Tender Offer, the percentage beneficial ownership of each director, executive officer and person who owns (to our knowledge based on our review of available Schedule 13D and 13G filings with the SEC) 5% or more of our outstanding shares after the Tender Offer will be approximately as appears in the table below.

Back to Contents

Unless otherwise indicated, the address of each person listed is c/o Savient Pharmaceuticals, Inc., One Tower Center, East Brunswick, New Jersey 08816.

	As of August 9, 2006
Name of Beneficial Owner	Shares Beneficially Owned (1)		% Beneficially Owned			% Beneficially Owned After Tender Offer (2)(3)

5% Stockholders

Palo Alto Investors (4)		8,844,000		14.29	%		17.05	%
Barclays (5)		4,143,690		6.70	%		7.99	%
Cadence (6)		3,090,178		4.99	%		5.96	%

Directors and Officers
Christopher G. Clement (7)		455,515		*			*
Herbert Conrad (8)		133,919		*			*
Paul Hamelin (9)		12,000		*			*
Brian J. Hayden (10)		—		*			*
Alan L. Heller (11)		10,306		*			*
Zebulun Horowitz, M.D. (12)		167,098		*			*
Steven O. Jaeger (13)		67,547		*			*
Joseph Klein III (14)		35,306		*			*
Robert Lamm (15)		74,654		*			*
Lee S. Simon, M.D. (16)		13,306		*			*
David Tendler (17)		137,757		*			*
Virgil Thompson (18)		135,320		*			*
Faye Wattleton (19)		126,202		*			*
Philip K. Yachmetz (20)		115,808		*			*
All Directors and Executive Officers as a group (14 persons) (21)		1,484,738		2.36	%		2.81	%

*	Less than 1% of the issued and outstanding common stock.

(1)	“Beneficial ownership” generally means any person who, directly or indirectly, has or shares voting or investment power with respect to a security or has the right to acquire such power within 60 days.

(2)	Assumes that the Company purchases 10,000,000 shares in the Tender Offer.

(3)	Assumes the stockholder in question does not participate in the Tender Offer.

(4)

Based solely upon a Schedule 13G filed on April 18, 2006 by Palo Alto Investors, Palo Alto Investors beneficially owns and has sole voting power and dispositive power as to 8,844,000 shares of our common stock. The address of Palo Alto Investors is 470 University Avenue, Palo Alto, California 94301.

(5)

Based solely upon a Schedule 13G filed on January 26, 2006 by Barclays Global Investors, N.A., Barclays Global Fund Advisors, Barclays Global Investors, Ltd. and Barclays Global Investors Japan Trust and Banking Company Limited, to which we refer collectively as Barclays. Barclays beneficially owns 4,143,690 shares of our common stock. Barclays Global Investors, NA has sole voting power as to 1,792,700 shares of our common stock and has sole dispositive power as to 2,050,100 shares of our common stock. Barclays Global Fund Advisors has sole voting power and sole dispositive power as to 2,093,590 shares of our common stock. The address of Barclays is 45 Fremont Street, San Francisco, California 94105.

(6)

Based solely upon a Schedule 13D filed on April 6, 2006 by Cadence Investment Management, LLC, Cadence Onshore, LP, Cadence Investment Partners, LLC, Philip R. Broenniman, Regis Special Situations Fund, L.P., Regis Public Investments, LLC, Regis Management Company, LLC, John Freidenrich, Robert E. Dye and Robert F.X. Burlinson, to which we refer collectively as Cadence. Cadence Investment Management, LLC beneficially owns and has shared voting and dispositive power as to 2,176,254 shares of our common stock. Each of Cadence Onshore, LP and Cadence Investment Partners, LLC beneficially own and has shared voting and dispositive power as to 212,611 shares of our common stock. Philip R. Broenniman beneficially owns and has shared voting and dispositive power as

Back to Contents

to 2,388,865 shares of our common stock. Each of Regis Special Situations Fund, L.P., Regis Public Investments, LLC, Regis Management Company, LLC, John Freidenrich, Robert E. Dye and Robert F.X. Burlinson beneficially own and has shared voting and dispositive power as to 701,313 shares of our common stock. The address of Cadence Investment Management, LLC, Cadence Onshore, LP, Cadence Investment Partners, LLC and Philip R. Broenniman is 800 Third Avenue, New York, New York 10022. The address of Regis Special Situations Fund, L.P., Regis Public Investments, LLC, Regis Management Company, LLC, John Freidenrich, Robert E. Dye and Robert F.X. Burlinson is 300 Hamilton Avenue, Palo Alto, California 94301.

(7)

Includes 309,375 shares of common stock issuable upon exercise of stock options exercisable within 60 days after August 9, 2006. As of August 9, 2006, Mr. Clement had unvested options to purchase 153,125 shares of common stock that do not become exercisable within 60 days of August 9, 2006 and are therefore not included in the above number.

(8)

Includes 107,500 shares of common stock issuable upon exercise of stock options exercisable within 60 days after August 9, 2006. As of August 9, 2006, Mr. Conrad had unvested options to purchase 20,000 shares of common stock that do not become exercisable within 60 days of August 9, 2006 and are therefore not included in the above number.

(9)	As of August 9, 2006, Mr. Hamelin had unvested options to purchase 60,000 shares of common stock that do not become exercisable within 60 days of August 9, 2006 and are therefore not included in the above number.

(10)	As of August 9, 2006, Mr. Hayden had unvested options to purchase 150,000 shares of common stock that do not become exercisable within 60 days of August 9, 2006 and are therefore not included in the above number.

(11)	As of August 9, 2006, Mr. Heller had unvested options to purchase 2,143 shares of common stock that do not become exercisable within 60 days of August 9, 2006 and are therefore not included in the above number.

(12)

Includes 100,000 shares of common stock issuable upon exercise of stock options exercisable within 60 days after August 9, 2006. As of August 9, 2006, Dr. Horowitz had unvested options to purchase 108,000 shares of common stock that do not become exercisable within 60 days of August 9, 2006 and are therefore not included in the above number.

(13)

Includes 40,833 shares of common stock issuable upon exercise of stock options exercisable within 60 days after August 9, 2006. As of August 9, 2006, Mr. Jaeger had unvested options to purchase 21,286 shares of common stock that do not become exercisable within 60 days of August 9, 2006 and are therefore not included in the above number.

(14)	As of August 9, 2006, Mr. Klein had unvested options to purchase 2,143 shares of common stock that do not become exercisable within 60 days of August 9, 2006 and are therefore not included in the above number.

(15)

Includes 55,250 shares of common stock issuable upon exercise of stock options exercisable within 60 days after August 9, 2006. As of August 9, 2006, Mr. Lamm had unvested options to purchase 46,750 shares of common stock that do not become exercisable within 60 days of August 9, 2006 and are therefore not included in the above number.

(16)

Includes 6,500 shares of common stock issuable upon exercise of stock options exercisable within 60 days after August 9, 2006. As of August 9, 2006, Dr. Simon had unvested options to purchase 2,143 shares of common stock that do not become exercisable within 60 days of August 9, 2006 and are therefore not included in the above number.

(17)

Includes 107,500 shares of common stock issuable upon exercise of stock options exercisable within 60 days after August 9, 2006. As of August 9, 2006, Mr. Tendler had unvested options to purchase 20,000 shares of common stock that do not become exercisable within 60 days of August 9, 2006 and are therefore not included in the above number.

(18)

Includes 100,000 shares of common stock issuable upon exercise of stock options exercisable within 60 days after August 9, 2006. As of August 9, 2006, Mr. Thompson had unvested options to purchase 20,000 shares of common stock that do not become exercisable within 60 days of August 9, 2006 and are therefore not included in the above number.

Back to Contents

(19)

Includes 110,625 shares of common stock issuable upon exercise of stock options exercisable within 60 days after August 9, 2006. As of August 9, 2006, Ms. Wattleton had unvested options to purchase 20,000 shares of common stock that do not become exercisable within 60 days of August 9, 2006 and are therefore not included in the above number.

(20)

Includes 48,750 shares of common stock issuable upon exercise of stock options exercisable within 60 days after August 9, 2006. As of August 9, 2006, Mr. Yachmetz had unvested options to purchase 102,750 shares of common stock that do not become exercisable within 60 days of August 9, 2006 and are therefore not included in the above number.

(21)	See footnotes 7 through 20. As of August 9, 2006, our directors and executive officers as a group had unvested options to purchase 728,340 shares of common stock that do not become exercisable within 60 days of August 9, 2006 and are therefore not included in the above number.

Recent Securities Transactions. Based on our records and on information provided to us by our directors, executive officers, affiliates, and subsidiaries, neither we nor any of our affiliates, subsidiaries, directors, or executive officers have effected any transactions involving shares of our common stock during the 60 days prior to August 14, 2006, except as follows:

Stock Option Plans:


		•	On June 30, 2006, pursuant to the 2004 Incentive Plan, we granted to our non-employee directors options to purchase shares of our common stock with an exercise price per share of $5.25, as set forth below:

Name	Shares Underlying Option

Herbert J. Conrad		5,000
Alan L. Heller		2,143
Stephen O. Jaeger		6,286
Joseph Klein III		2,143
Lee S. Simon		2,143
David Tendler		5,000
Virgil Thompson		5,000
Faye Wattleton		5,000


		•	On June 30, 2006, pursuant to a provision of the 2004 Incentive Plan that provides for automatic quarterly grants to non-employee directors, we granted to our non-employee directors shares of our common stock for no purchase price, as set forth below:

Name	Shares

Herbert J. Conrad		714
Alan L. Heller		306
Stephen O. Jaeger		1,061
Joseph Klein III		306
Lee S. Simon		306
David Tendler		714
Virgil Thompson		714
Faye Wattleton		714


		•	On July 5, 2006, we granted to Brian Hayden, our Senior Vice President, Chief Financial Officer and Treasurer, an option to purchase 150,000 shares of our common stock at an exercise price per share of $5.33.


		•	During the 60 days prior to August 14, 2006, we issued 55,833 shares of our common stock upon exercise of stock options outstanding under our equity compensation plans, with a weighted average exercise price of $3.28 per share.

Back to Contents

Stock Purchase Plan:


		•	On July 31, 2006 we issued 36,933 shares of our common stock to employees under the Stock Purchase Plan, for an average purchase price of $2.90 per share, including:

			•	537 shares of our common stock purchased by Robert Lamm, our Senior Vice President, Quality & Regulatory Affairs, at a purchase price of $2.32 per share.

•

2,609 shares of our common stock purchased by Zebulun Horowitz, our Senior Vice President, Chief Medical Officer, at a purchase price of $4.56 per share.


	Other Acquisitions:


		•	Joseph Klein III, who is one of our directors, completed the following transactions involving our common stock, each through a broker and pursuant to a trading plan adopted by Mr. Klein pursuant to Rule 10b5-1 under the Exchange Act: (i) on June 15, 2006, Mr. Klein purchased 3,000 shares at a price per share of $5.71; (ii) on July 3, 2006, Mr. Klein purchased 3,000 shares at a price per share of $5.34, (iii) on July 18, 2006, Mr. Klein purchased 3,000 shares at a price per share of $5.19; and (iv) on August 1, 2006, Mr. Klein purchased 3,000 shares at a price per share of $5.88.


12.	Effects of the Tender Offer on the Market for Shares; Registration under the Exchange Act

The purchase by us of shares in the Tender Offer will reduce the number of shares that might otherwise be traded publicly and may reduce the number of stockholders. As a result, trading of a relatively small volume of the shares after consummation of the Tender Offer may have a greater impact on trading prices than would be the case prior to consummation of the Tender Offer.

We believe that there will be a sufficient number of shares outstanding and publicly traded following completion of the Tender Offer to ensure a continued trading market for the shares. Based upon published guidelines of NASDAQ, we do not believe that our purchase of shares in the Tender Offer will cause the remaining outstanding shares to be delisted from NASDAQ. The Tender Offer is conditioned upon there not being any reasonable likelihood, in our reasonable judgment, that the consummation of the Tender Offer and the purchase of shares will cause the shares to be delisted from NASDAQ. See Section 7.

Our shares are currently “margin securities” under the rules of the Federal Reserve Board. This has the effect, among other things, of allowing brokers to extend credit to their customers using such shares as collateral. We believe that, following the purchase of shares in the Tender Offer, the shares will continue to be “margin securities” for purposes of the Federal Reserve Board’s margin rules and regulations.

The shares are registered under the Exchange Act, which requires, among other things, that we furnish certain information to our stockholders and the Commission and comply with the Commission’s proxy rules in connection with meetings of our stockholders. We believe that our purchase of shares in the Tender Offer pursuant to the terms of the Tender Offer will not result in the shares becoming eligible for deregistration under the Exchange Act.

13.

Legal Matters; Regulatory Approvals

We are not aware of any license or regulatory permit that is material to our business that might be adversely affected by our acquisition of shares as contemplated by the Tender Offer or of any approval or other action by any government or governmental, administrative or regulatory authority or agency, domestic, foreign or supranational, that would be required for the acquisition or ownership of shares by us as contemplated by the Tender Offer that is material to the success of the Tender Offer. Should any such approval or other action be required, we presently contemplate that we will seek that approval or other action where practicable if practicable within the time period contemplated by the Tender Offer. We are unable to predict whether we will be required to delay the acceptance for payment of or payment for shares tendered in the Tender Offer pending the outcome of any such matter. There can be no assurance that any such approval or other action, if needed, would be obtained or would be obtained without substantial cost or conditions or

Back to Contents

that the failure to obtain the approval or other action might not result in adverse consequences to our business and financial condition. Our obligation in the Tender Offer to accept for payment and pay for shares is subject to conditions. See Section 7.


14.	United States Federal Income Tax Consequences

The following describes material United States federal income tax consequences relevant to the Tender Offer for U.S. Holders (as defined below). This discussion is based upon the Internal Revenue Code of 1986, as amended (the “Code”), existing and proposed Treasury Regulations, administrative pronouncements and judicial decisions in effect on the date hereof, all of which are subject to change, possibly with retroactive effect, and to varying interpretations, which could result in United States federal income tax consequences different from those described below.

This discussion deals only with stockholders who hold their shares as capital assets. This discussion does not deal with all tax consequences that may be relevant to all categories of holders (including, without limitation, dealers in securities, foreign currencies, or commodities, traders in securities that elect to mark their holdings to market, financial institutions, regulated investment companies, real estate investment trusts, holders whose functional currency is not the United States dollar, insurance companies, tax-exempt organizations, foreign persons, holders with shares received through the exercise of qualified incentive stock options, holders who may be subject to the alternative minimum tax or personal holding company provisions of the Code, or holders who hold shares as part of a hedging, integrated, conversion or constructive sale transaction or as a position in a straddle). This discussion does not address the state, local, foreign or alternative minimum tax consequences of participating in the Tender Offer. Holders of shares should consult their tax advisors as to the particular consequences to them of participation in the Tender Offer.

As used herein, a “U.S. Holder” means a beneficial holder of shares that is for United States federal income tax purposes: (a) an individual citizen or resident of the United States, (b) a corporation, partnership, or other entity created or organized in or under the laws of the United States, any state thereof or the District of Columbia, (c) an estate the income of which is subject to United States federal income taxation regardless of its source, or (d) a trust the income from which is subject to United States federal income taxation regardless of source. The term also includes nonresident alien individuals, foreign corporations, foreign partnerships, and foreign estates and trusts (“foreign stockholders”) to the extent that their ownership of the shares is effectively connected with the conduct of a trade or business within the United States, as well as certain former citizens and residents of the United States who, under certain circumstances, are taxed on income from U.S. sources as if they were citizens or residents. It should also be noted that certain “single member entities” are disregarded for U.S. federal income tax purposes. Such foreign stockholders that are single member non-corporate entities should consult with their own tax advisors to determine the U.S. federal, state, local, and other tax consequences that may be relevant to them.

FOREIGN STOCKHOLDERS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE UNITED STATES FEDERAL INCOME TAX CONSEQUENCES AND ANY APPLICABLE FOREIGN TAX CONSEQUENCES OF THE TENDER OFFER AND ALSO SHOULD SEE SECTION 3 FOR A DISCUSSION OF APPLICABLE UNITED STATES WITHHOLDING RULES AND THE POTENTIAL FOR OBTAINING A REFUND OF ALL OR A PORTION OF ANY TAX WITHHELD.

If a limited liability company or partnership holds shares, the tax treatment of a member or partner will generally depend upon the status of such person and the activities of the limited liability company or partnership. A U.S. Holder that is a limited liability company or partnership should consult its own tax advisors regarding the treatment of its members or partners.

Non-Participation in the Tender Offer. U.S. Holders that do not participate in the Tender Offer will not incur any tax liability as a result of the consummation of the Tender Offer.

Exchange of Shares Pursuant to the Tender Offer. An exchange of shares for cash pursuant to the Tender Offer will be a taxable transaction for United States federal income tax purposes. A U.S. Holder that participates in the Tender Offer will be treated, depending on such U.S. Holder’s particular circumstances,

Back to Contents

either as recognizing gain or loss from the disposition of the shares or as receiving a dividend distribution from the Company.

Sale or Exchange Treatment. Under Section 302 of the Code, a U.S. Holder whose shares are exchanged in the Tender Offer will be treated as having sold such U.S. Holder’s shares, and thus will recognize capital gain or loss if the exchange (a) results in a “complete termination” of all such U.S. Holder’s equity interest in the Company, (b) results in a “substantially disproportionate” redemption with respect to such U.S. Holder, or (c) is “not essentially equivalent to a dividend” to the U.S. Holder. In applying the Section 302 tests, a U.S. Holder must take into account not only the shares that the U.S. Holder actually owns, but also stock that such U.S. Holder constructively owns under attribution rules, pursuant to which the U.S. Holder will be deemed to own Company shares owned by certain family members (except that in the case of a “complete termination” a U.S. Holder may waive, under certain circumstances, attribution from family members) and related entities and Company stock that the U.S. Holder has the right to acquire by exercise of an option.

An exchange results in a “complete termination” of a U.S. Holder’s equity interest in the Company if all of the shares that are owned or deemed owned by the U.S. Holder are exchanged in the Tender Offer.

An exchange of shares for cash will be a “substantially disproportionate” redemption with respect to a U.S. Holder if (i) the percentage of the then-outstanding voting shares owned or deemed owned by such U.S. Holder in the Company immediately after the exchange is less than 80% of the percentage of shares owned or deemed owned by such U.S. Holder in the Company immediately before the exchange.

If an exchange of shares for cash in the Tender Offer does not qualify as a “complete termination” of the U.S. Holder’s interest in the Company and also fails to satisfy the “substantially disproportionate” test, the U.S. Holder nonetheless may satisfy the “not essentially equivalent to a dividend” test. An exchange of shares for cash will satisfy the “not essentially equivalent to a dividend” test if it results in a “meaningful reduction” of the U.S. Holder’s equity interest in the Company. An exchange of shares for cash that results in a reduction of the proportionate equity interest in the Company of a U.S. Holder whose relative equity interest in the Company is minimal (e.g., an interest of less than one percent) and who does not exercise any control over or participate in the management of the Company’s corporate affairs may constitute such a meaningful reduction. A U.S. Holder should consult its tax advisor regarding the application of the rules of Section 302 in such U.S. Holder’s particular circumstances.

If a U.S. Holder is treated as recognizing gain or loss from the disposition of such U.S. Holder’s shares for cash, such gain or loss will be equal to the difference between the amount of cash received and such U.S. Holder’s adjusted tax basis in the shares exchanged therefor. Any such gain or loss will be capital gain or loss and will be long-term capital gain or loss if the U.S. Holder has held the shares for more than one year as of the date of the exchange. Specific limitations may apply to the deductibility of capital losses by U.S. Holders. Calculation of gain or loss must be made separately for each block of shares owned by the U.S. Holder. Under the tax laws, a U.S. Holder may be able to designate which blocks and the order of such blocks to be exchanged pursuant to the Tender Offer. Under current law, non-corporate U.S. Holders generally will be subject to United States federal income tax at a minimum rate of 15% on long-term capital gain. Short-term capital gain and ordinary income are subject to a tax at a maximum of 35%.

Dividend Treatment. If a U.S. Holder does not meet the requirements of Section 302 of the Code, the exchange of the U.S. Holder’s shares by the Company in the Tender Offer will not be treated as a sale or exchange under Section 302 of the Code with respect to the U.S. Holder. Instead, the cash received by such U.S. Holder pursuant to the exchange will be treated as a distribution, taxable as a dividend to the extent of the portion of the Company’s current and accumulated earnings and profits allocable to such shares. To the extent that amounts received pursuant to the Tender Offer exceed a U.S. Holder’s allocable share of the Company’s current and accumulated earnings and profits, the distribution will first be treated as a non-taxable return of capital, causing a reduction in the adjusted tax basis of such U.S. Holder’s shares, and any amounts in excess of the U.S. Holder’s adjusted tax basis will constitute capital gain. Any remaining adjusted tax basis in the shares tendered will be transferred to any remaining shares held by such U.S. Holder. The amount of the current and accumulated earnings and profits of the Company has not been established.

Back to Contents

Provided certain holding period requirements are satisfied, non-corporate U.S. Holders generally will be subject to United States federal income tax at a maximum rate of 15% on amounts treated as dividends, i.e., the entire amount of cash received without reduction for the tax basis of the shares exchanged.

To the extent that cash received in exchange for shares is treated as a dividend to a corporate U.S. Holder, it may be (i) eligible for a dividends-received deduction (subject to applicable limitations) and (ii) subject to the “extraordinary dividend” provisions of Section 1059 of the Code. Corporate U.S. Holders should consult their tax advisors concerning the availability of the dividends-received deduction and the application of the “extraordinary dividend” provisions of the Code in their particular circumstances.

We cannot predict whether or the extent to which the Tender Offer will be oversubscribed. If the Tender Offer is oversubscribed, proration of tenders pursuant to the Tender Offer will cause the Company to accept fewer shares than are tendered. Therefore, a U.S. Holder can be given no assurance that a sufficient number of such U.S. Holder’s shares will be purchased pursuant to the Tender Offer to ensure that such purchase will be treated as a sale or exchange, rather than as a distribution, for United States federal income tax purposes pursuant to the rules discussed above.

See Section 3 with respect to the application of United States federal income tax withholding and backup withholding.

THE FEDERAL TAX DISCUSSION SET FORTH ABOVE MAY NOT BE APPLICABLE DEPENDING UPON A HOLDER’S PARTICULAR SITUATION. HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISORS CONCERNING THE TAX IMPLICATIONS OF THE TENDER OFFER UNDER APPLICABLE FEDERAL, STATE OR LOCAL LAWS. FOREIGN STOCKHOLDERS SHOULD ALSO CONSULT THEIR OWN TAX ADVISORS REGARDING THE TAX CONSEQUENCES UNIQUE TO HOLDERS WHO ARE NOT U.S. PERSONS.

CIRCULAR 230 NOTICE. TO ENSURE COMPLIANCE WITH REQUIREMENTS IMPOSED BY UNITED STATES TREASURY REGULATIONS, STOCKHOLDERS SHOULD NOTE THAT: (1) ANY UNITED STATES FEDERAL TAX ADVICE CONTAINED HEREIN IS NOT INTENDED OR WRITTEN TO BE USED, AND CANNOT BE USED, BY ANY TAXPAYER FOR THE PURPOSE OF AVOIDING UNITED STATES FEDERAL TAX PENALTIES THAT MAY BE IMPOSED ON THE TAXPAYER; (2) ANY SUCH ADVICE IS WRITTEN TO SUPPORT THE PROMOTION OR MARKETING OF THE TENDER OFFER; AND (3) EACH TAXPAYER SHOULD SEEK ADVICE BASED ON THE TAXPAYER’S PARTICULAR CIRCUMSTANCES FROM AN INDEPENDENT TAX ADVISOR.

15.

Extension of the Tender Offer; Termination; Amendment

We expressly reserve the right, in our sole discretion, at any time and from time to time, and regardless of whether or not any of the events described in Section 7 shall have occurred or shall be deemed by us to have occurred, to extend the period of time during which the Tender Offer is open and thereby delay acceptance for payment of, and payment for, any shares by giving oral or written notice of such extension to the Depositary and making a public announcement of such extension. We also expressly reserve the right, if any event described in Section 7 has not occurred or has occurred, to terminate the Tender Offer and reject for payment and not pay for any shares not theretofore accepted for payment or paid for or, subject to applicable law, to postpone payment for shares by giving oral or written notice of such termination or postponement to the Depositary and making a public announcement of such termination or postponement. Our reservation of the right to delay payment for shares which we have accepted for payment is limited by Rule 13e-4(f)(5) promulgated under the Exchange Act, which requires that we must pay the consideration offered or return the shares tendered promptly after termination or withdrawal of a tender offer. Subject to compliance with applicable law, we further reserve the right, in our sole discretion, and regardless of whether any of the events described in Section 7 shall have occurred or shall be deemed by us to have occurred, to amend the Tender Offer in any respect, including, without limitation, by decreasing or increasing the consideration offered in the Tender Offer to holders of shares or by decreasing or increasing the number of shares being sought in the Tender Offer. Amendments to the Tender Offer may be made at any time and from time to time effected by public announcement, such announcement, in the case of an extension, to be

Back to Contents

issued no later than 9:00 a.m., New York City time, on the next business day after the last previously scheduled or announced Expiration Time. Any public announcement made in the Tender Offer will be disseminated promptly to stockholders in a manner reasonably designed to inform stockholders of such change. Without limiting the manner in which we may choose to make a public announcement, except as required by applicable law, we shall have no obligation to publish, advertise or otherwise communicate any such public announcement other than by making a release through PR Newswire or another comparable service. In addition, we would file such press release as an exhibit to the Schedule TO.

If we materially change the terms of the Tender Offer or the information concerning the Tender Offer, we will extend the Tender Offer to the extent required by SEC rules. These rules and certain related releases and interpretations of the Commission provide that the minimum period during which a tender offer must remain open following material changes in the terms of the Tender Offer or information concerning the Tender Offer (other than a change in price or a change in percentage of securities sought) will depend on the facts and circumstances, including the relative materiality of such terms or information; however, in no event will the Tender Offer remain open for fewer than five business days following such a material change in the terms of, or information concerning, the Tender Offer. If (1)(i) we increase or decrease the price to be paid for shares beyond the range, (ii) decrease the number of shares being sought in the Tender Offer, or (iii) increase the number of shares being sought in the Tender Offer by more than 2% of our outstanding shares (or approximately 1,200,000 shares) and (2) the Tender Offer is scheduled to expire at any time earlier than the expiration of a period ending at 12:00 midnight, New York City time, on the tenth business day from, and including, the date that such notice of an increase or decrease is first published, sent or given to stockholders in the manner specified in this Section 15, the Tender Offer will be extended until the expiration of such period of ten business days.

16.

Fees and Expenses

We have retained Citigroup Global Markets Inc. to act as the Dealer Manager in connection with the Tender Offer. In its role, Citigroup Global Markets Inc. may contact brokers, dealers and similar entities and may provide information regarding the Tender Offer to those that it contacts or persons that contact it. The Dealer Manager will receive reasonable and customary compensation. We also have agreed to indemnify the Dealer Manager against certain liabilities in connection with the Tender Offer, including certain liabilities under the federal securities laws.

The Dealer Manager and its affiliates have provided, and may in the future provide, various investment banking and other services to us for which future services we would expect they would receive customary compensation from us. In the ordinary course of business, including in their trading and brokerage operations and in a fiduciary capacity, the Dealer Manager and its affiliates may hold positions, both long and short, for their own accounts and for those of their customers, in our securities.

We have retained MacKenzie Partners, Inc. to act as Information Agent and American Stock Transfer & Trust Company to act as Depositary in connection with the Tender Offer. The Information Agent may contact holders of shares by mail, facsimile and personal interviews and may request brokers, dealers, commercial banks, trust companies and other nominee stockholders to forward materials relating to the Tender Offer to beneficial owners. The Information Agent and the Depositary will each receive reasonable and customary compensation for their respective services, will be reimbursed by us for reasonable out-of-pocket expenses and will be indemnified against certain liabilities in connection with the Tender Offer, including certain liabilities under the federal securities laws.

We will not pay any fees or commissions to brokers, dealers or other persons (other than fees to the Dealer Manager and the Information Agent as described above) for soliciting tenders of shares in the Tender Offer. Stockholders holding shares through brokers or banks are urged to consult the brokers or banks to determine whether transaction costs may apply if stockholders tender shares through the brokers or banks and not directly to the Depositary. We will, however, upon request, reimburse brokers, dealers and commercial banks for customary mailing and handling expenses incurred by them in forwarding the Tender Offer and related materials to the beneficial owners of shares held by them as a nominee or in a fiduciary capacity. No broker, dealer, commercial bank or trust company has been authorized to act as our agent or the agent of the

Back to Contents

Dealer Manager, the Information Agent or the Depositary for purposes of the Tender Offer. We will pay or cause to be paid all stock transfer taxes, if any, on our purchase of shares, except as otherwise provided in Instruction 7 in the Letter of Transmittal.


17.	Miscellaneous

Pursuant to Rule 13e-4(c)(2) under the Exchange Act, we have filed with the Commission an Issuer Tender Offer Statement on Schedule TO, which contains additional information with respect to the Tender Offer. The Schedule TO, including the exhibits and any amendments and supplements thereto, may be examined, and copies may be obtained, at the same places and in the same manner as is described in Section 10 with respect to information concerning us.

This Offer to Purchase and the Letter of Transmittal do not constitute an offer to purchase securities in any jurisdiction in which such offer is not permitted or would not be permitted. If we become aware of any jurisdiction where the making of the Tender Offer or the acceptance of shares pursuant thereto is not in compliance with applicable law, we will make a good faith effort to comply with the applicable law where practicable. If, after such good faith effort, we cannot comply with the applicable law, the Tender Offer will not be made to (nor will tenders be accepted from or on behalf of) the holders of shares in such jurisdiction.

You should only rely on the information contained (or incorporated by reference) in this Offer to Purchase or to which we have referred to you. We have not authorized any person to make any recommendation on behalf of us as to whether you should tender or refrain from tendering your shares in the Tender Offer. We have not authorized any person to give any information or to make any representation in connection with the Tender Offer other than those contained in this Offer to the Purchase or in the Letter of Transmittal. If given or made, any recommendation or any such information or representation must not be relied upon as having been authorized by us, the Dealer Manager, the Depositary or the Information Agent.

Savient Pharmaceuticals, Inc.

August 14, 2006

Back to Contents

The Letter of Transmittal, certificates for shares and any other required documents should be sent or delivered by each stockholder of the Company or his or her bank, broker, dealer, trust company or other nominee to the Depositary as follows:

The Depositary for the Tender Offer is:

American Stock Trust & Trust Company

By Mail:

American Stock Transfer
& Trust Company
Attention: Operations Center
59 Maiden Lane
New York, New York 10038

By Hand or Overnight Courier:

American Stock Transfer
& Trust Company
Attention: Operations Center
6201 15^th Avenue
Brooklyn, New York 11219

Delivery of the letter of transmittal to an address other than as set forth above will not constitute a valid delivery to the Depositary.

Questions and requests for assistance may be directed to the Information Agent, or to the Dealer Manager, at their respective and telephone numbers set forth below. Requests for additional copies of this Offer to Purchase, the related Letter of Transmittal or the Notice of Guaranteed Delivery should be directed to the Information Agent.

The Information Agent for the Tender Offer is:

105 Madison Avenue
New York, New York 10016
(212) 929-5500 (Call Collect)
E-mail: proxy@mackenziepartners.com
or
CALL TOLL-FREE (800) 322-2885

The Dealer Manager for the Tender Offer is:

Citigroup Global Markets Inc.
Special Equity Transactions Group
390 Greenwich Street, 5th Floor
New York, New York 10013
(877) 531-8365 (toll free)
(212) 723-7236 (collect)

GRAPHIC 5 citigrouplogo.jpg GRAPHIC begin 644 citigrouplogo.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#`!`+#`X,"A`.#0X2$1`3&"@:&!86 M&#$C)1TH.C,]/#DS.#=`2%Q.0$17137!D>%QE9V/_ MVP!#`1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P``1"`!.`1H#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#T"BBB@`HH MHH`****`"BBB@`HIKND:%Y&55'4L<`5%!>6UR2+>XBE(Z['#8_*@">BHA<0& M5HA-'YBC)7<,C\*Q9O$`'B*WL4D@^RE2SR[@"<_*#_6L.X\07TXPS(H#! ML*O<'(_45=A\-0W,/F6VI1S>ZJ",_4&D?PZEK;B6[G8DLJ[8ATR<=30!';^* M+R-AYR1RKWXP:Z/3=3M]1BW0G#C[R'J*PV\)R>=A;I?*]2OS#\*LVOAZ:PNH M[BVNPS*>59,!AW&+M89'E>*RA0-L4_YYSGFM5/"5M;W<%Q9W$T)C8%ANSN%96V M7PCK#2B)I;*9`N1V_P#KY_G6G'XNANKR"WLK6:4R,`Q(P0*`*EDH?QW?H>C1 ML#^2U1ET*S3Q9!IH\SR'C+'YN<[2>OX5H:?_`,C_`'O^X?Y+3-;N5TSQC:WT MZL8/*QE1[,/ZT`+XQM8[+0;*VASY<)5"/CMU'\C^E`$7 MB/PY9V&DRW5F9(C'M#+N)#@L!S_.JFMJSZ'H"(<,RX!]#\M6?$/B2VU'29;: MTBE??M+NRX"`,#_,8J'5/^05X<_#_P!EH`T[G1;#0+)]2A#O<6Z_*SMD%C\H M)'U-5]#\.V^IZ>+_`%%I)9K@EL[R,#.*Z+5[+^T-+N+4'!D7Y3[CD?J*YK1? M$<6DV/\`9^HQ2I+;D@87.1G-`$-HTVDW^IZ.TC20&WD:/=V^3(_3K6KX%_Y` M;_\`7=OY"L[2;:?7-6OM3D0QQ21-''GW7:/TIGAW6X=#@GL-1CDC=9"PPN>P M&/TH`M6__)1+C_<_]D6L[PMHUOJIN6NV=HXF`$8;`).>34VBW?V_QM)=;"@D M0E5;KC:`/TJOX8UJ'26N5N8W\J5A\ZC.",\4`7&M_P#A'?%5I':.PMKO"LA. M>IQ^G!KI-;_X\D_Z[1_^A"N<\\^)/$]K-:QL+6TPS.PQT.?UXK9O[V.ZMO+& M%E6Z6/RR>3ANN*`-JBDI:`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`&NBNNUU##T(ID5M!"28HD0G^ZN*EHH`8(HQ(9`BASU;'-)+#%, M`)8U<#IN&:DHH`C:&)D"-&I4=`1P*0V[!9'PQ&<`9./ M6@#E[ZUU35-UA#I\=G;;_GD'\6#_`)-=1;V<4-K!!M#+"@52P]!39-0MHFVO M)C`!)P<#/3/I3FO8%G\@OF3C*@9QGI0!8J&6TMYF#2PQN1W95YGS;MO3C/IF@"=555"J``.PJ.6TMYG#RPQNP[E_MXU4LY^89`P?RYV#E%B6/>6+)+Z(V\CM.2T>%R&RH&#Z8(Q4MA; MO!=7.\$_NXE#_P!["G-7%N[=M^V9#L^]STISRQH2'=5^4MR>WK0!C6!:YT_2 M8DB=3$(W9BN``%ZY]_ZT]$D-C'8>2_FK*N6QQ@/G=GZ#\S6E#/:I:@Q2((8@ M%&#PH'05%/J5O$;006X(]\U/)'):Z/LLP^Y5&T'E@,\_CC-6DNH'1G29 M"J?>(/2F/?6XAFD656\I26`-`&3<023"\,2W$BO9L@,G4MGH*MZM;2SN!"F< MVLR>V3LP/QP:NVEPEU;1S(00R@G!Z''2H['4(;R"!@ZB26-9/+SR,C-`$"2F MYU*VD2"142-PQ9<8)V\?I6E4*74$DIC256 MM+%-',"8G5P#@D'H>O\`6@"2BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@ M`HHHH`****`"L76T9DO]JDYLB!@=3DUM4E`&;=VB2WL4(3;&]K+&2HZ?NCMI;CRRD5V09E7"N/+;YOS./J*VZ*`,26W5[/4MT62]T#TY(^2GZI M!(SW:VZX9K51\HZX8Y'OQFMBB@#GYH?/M[J9;I)\6QC*1Q;1S@C/)Y&#Q[U= MOH?]-01Q\&TF4X'NF!_.M.B@"KI;QOIUN8R"!&H./7'-9=DT;Z?I4,*?Z1$$ M9EQ@KA.<_7I^-;U%`&%;R-/=:;(9@[^8QDC6/'EDQOP?3GUJ2U@":7I.(]KJ MZ$\ GRAPHIC 6 mackenzielogo.jpg GRAPHIC begin 644 mackenzielogo.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#`!`+#`X,"A`.#0X2$1`3&"@:&!86 M&#$C)1TH.C,]/#DS.#=`2%Q.0$17137!D>%QE9V/_ MVP!#`1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P``1"``W`/<#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#T"BBB@`HH MHH`****`,S7MI/ M:@#L'ECCQYDBKG^\<56U'4H-/TV:^D8-%$N3M(Y/8#W)XK)T[P?IT$0?4$.H M7;#]Y-.2V3[`_P#ZZY3QKI]GH,)M;`N@OG$CQ[LJBKV'U)S_`,!H`[/P[XCB M\0"9K>VFB2'`+28Y)[#%%QXCMTU9=,M();VY_P"6GE8VQ?[Q/2N,\-7TMS90 M>'])E^S2S;I;JZ(Y'J$'KC`S_P#KKKIH++PEX;N9;1,,B$[V.6D<\`D_4T`; M7VF`<&:,'N-XI5FB8965"/9A7FO@K0-/U6VN;O5L."X6,-(5.>K'KSU'Y&JW MC2UM+&=-/TJ%EMK<>;,0Q8!W`QG/L!^?O0!ZO32R@X+`'ZU@^#-:_MC1$,KY MN;?]W+GJ?1OQ'ZYJEH^GP:_CJ MP1SB64MP!)+C&?HNW]:]"LO"WAD31O;012S1$."+AFY'N<\82&Z6QT6-L M/J$P#X[1KRQ_E0!ROB&QD3P5:7TXS<75V;B4X/&]3CZ#`6G^#=*NM;M88[[( MTBTD+K'C'G.?7U`_SWKI_''V2+PQ(+E&,:L@C1&"DG/`R0>V:RCXCU+2_#MI M?1Z5:PV#@)&BRG>HYP>G?'O0!@.1K7Q%4`_N_M0`]-L?^(7]:Z>\OK[Q#JFW M2;>&XL+"3YS,Y5)91TZ=0.OZ^E5-"$Z;=V5O?PWMY!+<1$[=Z%@""&P=OU& M:ZZQM;/2+&&SA*11QC`W$`MZD^]`'F^OS7K>-K-]0CABG1X>(F++C=D')J?P M(WG>,[F6[`$Y25L'LY89_0M75ZGX9TK5=3&ISW5:JW_``D_CL6Z-F'S!"IS M_`O+$?\`CQKN8?#=LS^;<7][>R+S&TT^X1G'#*!QD=>0>:BT;PKI>@7YNH;B M9I?+*XF=<`$CG@#TH`\_B_XISQJ`?ECM[G')Z1GC_P!!-=+\3=1/EVFF1'+. M?.<`\XZ*/SS^0K7U?PIHVMZB;N:ZE29P%(AD0!L<`\@\_P"%1W_A+2=2O%N9 M]2NC,%5`5F08V@`8^7VS]:`&VG@W0[32(IM2M`TT46^>0RN!D#)XR!BF^'-, MCUC1=1N[V/\`Y"LC$9'*(.$Q]#T_"K7_``BEG#;7"3:IJ+1S)Y;&6X!VC()Q MD8YQCZ$UN6,,%M90P6I!AB0(F#G@<=:`/(+6ZU'PSJEY:1#]\RM`RCN3]UA[ M\@BNIU76_P"P]+MO#NC_`+R^"".1XQG:QZX_VB2?I6_K?AK3;^\&J7,DT$L" M9+Q,!]WD,<@\C^EZ@BB(P_G+N9B>!]WKP:`.Q$>%H]%B^ MTW6)+^0?,W41CT']37+^(IX];\<"!V_T2T^60YX"H"TA]NX_`5U-MX,LK:YB MG_M#47\I@^V2<%3@YY^7I3T\(:3%]IEW3YN4*RN9>H)!//OB@#D?"6GIXE\1 M7E]?PB2!Q;^(_S_`#%;^IO(++5=2L[6">R&G:;:[52+S%>25L;5"@=^P^I)JSHN@:G-XPGUC5;;R8\ ML\0,BL<]%'RD]!_*MJ;29=9U%YM362*VMSMM84EVDGO(2IZGH!V&?6@#E?#< M$]GX_P#LEPPW0V^P*IR$78"%'TSU[]>],UG5=.O/'#OJC[K"R0QJFTL)&`Y& M![D_]\BKQ\/:KI_C"74-.M));58V\MGN`2Q,6`#N;/WO6H#X.OCX0>-H-VJ/ M$[^ZT+Q&+74@434% M5FW?WFY5OUP?K[4WQ??->7-S)'E_M$HM8%`R3'&.?#DNLVL, M]C$'O(3MVY"[D/;)XXZ_G6.OA_6+'7;.>'2A=VMC&J1*)TCW'&2W)_O$GIZ4 M`3W)T32_#TUY863QWD,8ACFEB9&+L,9&[J<9-<_;:=;:MI%EI^DP>?J6\RW, M^TJL2G(VDG\/RXKK-:]!TRRL[&T$=A&L<#DR`+T.[G-3\Q`^F/RK:T72F@TVXBOHT,EW([S(#N`4\!?H%`%`&#?\`B6/4 M?!4;E]L]R?(F"]5P,R''^Z"?Q%'ABP?Q$IU/506LT/EVEGG]TJKQG'?TY]#[ M52TWP+=1W&J1S[5C\MH[21F!W$_Q''(X&#QWK7\-_P!MZ/IBZ;-HS2F)F$<]SV_"@#;M]"TRUU!;ZVLXH9E0H/+4*,'O@<9]ZT:S=.?6'NYO[1 MBM([<`>4(6);/?)/;\!6E0`4444`%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`V2-)%VNH9<@X/MS3J**`"BBB@`HHHH`** 5**`"BBB@`HHHH`****`"BBB@#__9 ` end GRAPHIC 7 savientlogo.jpg GRAPHIC begin 644 savientlogo.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#`!`+#`X,"A`.#0X2$1`3&"@:&!86 M&#$C)1TH.C,]/#DS.#=`2%Q.0$17137!D>%QE9V/_ MVP!#`1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P``1"`!,`/P#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#T"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`$HJGK,\EKHU]<0MMEBMY'1L9P0I(-36; MM+9P2.BYCU6QD/H\.W^0J?PGKLFM6DZW2(EW;2>7*$Z M'T(_(_E0!OTE!(4$DX`ZFN"O_%FKW5U?SZ*L+6%B!O9EW;QG&?Y_@*`.]HJI MI6HP:KI\-Y;,"DBY(SRI[@^XK$TO6KZ#Q+/HNKE69AOMI0H7>OT]QG\C0!T] M)15+6-2ATC3)[V?[L8X7NS'H/SH`NT5S>B7VKR^'+G5-1DBWO$TMNBQXV@`D M$^N>./3Z\3>%M5NM4\.F]NF4S!G&57`XZ<4`;U+7":#J/BK7K-[JUN[&-$D, M9$D9!R`#V!]:T_LOC/\`Y_\`3/\`OAO_`(F@#IZ*Q-*@\1I>AM4N[*6VPV]A"MQ;6>R1X@@W%,+GGKW[=*`.XI:S=$UNSUNT$]J MXW`#S(B?F0^X_K6C0`45@1:M=/XVFTLLOV5+82`;>=W'?\:97'G&,=<@>HK7^R^,_ M^?\`TS_OAO\`XF@#IZ6J>EI?1V2+J(M%U+_A(+37-(CBE MFA3:\3MMW=1WXZ$CKZ4Y=9\4`8?PXA/^S)H MX6.T'##)'3N#D^E7%\<^'R`3>.">QA?C]*`(7UKQ0/F'AM=HZCSP2:O^&];L MM82?[/;&UN8B!/$R8()SW[\@^]5)O'F@QQEDN)96'1$B8$_G@?K6=X6$MK-K M/B+4(FM;:"?QZ?GZ5 MJZ)I$6DZ/%8[4?"_O3MX=CU)]?3Z5Q^B:+>^)[J?6[^[NK4LQ%N8CM8+SP#V M49Q[\UN?\(A)_P!#!J__`'_H`S=&F/A/Q'-HUT_^@WA$ELYZ*Q.`#_(_0>M7 M_'>C2:AIZ7MFK&\M#N79PQ7OCW'4?C535_`KW-F[)JE['H#Z]S^)H`U=618]#O410JK;.``,` M#:>*P/`?_(G-_OR5T.K@MH]Z%!),$@`'?Y37/^!%(\'D$'):3'%`&#X*O-#/%%AH>ER MVUXDY=YC(#&@(QM4>OL:Z#_A86B_W+O_`+]#_&@#2T>]UVXNV35-+CM(`A(= M9E#6M!(AO8\NZ+UD8]2,\9P3D=Z`'V__)3K MG_KS'_LM==7`>&-3;5_',MV\#0O]DV.A[,-H/ZUW]`'!?$O_`(^M&_WI/YI7 M>5PGQ*!-UHV`3\TG3ZI7=T`+1110`4444`%%%%`"5FRZN\H/M)&Y8U M(/N/FZ5I44`>1ILFNKR5HBI:YD.UU^8<]#[U)&$AO[&58BQ6ZB.U%&X_,.![ MUO:IX3N+.'4=034(RH\RXV&$Y[MC.ZI;#PA.?8(2"<$'&=U` M'0?VP_\`T"=2_P"_2_\`Q5+_`&R__0(U+_OTO_Q5%]J%Y%J*65E91W#&$RLS MS^6``<8^Z<]:KQZ_,M\EE=V(AG,ZQ';-O4!D+!@<#/W2,4`6/[9?_H$:E_WZ M7_XJC^V7_P"@3J7_`'Z7_P"*J[+=".Y@AQN,Q89!Z8&:J)JP?66L3"1%@JL^ M[AY``2@'J`<_@?2@!O\`;+_]`G4O^_2__%4?VR__`$"=2_[]+_\`%5$-5U&> MZNX[+3H98[:7RB\ET4+':#TV'U]:(M>)GL(KBS>+[4&#D,&$+@[0I/<$Y&?7 M'K0!+_;+_P#0)U+_`+]+_P#%4?VR_P#T"=2_[]+_`/%4:MK*Z?=6MLD/GR32 M(K@/CRD9@H<\>IQCOSZ4M]K*66I0VTD1\EQF6X)PD1)(0'ZD$>W%`"?VR_\` MT"=2_P"_2_\`Q5']LO\`]`G4O^_2_P#Q5%SJ5W_:;V-C9QSM%$LDCR3^6!N) M``PIR>#4,NKZC#MBDTM%N'G$48^T?NW!1FW!MO\`LD8Q0!-_;+_]`G4O^_2_ M_%4?VR__`$"=2_[]+_\`%4J:A?1IOO;*&)3)&B^7<;R2SA?[HZ9S5J]NFM5A MVQ^8TL@C`W8P3G_"@"I_;+_]`G4O^_2__%4?VR__`$"=2_[]+_\`%5"NIZPU MV]L-)MMZ1K(3]M.,$D#^#_9-+_;-S-)'%9V*RRM+.A#S[%58VVEB=IZDCC'? M\:`)?[9?_H$ZE_WZ7_XJC^V7_P"@3J7_`'Z7_P"*J:SN[Q[B2*^LTMPJ!UDC ME,B-R0025&".#^-0:1KL6JW,\20R1JOS0R-TGCR1O'XC\B#WH`7^V7_Z!.I? M]^E_^*H_ME_^@3J7_?I?_BJN6=T+FR2Y*E`RYVYSBLJ+6=3N+!;ZVTJ*2%U\ MQ$^UXD9>WR[,9QVS0!9_ME_^@3J7_?I?_BJ/[9?_`*!.I?\`?I?_`(JM-3N4 M'!&1G!K%E\1+#/`LELPA=IQ)*K9\H1R;-Q&.A)&?2@"?^V7_`.@3J7_?I?\` MXJC^V7_Z!.I?]^E_^*J2^U5+*_LK5T+"Z$AW@_="+N/'>J<6K:O-IRWT6D0L MCQ^:D?VL[V&,CC9C)';-`&O:SFY@64PRPDY^24`,/R)J:FQMO16P1N`.",$4 MZ@`HHHH`****`"DI:*`*NI6IO=,NK56"M/"\88CID$9_6I;:(PVT41.2B!<^ MN!4M%`&9=Z-;7VII=7<44Z)"8Q')&&`.[.>?RIEQH-FYM%M[>W@A@G\YXUB& MV3Y2O3\1^5:U%`&=-I<:RQSV4=O!-&&VGRA@DC`SC'%46\,1BQCABO;E)8F\ MV-]V0LO)W8[\D\>];]%`&/!X=LC<7<][;6UU)<3&0-)""5&T#;DY[@G\:X2\NII'NF+7`0[4O85N MT4`8:Z3>FWEC,FGQ.6C=&@M2F&5PPW?-R./;K4JV6JSW$!OKFT,,4@DVPPLK M$@'')8\<^E:]%`%9;8KJ,MUNX>)(]N.FTL<_^/?I6<-)O+=A+974*S"2=CYL M192LCA\<,.1@12I=ZE&BR*(RMM$5&TD%NI/S$#`/;)J0Z($ MEM9H;N?S+9AL$C;EV]&7''4<>W!K6HH`Q[6RU>U2.%;RR,"''_'NV_;GUWXS M^%4+GPW=W$,L$C:6XD4H;A[+,QR,;LAL;O?UKIZ*`*UG'-"KQRLK(I"Q$==H M51\WOG=^&*J6ND^3=I,T@=5%P"I7KYL@?],8]ZU**`.?/AH)J=O+!<".Q@\S M;;;,[2ZX;:V>!WQ]:DM[#7+:SCM(K^Q$<<8B60VS;P`,`_?QFMRB@".%&2,* 2[[R!C<1R?K4E%%`!1110!__9 ` end EX-99.A(1B) 8 b414446_exa1b.htm EXHIBIT (A)(1)(B) Prepared and filed by St Ives Burrups

Back to Contents

Exhibit (a)(1)(B)

Letter of Transmittal
To Tender Shares of Common Stock
(Including the Associated Preferred Share Purchase Rights)
Pursuant to the Offer to Purchase for Cash
Dated August 14, 2006
by
SAVIENT PHARMACEUTICALS, INC.
of
Up to 10,000,000 Shares of its Common Stock
(Including the Associated Preferred Share Purchase Rights)
at a Purchase Price Not Greater Than $6.80 nor Less Than $5.80 Per Share

THE TENDER OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL
EXPIRE AT 9:00 A.M., NEW YORK CITY TIME, ON SEPTEMBER 12, 2006,
UNLESS THE TENDER OFFER IS EXTENDED

The Depositary for the Tender Offer is:

AMERICAN STOCK TRANSFER & TRUST COMPANY


By Mail:		By Hand or Overnight Courier:

American Stock Transfer & Trust Company Attention: Operations Center 59 Maiden Lane New York, New York 10038		American Stock Transfer & Trust Company Attention: Operations Center 6201 15^th Avenue Brooklyn, New York 11219

Delivery of this Letter of Transmittal to an address other than as set forth above does not constitute a valid delivery.

The Offer to Purchase and this Letter of Transmittal, including the accompanying instructions, should be read carefully before this Letter of Transmittal is completed.



DESCRIPTION OF SHARES TENDERED (See Instructions 3 and 4)


Name(s) and Address(es) of Registered Holder(s)	Shares of Common Stock Tendered (Attach Additional Signed List, if Necessary)
(Please fill in, if blank, exactly as name(s) appear(s) on certificate(s))		Certificate Number(s)*	Total Number of Shares Represented by Certificate(s)*	Number of Shares Tendered**

*	Need not be completed if shares are tendered by book-entry transfer.

**	Unless otherwise indicated, it will be assumed that all shares described above are being tendered. See Instruction 4.

Back to Contents

Complete only if you are submitting more than one certificate:

Indicate below the order (by certificate number) in which shares are to be purchased in the event of proration (attach additional signed list if necessary). If you do not designate an order, if less than all shares tendered are purchased due to proration, shares will be selected for purchase by the Depositary. See Instruction 15.

1st: 2nd: 3rd: 4th: 5th:


	Lost Certificates.


	I have lost my certificate(s) for shares and require assistance in replacing the shares. See Instruction 12.

This Letter of Transmittal is to be used either if certificates for shares (as defined below) are to be forwarded herewith or, unless an agent’s message (as defined in Section 3 of the Offer to Purchase (as defined below)) is utilized, if delivery of shares is to be made by book-entry transfer to an account maintained by the Depositary (as defined below) at the book-entry transfer facility (as defined in Section 3 of the Offer to Purchase) pursuant to the procedures set forth in Section 3 of the Offer to Purchase. If you wish to tender shares in the Tender Offer and your certificates for shares are not immediately available or the procedures for book-entry transfer cannot be completed on a timely basis or time will not permit all required documents to reach the Depositary prior to the Expiration Time (as defined in Section 1 of the Offer to Purchase), you can still tender your shares if you comply with the guaranteed delivery procedures set forth in Section 3 of the Offer to Purchase. See Instruction 2.

Your attention is directed in particular to the following:

1. If you want to retain your shares, you do not need to take any action.

2. If you want to participate in the Tender Offer (as defined below) and wish to maximize the chance that your shares will be purchased in the Tender Offer, you should check the box marked “Shares Tendered at Price Determined in the Tender Offer” below and complete the other portions of this Letter of Transmittal as appropriate. If you agree to accept the purchase price determined in the Tender Offer, your shares will be deemed to be tendered at the minimum price of $5.80 per share. You should understand that this election may lower the purchase price paid for all shares in the Tender Offer and could result in the tendered shares being purchased at the minimum price of $5.80 per share.

3. If you wish to select a specific price at which you will be tendering your shares, you should select one of the boxes in the section captioned “Shares Tendered at Price Determined by Stockholder” below and complete the other portions of this Letter of Transmittal as appropriate. You should be aware that this election could mean that none of your shares will be purchased if the price you selected is higher than the purchase price that Savient Pharmaceuticals, Inc. (the “Company”) eventually determines after the Expiration Time.


	DELIVERY OF DOCUMENTS TO THE BOOK-ENTRY TRANSFER FACILITY DOES NOT CONSTITUTE DELIVERY TO THE DEPOSITARY.

	CHECK HERE IF TENDERED SHARES ARE BEING DELIVERED BY BOOK-ENTRY TRANSFER MADE TO AN ACCOUNT MAINTAINED BY THE DEPOSITARY WITH THE BOOK-ENTRY TRANSFER FACILITY AND COMPLETE THE FOLLOWING (ONLY PARTICIPANTS IN THE BOOK-ENTRY TRANSFER FACILITY MAY DELIVER SHARES BY BOOK-ENTRY TRANSFER):

	Name of Tendering Institution:

	Account Number:		Transaction Code Number:

	CHECK HERE IF TENDERED SHARES ARE BEING DELIVERED PURSUANT TO A NOTICE OF GUARANTEED DELIVERY PREVIOUSLY SENT TO THE DEPOSITARY. ENCLOSE A PHOTOCOPY OF THE NOTICE OF GUARANTEED DELIVERY AND COMPLETE THE FOLLOWING:

	Name(s) of Registered Owner(s):

	Date of Execution of Notice of Guaranteed Delivery:

	Name of Institution that Guaranteed Delivery:

	If delivered by book-entry transfer, check box:

	Name of Tendering Institution:

	Account Number:		Transaction Code Number:

Back to Contents

THE UNDERSIGNED IS TENDERING SHARES AS FOLLOWS (CHECK ONLY ONE BOX):

(1) SHARES TENDERED AT PRICE DETERMINED BY STOCKHOLDER (SEE INSTRUCTION 5)

By checking ONE of the following boxes below INSTEAD OF THE BOX UNDER “Shares Tendered at Price Determined in the Tender Offer,” the undersigned hereby tenders shares at the price checked. This action could result in none of the shares being purchased if the purchase price determined by the Company for the shares is less than the price checked below. A STOCKHOLDER WHO DESIRES TO TENDER SHARES AT MORE THAN ONE PRICE MUST COMPLETE A SEPARATE LETTER OF TRANSMITTAL FOR EACH PRICE AT WHICH SHARES ARE TENDERED. The same shares cannot be tendered, unless previously properly withdrawn as provided in Section 4 of the Offer to Purchase, at more than one price.

PRICE (IN DOLLARS) PER SHARE AT WHICH SHARES
ARE BEING TENDERED

$5.80                $6.20                $6.60
$5.90                $6.30                $6.70
$6.00                $6.40                $6.80
$6.10                $6.50

(2) SHARES TENDERED AT PRICE DETERMINED IN THE TENDER OFFER (SEE INSTRUCTION 5)

By checking the box below INSTEAD OF ONE OF THE BOXES UNDER “Shares Tendered at Price Determined by Stockholder,” the undersigned hereby tenders shares at the purchase price determined in the Tender Offer.

The undersigned wants to maximize the chance of having his, her or its shares purchased in the Tender Offer (subject to the possibility of proration). Accordingly, by checking this box instead of one of the price boxes above, the undersigned hereby tenders shares at, and is willing to accept, the purchase price determined in the Tender Offer. For purposes of determining the purchase price, those shares that are tendered by the undersigned agreeing to accept the purchase price determined in the Tender Offer will be deemed to be tendered at the minimum price. THE UNDERSIGNED UNDERSTANDS THAT THIS ELECTION MAY LOWER THE PURCHASE PRICE PAID FOR ALL SHARES IN THE TENDER OFFER AND COULD RESULT IN THE TENDERED SHARES BEING PURCHASED AT THE MINIMUM PRICE OF $5.80 PER SHARE.

CHECK ONLY ONE BOX ABOVE. IF MORE THAN ONE BOX IS CHECKED ABOVE, OR IF NO BOX IS CHECKED, THERE IS NO VALID TENDER OF SHARES.

Back to Contents

ODD LOTS
(See Instruction 14)

To be completed only if shares are being tendered by or on behalf of a person owning beneficially or of record fewer than 100 shares in the aggregate. The undersigned either (check one box):

	is the beneficial or record owner of fewer than 100 shares in the aggregate, all of which are being tendered; or

	is a broker, dealer, commercial bank, trust company, or other nominee that (a) is tendering for the beneficial owner(s), shares with respect to which it is the record holder, and (b) believes, based upon representations made to it by the beneficial owner(s), that each such person is the beneficial owner of an aggregate of fewer than 100 shares and is tendering all of the shares.

	In addition, the undersigned is tendering either (check one box):

	at the price per share indicated above in the section captioned “Shares Tendered at Price Determined by Stockholder”; or

	at the purchase price, as the same will be determined by the Company in accordance with the terms of the Tender Offer (persons checking this box need not indicate the price per share above).

CONDITIONAL TENDER
(See Instruction 13)

A tendering stockholder may condition his, her or its tender of shares upon the Company purchasing a specified minimum number of the shares tendered, all as described in Section 6 of the Offer to Purchase. Unless at least the minimum number of shares you indicate below is purchased by the Company pursuant to the terms of the Tender Offer, none of the shares tendered by you will be purchased. It is the tendering stockholder’s responsibility to calculate the minimum number of shares that must be purchased if any are purchased, and each stockholder is urged to consult his, her or its own tax and investment advisors before completing this section. Unless this box has been checked and a minimum specified, the tender will be deemed unconditional.

	The minimum number of shares that must be purchased from the undersigned, if any are purchased from the undersigned, is: shares.

	If, because of proration, the minimum number of shares designated will not be purchased, the Company may accept conditional tenders by random lot, if necessary. However, to be eligible for purchase by random lot, the tendering stockholder must have tendered all of his, her or its shares and checked this box:

	The tendered shares represent all shares owned beneficially or of record by the undersigned.

Back to Contents

Ladies and Gentlemen:

The undersigned hereby tenders to Savient Pharmaceuticals, Inc. (the “Company”) the above-described shares of common stock, par value $0.01 per share, including the associated preferred share purchase rights (the “rights”) issued under the Rights Agreement dated as of October 7, 1998, between the Company and American Stock Transfer & Trust Company, as Rights Agent, as amended, of Savient Pharmaceuticals, Inc. (the “shares”), at the price per share indicated in this Letter of Transmittal, net to the seller in cash, less any applicable withholding taxes and without interest, on the terms and subject to the conditions set forth in the Company’s Offer to Purchase dated August 14, 2006 (the “Offer to Purchase”), and this Letter of Transmittal (which together, as they may be amended or supplemented from time to time, constitute the “Tender Offer”), receipt of which is hereby acknowledged. Unless the context otherwise requires, all references to the shares shall refer to the common stock of the Company and shall include the rights, and unless the rights are redeemed prior to the expiration of the Tender Offer, a tender of the shares will constitute a tender of the rights.

Subject to and effective on acceptance for payment of, and payment for, the shares tendered with this Letter of Transmittal in accordance with the terms and subject to the conditions of the Tender Offer, the undersigned hereby sells, assigns and transfers to, or upon the order of, the Company, all right, title and interest in and to all the shares that are being tendered hereby and irrevocably constitutes and appoints American Stock Transfer & Trust Company (the “Depositary”), the true and lawful agent and attorney-in-fact of the undersigned, with full power of substitution (such power of attorney being deemed to be an irrevocable power coupled with an interest), to the full extent of the undersigned’s rights with respect to such shares, to (i) deliver certificates for such shares or transfer ownership of such shares on the account books maintained by the book-entry transfer facility, together, in any such case, with all accompanying evidences of transfer and authenticity to, or upon the order of the Company, (ii) present such shares for cancellation and transfer on the Company’s books and (iii) receive all benefits and otherwise exercise all rights of beneficial ownership of such shares, all in accordance with the terms and subject to the conditions of the Tender Offer.

The undersigned hereby represents and warrants that the undersigned has full power and authority to tender, sell, assign and transfer the shares tendered hereby and that, when the same are accepted for payment by the Company, the Company will acquire good title thereto, free and clear of all security interests, liens, restrictions, claims and encumbrances, and the same will not be subject to any adverse claim or right. The undersigned will, on request by the Depositary or the Company, execute and deliver any additional documents deemed by the Depositary or the Company to be necessary or desirable to complete the sale, assignment and transfer of the shares tendered hereby, all in accordance with the terms of the Tender Offer. The undersigned acknowledges that the undersigned may not tender restricted stock, restricted stock units or the shares represented by such units unless such restrictions have lapsed.

All authority conferred or agreed to be conferred pursuant to this Letter of Transmittal shall be binding on the successors, assigns, heirs, personal representatives, executors, administrators and other legal representatives of the undersigned and shall not be affected by, and shall survive, the death or incapacity of the undersigned. Except as stated in the Offer to Purchase, this tender is irrevocable.

The undersigned understands that it is a violation of Rule 14e-4 promulgated under the Exchange Act for a person acting alone or in concert with others, directly or indirectly, to tender shares for such person’s own account unless at the time of tender and at the Expiration Time such person has a “net long position” in (1) a number of shares that is equal to or greater than the amount tendered and will deliver or cause to be delivered such shares for the purpose of tendering to the Company within the period specified in the Tender Offer or (2) other securities immediately convertible into, exercisable for or exchangeable into a number of shares (“Equivalent Securities”) that is equal to or greater than the number of shares tendered and, upon the acceptance of such tender, will acquire such shares by conversion, exchange or exercise of such Equivalent Securities to the extent required by the terms of the Tender Offer and will deliver or cause to be delivered such shares so acquired for the purpose of tender to the Company within the period specified in the Tender Offer. The undersigned understands that Rule 14e-4 also provides a similar restriction applicable to the tender or guarantee of a tender on behalf of another person. The undersigned understands that this Letter of Transmittal constitutes the undersigned’s acceptance of the terms and conditions of the Tender Offer, as well as the tendering stockholder’s representation and warranty to the Company that (1) the undersigned has a “net long position” in a number of shares or Equivalent Securities at least equal to the shares being tendered within the meaning of Rule 14e-4, and (2) such tender of shares complies with Rule 14e-4.

The undersigned understands that the Company’s acceptance for payment of shares tendered pursuant to the Tender Offer will constitute a binding agreement between the undersigned and the Company upon the terms and subject to the conditions of the Tender Offer.

The undersigned understands that the Company will, upon the terms and subject to the conditions of the Tender Offer, determine a single per share purchase price, not greater than $6.80 nor less than $5.80 per share, net to the seller in cash, less any applicable withholding taxes and without interest, that it will pay for shares properly tendered and not properly withdrawn in the Tender Offer, taking into account the number of shares so tendered and the prices specified by tendering stockholders. The undersigned understands that the Company will select the lowest purchase price (in multiples of $0.10) within the price range specified above that will allow it to purchase 10,000,000 shares, subject to its right to increase the total number of shares purchased to the extent permitted by

Back to Contents

applicable law. If fewer shares are properly tendered and not properly withdrawn, the Company will select the lowest price that will allow it to buy all the shares that are properly tendered and not properly withdrawn. The undersigned understands that if the Tender Offer is completed, all shares properly tendered at prices at or below the purchase price the Company determines and not properly withdrawn will be purchased at the purchase price, net to the seller in cash, less any applicable withholding taxes and without interest, upon the terms and subject to the conditions of the Tender Offer, including its proration provisions, “odd lot” priority and conditional tender provisions, and that the Company will return all other shares, including shares tendered at prices greater than the purchase price and not properly withdrawn and shares not purchased because of “odd lot” priority, proration and conditional tender provisions, at the Company’s expense promptly after the Expiration Time.

In participating in the Tender Offer, the undersigned acknowledges that: (1) the Tender Offer is established voluntarily by the Company, it is discretionary in nature and it may be extended, modified, suspended or terminated by the Company as provided in the Tender Offer; (2) the undersigned is voluntarily participating in the Tender Offer; (3) the future value of the Company’s common stock is unknown and cannot be predicted with certainty; (4) the undersigned has received the Offer to Purchase; and (5) regardless of any action that the Company takes with respect to any or all income/capital gains tax, social security or insurance, transfer tax or other tax-related items (“Tax Items”) related to the Tender Offer and the disposition of shares, the undersigned acknowledges that the ultimate liability for all Tax Items is and remains his or her sole responsibility. In that regard, the undersigned authorizes the Company to withhold all applicable Tax Items legally payable by the undersigned.

Unless otherwise indicated herein under “Special Payment Instructions,” please issue the check for payment of the purchase price and/or return any certificates for shares not tendered or accepted for payment (and accompanying documents, as appropriate) in the name(s) of the registered holder(s) appearing under “Description of Shares Tendered.” Similarly, unless otherwise indicated under “Special Delivery Instructions,” please mail the check for payment of the purchase price and/or return any certificates for shares not tendered or accepted for payment (and accompanying documents, as appropriate) to the address(es) of the registered holder(s) appearing under “Description of Shares Tendered.” In the event that both the “Special Delivery Instructions” and the “Special Payment Instructions” are completed, please issue the check for payment of the purchase price and/or return any certificates for shares not tendered or accepted for payment (and any accompanying documents, as appropriate) in the name(s) of, and deliver such check and/or return such certificates (and any accompanying documents, as appropriate) to, the person or persons so indicated. Please credit any shares tendered herewith by book-entry transfer that are not accepted for payment by crediting the account at the book-entry transfer facility designated above. The undersigned recognizes that the Company has no obligation pursuant to the “Special Payment Instructions” to transfer any shares from the name of the registered holder(s) thereof if the Company does not accept for payment any of the shares so tendered.

Back to Contents

SPECIAL PAYMENT INSTRUCTIONS
(See Instructions 1, 6, 7 and 8)

To be completed ONLY if certificates for shares not tendered or not accepted for payment and/or the check for payment of the purchase price of shares accepted for payment are to be issued in the name of someone other than the undersigned, or if shares tendered hereby and delivered by book-entry transfer which are not purchased are to be returned by crediting them to an account at the book-entry transfer facility other than the account designated above.

Issue:		Check
		Certificate(s) to:

Name:

	(Please Print)

Address:





	(Include Zip Code)

(Taxpayer Identification Number)
(See Instruction 10 and Substitute Form W-9 Included Herewith)

Check and complete if applicable:

	Credit shares delivered by book-entry transfer and not purchased to the account set forth below:

Account Number:

SPECIAL DELIVERY INSTRUCTIONS
(See Instructions 1, 6, 7 and 8)

To be completed ONLY if certificates for shares not tendered or not accepted for payment and/or the check for payment of the purchase price of shares accepted for payment are to be sent to someone other than the undersigned or to the undersigned at an address other than that above.

Mail:		Check
		Certificate(s) to:

Name:

	(Please Print)

Address:





	(Include Zip Code)

(Taxpayer Identification Number)
(See Instruction 10 and Substitute Form W-9 Included Herewith)

Back to Contents

SIGN HERE
(Also Complete Substitute Form W-9 Included Herewith or the Appropriate IRS Form)

X

X

	(Signature(s) of Stockholder(s))

Dated:

(Must be signed by registered holder(s) exactly as name(s) appear(s) on stock certificate(s) for the shares or on a security position listing or by person(s) authorized to become registered holder(s) by certificates and documents transmitted herewith. If signature is by a trustee, executor, administrator, guardian, attorney-in-fact, officer of a corporation or other person acting in a fiduciary or representative capacity, please provide the following information and see Instruction 6.)

Authorized Signature(s):

Name(s):

	(Please Print)

Capacity (full title):

Address:

	(Include Zip Code)

Daytime Area Code and Telephone Number:

Taxpayer Identification Number:

(Complete Accompanying Substitute Form W-9 or the Appropriate IRS Form)

GUARANTEE OF SIGNATURE(S)
(If Required–See Instructions 1 and 6)

Authorized Signature:

Name(s):

	(Please Print)

Name of Firm:

Title:

Address:



	(Include Zip Code)

Daytime Area Code and Telephone Number:

Dated:

Back to Contents

TO BE COMPLETED BY ALL TENDERING STOCKHOLDERS
(See Instruction 10)

PAYOR’S NAME: AMERICAN STOCK TRANSFER & TRUST COMPANY

SUBSTITUTE Form W-9 Department of the Treasury Internal Revenue Service Payor’s Request for Taxpayer Identification Number (“TIN”) and Certification	Part 1 — PLEASE PROVIDE YOUR TIN IN THE BOX AT THE RIGHT AND CERTIFY BY SIGNING AND DATING BELOW. For individuals, this is your Social Security Number (“SSN”). For a sole proprietor, a resident alien, a disregarded entity, or if your account is in more than one name, see enclosed W-9 Guidelines. For other entities, it is your Employer Identification Number (“EIN”). If you do not have a number, see how to get a TIN by consulting the enclosed W-9 Guidelines.
		TIN:
			Social Security Number
		OR
			Employer Identification Number
	Part 2 — Awaiting TIN. (If you check the box in Part 2, also complete the “Certificate of Awaiting Taxpayer Identification Number” below.)
	Part 3 — Exempt Payee. (Check the box in Part 3 if you are an exempt payee.)

CERTIFICATION — UNDER PENALTIES OF PERJURY, I CERTIFY THAT:
(1)	the number shown on this form is my correct Taxpayer Identification Number (or I am waiting for a number to be issued to me),
(2)	I am not subject to backup withholding because (a) I am exempt from backup withholding, or (b) I have not been notified by the Internal Revenue Service (the “IRS”) that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the IRS has notified me that I am no longer subject to backup withholding, and
(3)	I am a U.S. person (including a U.S. resident alien).
Certification Instructions — You must cross out item (2) of the above certification if you have been notified by the IRS that you are currently subject to backup withholding because of underreporting of interest or dividends on your tax return and you have not received another notification from the IRS that you are no longer subject to backup withholding. The IRS does not require your consent to any provision of this Substitute Form W-9 other than the certifications required to avoid backup withholding.


Please	Signature of U.S. Person	Date
Sign

Here	Name

	Business name (if different from above)

	Address


City	State	Zip

	Check the appropriate box:
	Individual/Sole Proprietor	Corporation
	Partnership	Other ________________


NOTE:	FAILURE TO COMPLETE AND RETURN THIS FORM MAY RESULT IN BACKUP WITHHOLDING ON ANY PAYMENTS MADE TO YOU PURSUANT TO THE TENDER OFFER. IN ADDITION, FAILURE TO PROVIDE SUCH INFORMATION MAY RESULT IN A PENALTY IMPOSED BY THE IRS. PLEASE REVIEW THE ENCLOSED GUIDELINES FOR CERTIFICATION OF TAXPAYER IDENTIFICATION NUMBER ON SUBSTITUTE FORM W-9 FOR ADDITIONAL DETAILS.

Back to Contents

YOU MUST COMPLETE THE FOLLOWING CERTIFICATE IF YOU CHECKED
THE BOX IN PART 2 OF SUBSTITUTE FORM W-9.

CERTIFICATE OF AWAITING TAXPAYER IDENTIFICATION NUMBER

I certify, under penalties of perjury, that a taxpayer identification number has not been issued to me, and either (a) I have mailed or delivered an application to receive a taxpayer identification number to the appropriate Internal Revenue Service Center or Social Security Administration Office or (b) I intend to mail or deliver an application in the near future. I understand that if I do not provide a taxpayer identification number by the time of payment, the payor may withhold a percentage (currently 28%) of all reportable payments paid to my account until I provide a number. I understand that if I do not provide a taxpayer identification number to the payor within 60 days of the payor’s receipt of this form, such retained amounts will be remitted to the Internal Revenue Service as backup withholding and the specified rate of all reportable payments made to me thereafter will be withheld and remitted to the Internal Revenue Service until I provide a taxpayer identification number.

Signature:

Date:

Back to Contents

INSTRUCTIONS

Forming Part of the Terms and Conditions of the Tender Offer

1. Guarantee of Signatures.

No signature guarantee is required on this Letter of Transmittal if either (i) this Letter of Transmittal is signed by the registered holder(s) (which term, for purposes of this Instruction 1, includes any participant in the book-entry transfer facility’s system whose name appears on a security position listing as the owner of the shares) of shares tendered herewith, unless such registered holder(s) has completed either the box entitled “Special Payment Instructions” or the box entitled “Special Delivery Instructions” on this Letter of Transmittal or (ii) such shares are tendered for the account of a firm that is a participant in any of the following: (1) the Securities Transfer Agents Medallion Program; (2) the New York Stock Exchange, Inc. Medallion Signature Program; or (3) the Stock Exchange Medallion Program (each, an “eligible institution”). In all other cases, all signatures on this Letter of Transmittal must be guaranteed by an eligible institution. Stockholders may also need to have any certificates they deliver endorsed or accompanied by a stock power, and the signatures on these documents also may need to be guaranteed. See Instruction 6.

2. Requirements of Tender.

This Letter of Transmittal is to be completed by stockholders either if certificates are to be forwarded herewith or, unless an agent’s message (as defined below) is utilized, if delivery of shares is to be made pursuant to the procedures for book-entry transfer set forth in Section 3 of the Offer to Purchase. For a stockholder validly to tender shares pursuant to the Tender Offer, either (i) a Letter of Transmittal, properly completed and duly executed, together with any required signature guarantees, or, in the case of a book-entry transfer, an agent’s message, and any other required documents, must be received by the Depositary at one of its addresses set forth on the back of this Letter of Transmittal prior to the Expiration Time (as defined in Section 1 of the Offer to Purchase) and either certificates for tendered shares must be received by the Depositary at one of such addresses or shares must be delivered pursuant to the procedures for book-entry transfer set forth herein (and a book-entry confirmation must be received by the Depositary), in each case prior to the Expiration Time, or (ii) the tendering stockholder must comply with the guaranteed delivery procedures set forth below and in Section 3 of the Offer to Purchase.

Stockholders who wish to tender shares in the Tender Offer and whose certificates for shares are not immediately available or for whom the procedures for book-entry transfer cannot be completed on a timely basis or for whom time will not permit all required documents to reach the Depositary prior to the Expiration Time can still tender their shares if they comply with the guaranteed delivery procedures set forth in Section 3 of the Offer to Purchase. Pursuant to those procedures, (i) tender must be made by or through an eligible institution, (ii) a properly completed and duly executed Notice of Guaranteed Delivery in the form provided must be received by the Depositary prior to the Expiration Time, and (iii) the certificates for all tendered shares in proper form for transfer (or a book-entry confirmation with respect to all such shares), together with all required documents and a Letter of Transmittal, which has been properly completed and duly executed and includes all signature guarantees required thereon, or, in the case of a book-entry transfer, all other required documents and either a Letter of Transmittal, which has been properly completed and duly executed and includes all signature guarantees required thereon, or an agent’s message, must be received by the Depositary, in each case within the period of three business days after the date of execution of the Notice of Guaranteed Delivery as provided in Section 3 of the Offer to Purchase. The term “agent’s message” means a message transmitted by the book-entry transfer facility to, and received by, the Depositary and forming a part of a book-entry confirmation, stating that the book-entry transfer facility has received an express acknowledgment from the participant tendering shares through the book-entry transfer facility that the participant has received and agrees to be bound by the terms of the Letter of Transmittal and that the Company may enforce that agreement against that participant.

THE METHOD OF DELIVERY OF SHARES, THIS LETTER OF TRANSMITTAL AND ALL OTHER REQUIRED DOCUMENTS, INCLUDING DELIVERY THROUGH THE BOOK-ENTRY TRANSFER FACILITY, IS AT THE SOLE ELECTION AND RISK OF THE TENDERING STOCKHOLDER. SHARES WILL BE DEEMED DELIVERED ONLY WHEN ACTUALLY RECEIVED BY THE DEPOSITARY (INCLUDING, IN THE CASE OF A BOOK-ENTRY TRANSFER, BY BOOK-ENTRY CONFIRMATION). IF DELIVERY IS BY MAIL, REGISTERED MAIL WITH RETURN RECEIPT REQUESTED, PROPERLY INSURED, IS RECOMMENDED. IN ALL CASES, SUFFICIENT TIME SHOULD BE ALLOWED TO ENSURE TIMELY DELIVERY.

Except as specifically provided by the Offer to Purchase, no alternative, conditional or contingent tenders will be accepted. No fractional shares will be purchased. All tendering stockholders, by execution of this Letter of Transmittal, waive any right to receive any notice of the acceptance for payment of their shares.

3. Inadequate Space.

If the space provided in the box entitled “Description of Shares Tendered” in this Letter of Transmittal is inadequate, the certificate numbers and/or the number of shares of common stock should be listed on a separate signed schedule attached hereto.

Back to Contents

4. Partial Tenders (Not Applicable to Stockholders Who Tender by Book-Entry Transfer).

If fewer than all the shares represented by any certificate submitted to the Depositary are to be tendered, fill in the number of shares that are to be tendered in the box entitled “Number of Shares Tendered.” In that case, if any tendered shares are purchased, new certificate(s) for the remainder of the shares that were evidenced by the old certificate(s) will be sent to the registered holder(s), unless otherwise provided in the appropriate box on this Letter of Transmittal, promptly after the acceptance for payment of, and payment for, the shares tendered herewith. All shares represented by certificates delivered to the Depositary will be deemed to have been tendered unless otherwise indicated.

5. Indication of Price at Which Shares are Being Tendered.

For shares to be properly tendered, the stockholder MUST either (1) check a box indicating the price per share at which such stockholder is tendering shares under the section captioned “Shares Tendered at Price Determined by Stockholder” or (2) check the box in the section captioned “Shares Tendered at Price Determined in the Tender Offer” in order to maximize the chance of having the Company purchase all of the shares tendered (subject to the possibility of proration). For purposes of determining the purchase price, those shares that are tendered by stockholders agreeing to accept the purchase price determined in the Tender Offer will be deemed to be tendered at the minimum price of $5.80 per share. Selecting option (1) could result in none of the stockholder’s tendered shares being purchased if the purchase price for the shares turns out to be less than the price selected by the stockholder. Selecting option (2) may lower the purchase price paid for all shares in the Tender Offer and could result in the stockholder receiving the minimum price of $5.80 per share. ONLY ONE BOX UNDER (1) OR (2) MAY BE CHECKED. IF MORE THAN ONE BOX IS CHECKED, OR IF NO BOX IS CHECKED, THERE IS NO PROPER TENDER OF SHARES. A STOCKHOLDER WISHING TO TENDER PORTIONS OF SUCH STOCKHOLDER’S SHARE HOLDINGS AT DIFFERENT PRICES MUST COMPLETE A SEPARATE LETTER OF TRANSMITTAL FOR EACH PRICE AT WHICH SUCH STOCKHOLDER WISHES TO TENDER EACH SUCH PORTION OF SHARES. THE SAME SHARES CANNOT BE TENDERED, UNLESS PREVIOUSLY PROPERLY WITHDRAWN AS PROVIDED IN SECTION 4 OF THE OFFER TO PURCHASE, AT MORE THAN ONE PRICE.

6. Signatures on Letter of Transmittal, Stock Powers and Endorsements.

If this Letter of Transmittal is signed by the registered holder(s) of the shares tendered hereby, the signature(s) must correspond exactly with the name(s) as written on the face of the certificate(s) without any change whatsoever.

If any of the shares tendered hereby are owned of record by two or more joint owners, all such persons must sign this Letter of Transmittal.

If any shares tendered hereby are registered in different names on several certificates, it will be necessary to complete, sign and submit as many separate Letters of Transmittal as there are different registrations of certificates.

If this Letter of Transmittal or any certificate or stock power is signed by a trustee, executor, administrator, guardian, attorney-in-fact, officer of a corporation or other person acting in a fiduciary or representative capacity, he or she should so indicate when signing, and proper evidence satisfactory to the Company of his or her authority to so act must be submitted with this Letter of Transmittal.

If this Letter of Transmittal is signed by the registered owner(s) of the shares tendered hereby, no endorsements of certificates or separate stock powers are required unless payment of the purchase price is to be made, or certificates for shares not tendered or accepted for payment are to be issued, to a person other than the registered owner(s).

If this Letter of Transmittal is signed by a person other than the registered owner(s) of the shares tendered hereby, or if payment is to be made or certificate(s) for shares not tendered or not purchased are to be issued to a person other than the registered owner(s), the certificate(s) representing such shares must be properly endorsed for transfer or accompanied by appropriate stock powers, in either case signed exactly as the name(s) of the registered owner(s) appear(s) on the certificates(s). The signature(s) on any such certificate(s) or stock power(s) must be guaranteed by an eligible institution. See Instruction 1.

7. Stock Transfer Taxes.

Tendering stockholders will not be obligated to pay any stock transfer taxes with respect to the transfer and sale of shares to the Company pursuant to the Tender Offer. If, however, payment of the purchase price is to be made to, or if shares not tendered or accepted for payment are to be registered in the name of, any person(s) other than the registered owner(s), or if shares tendered hereby are registered in the name(s) of any person(s) other than the person(s) signing this Letter of Transmittal, the amount of any stock transfer taxes (whether imposed on the registered owner(s) or such person(s)) payable on account of the transfer to such person(s) will be deducted from the purchase price unless satisfactory evidence of the payment of such taxes or exemption therefrom is submitted with this Letter of Transmittal.

Except as provided in this Instruction 7, it will not be necessary for transfer tax stamps to be affixed to the certificates listed in this Letter of Transmittal.

Back to Contents

8. Special Payment and Special Delivery Instructions.

If a check for the purchase price of any shares accepted for payment is to be issued in the name of, and/or certificates for any shares not accepted for payment or not tendered are to be issued in the name of and/or returned to, a person other than the signer of this Letter of Transmittal or if a check is to be sent, and/or such certificates are to be returned, to a person other than the signer of this Letter of Transmittal or to an address other than that shown above, the appropriate boxes on this Letter of Transmittal should be completed and signatures must be guaranteed as described in Instructions 1 and 6.

9. Irregularities.

All questions as to the number of shares to be accepted, the price to be paid for shares to be accepted and the validity, form, eligibility (including time of receipt) and acceptance for payment of any tender of shares will be determined by the Company, in its sole discretion, and each such decision will be final and binding on all parties. The Company reserves the absolute right prior to the Expiration Time to reject any or all tenders it determines not to be in proper form or the acceptance for payment of or payment for which may, in the opinion of the Company’s counsel, be unlawful. The Company also reserves the absolute right subject to applicable law to waive any conditions of the Tender Offer with respect to all stockholders or any defect or irregularity in any tender with respect to any particular shares or any particular stockholder whether or not the Company waives similar defects or irregularities in the case of other stockholders. No tender of shares will be deemed to have been validly made until all defects or irregularities relating thereto have been cured or waived. None of the Company, the Dealer Manager, the Depositary, the Information Agent or any other person will be under any duty to give notification of any defects or irregularities in tenders or incur any liability for failure to give any such notification. The Company’s reasonable interpretation of the terms of and conditions to the Tender Offer, including the Letter of Transmittal and the instructions thereto, will be final and binding on all parties. By tendering shares to the Company, the stockholder agrees to accept all decisions the Company makes concerning these matters and waives any right the stockholder might otherwise have to challenge those decisions.

10. Backup Withholding; Substitute Form W-9.

Under United States federal income tax law, a U.S. Holder (as defined in the Offer to Purchase) whose tendered shares are accepted for purchase may be subject to backup withholding (currently at a 28% rate) on payments that may be made by the Company pursuant to the Tender Offer. To prevent backup withholding, each U.S. Holder of tendered shares must provide to the Depositary such U.S. Holder’s correct taxpayer identification number (“TIN”) by completing the Substitute Form W-9 below, certifying that the stockholder is a United States person (including a United States resident alien), that the TIN provided is correct (or that the stockholder is awaiting a TIN), and that (i) the U.S. Holder is exempt from backup withholding, (ii) the U.S. Holder has not been notified by the Internal Revenue Service (the “IRS”) that the U.S. Holder is subject to backup withholding as a result of a failure to report all interest or dividends, or (iii) the IRS has notified the U.S. Holder that the U.S. Holder is no longer subject to backup withholding. If the Depositary is not provided with the correct TIN, the tendering U.S. Holder may be subject to a $50 penalty imposed by the IRS. In addition, the U.S. Holder may be subject to backup withholding on all reportable payments made pursuant to the Tender Offer.

If the stockholder is an individual, the TIN is his or her social security number. If the stockholder is a nonresident alien or a foreign entity not subject to backup withholding, the stockholder must provide to the Depositary the appropriate completed Form W-8 rather than a Substitute Form W-9. These forms may be obtained from the Depositary. See the enclosed Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9 (the “W-9 Guidelines”) for additional instructions. If the shares are in more than one name or are not in the name of the actual owner, the tendering stockholder should consult the W-9 Guidelines for information regarding which TIN to report.

If the U.S. Holder whose shares are tendered does not have a TIN or does not know its TIN, the U.S. Holder should check the box in Part 2 of the Substitute Form W-9, write “Applied For” in lieu of its TIN in Part 1, sign and date the form and provide it to the Depositary. In addition, such U.S. Holder also must sign and date the Certificate of Awaiting Taxpayer Identification Number. A U.S. Holder that does not have a TIN should consult the W-9 Guidelines for instructions on applying for a TIN. Note: Checking the box in Part 2 of the Substitute Form W-9 and writing “Applied For” in Part 1 means that the U.S. Holder has already applied for a TIN or that the U.S. Holder intends to apply for one in the near future. If a U.S. Holder checks the box in Part 2 and writes “Applied For” in Part 1, backup withholding at the applicable rate will nevertheless apply to all reportable payments made to such U.S. Holder. If such a U.S. Holder furnishes its properly certified TIN to the Depositary within 60 days of the Depositary’s receipt of the Substitute Form W-9, however, any amounts so withheld shall be refunded to such U.S. Holder. If, however, the U.S. Holder has not provided the Depositary with its TIN within such 60-day period, such previously retained amounts will be remitted to the IRS as backup withholding.

Back to Contents

Backup withholding is not an additional federal income tax. Rather, the federal income tax liability of persons subject to backup withholding will be reduced by the amount of tax withheld. If withholding results in overpayment of taxes, a refund may be obtained from the IRS.

11. Requests for Assistance or Additional Copies.

Questions and requests for assistance or additional copies of the Offer to Purchase, this Letter of Transmittal, the Notice of Guaranteed Delivery and the Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9 may be directed to the Information Agent at its address or telephone number set forth on the back cover of this Letter of Transmittal.

12. Lost, Destroyed or Stolen Certificates.

If your certificate(s) for part or all of your shares has been lost, stolen, destroyed or mutilated, you should check the box for “Lost Certificates” and promptly send the completed Letter of Transmittal to the Depositary. Upon receipt of your Letter of Transmittal, the Depositary will provide you with instructions on how to obtain a replacement certificate. You may be asked to post a bond to secure against the risk that the certificate may be subsequently recirculated. There may be a fee and additional documents may be required to replace lost certificates. This Letter of Transmittal and related documents cannot be processed until the procedures for replacing lost, stolen, destroyed or mutilated certificates have been followed. You are urged to send the properly completed Letter of Transmittal to the Depositary immediately to ensure timely processing of documentation. If you have questions, you may contact the Depositary at (877) 248-6417.

13. Conditional Tenders.

As described in Sections 1 and 6 of the Offer to Purchase, stockholders may condition their tenders on all or a minimum number of their tendered shares being purchased.

If you wish to make a conditional tender, you must indicate this in the box captioned “Conditional Tender” in this Letter of Transmittal and, if applicable, in the Notice of Guaranteed Delivery. In the box in this Letter of Transmittal and, if applicable, in the Notice of Guaranteed Delivery, you must calculate and appropriately indicate the minimum number of shares that must be purchased from you if any are to be purchased from you.

As discussed in Sections 1 and 6 of the Offer to Purchase, proration may affect whether the Company accepts conditional tenders and may result in shares tendered pursuant to a conditional tender being deemed withdrawn if the required minimum number of shares would not be purchased. If, because of proration, the minimum number of shares that you designate will not be purchased, the Company may accept conditional tenders by random lot, if necessary. However, to be eligible for purchase by random lot, you must have tendered all your shares of common stock and checked the box so indicating. Upon selection by lot, if any, the Company will limit its purchase in each case to the designated minimum number of shares of common stock.

All tendered shares of common stock will be deemed unconditionally tendered unless the “Conditional Tender” box is completed.

The conditional tender alternative is made available so that a stockholder may seek to structure the purchase of shares of common stock pursuant to the Tender Offer in such a manner that the purchase will be treated as a sale of such shares of common stock by the stockholder, rather than the payment of a dividend to the stockholder, for United States federal income tax purposes. If you are an odd lot holder and you tender all of your shares of common stock, you cannot conditionally tender, since your shares of common stock will not be subject to proration. It is the tendering stockholder’s responsibility to calculate the minimum number of shares of common stock that must be purchased from the stockholder in order for the stockholder to qualify for sale rather than dividend treatment. Each stockholder is urged to consult his or her own tax and investment advisor. See Section 14 of the Offer to Purchase.

14. Odd Lots.

As described in Section 1 of the Offer to Purchase, if the Company is to purchase fewer than all shares properly tendered before the Expiration Time and not properly withdrawn, the shares purchased first will consist of all shares properly tendered by any stockholder who owned, beneficially or of record, an aggregate of fewer than 100 shares, and who tenders all of the holder’s shares at or below the purchase price. This preference will not be available to you unless you complete the section captioned “Odd Lots” in this Letter of Transmittal and, if applicable, in the Notice of Guaranteed Delivery.

15. Order of Purchase in Event of Proration.

As described in Section 1 of the Offer to Purchase, stockholders may designate the order in which their shares are to be purchased in the event of proration. The order of purchase may have an effect on the United States federal income tax classification of any gain or loss on the shares purchased. See Sections 1 and 14 of the Offer to Purchase.

Back to Contents

GUIDELINES FOR CERTIFICATION OF TAXPAYER IDENTIFICATION
NUMBER ON SUBSTITUTE FORM W-9

Guidelines for Determining the Proper Identification Number to Give the Payor. — Social Security numbers have nine digits separated by two hyphens: i.e., 000-00-0000. Employer identification numbers have nine digits separated by only one hyphen: i.e., 00-0000000. The table below will help determine the number to give the payor.


For this type of account:			Give the SOCIAL SECURITY number of:

1.	An individual’s account		The individual

2.	Two or more individuals (joint account)		The actual owner of the account or, if combined funds, the first individual on the account(l)

3.	Custodian account of a minor (Uniform Gift to Minors Act)		The minor(2)

4.	a.	The usual revocable savings trust account (grantor is also trustee)	The grantor-trustee(1)

	b.	So-called trust account that is not a legal or valid trust under state law	The actual owner(1)

5.	Sole proprietorship account or an account of a single-owner LLC		The owner(3)

6.	Sole proprietorship account or an account of a single-owner LLC		The owner(3)

7.	A valid trust, estate, or pension trust account		The legal entity (do not furnish the identifying number of the personal representative or trustee unless the legal entity itself is not designated in the account title)(4)


For this type of account:		Give the EMPLOYER IDENTIFICATION number of:

8.	Corporate account or an account of an LLC electing corporate status on Form 8832	The corporation

9.	Association, club, religious, charitable, educational, or other tax-exempt organization account	The organization

10.	Partnership or multi-member LLC account	The partnership

11.	A broker or registered nominee	The broker or nominee

12.	Account with the Department of Agriculture in the name of a public entity (such as a state or local government, school district, or prison) that receives agricultural program payments	The public entity

(1)	List first and circle the name of the person whose number you furnish. If only one person on a joint account has a Social Security number, that person’s number must be furnished.

(2)	Circle the minor’s name and furnish the minor’s Social Security number.

(3)	You must show your individual name and you may also enter your business or “doing business as” name on the second name line. You may use either your Social Security number or employer identification number (if you have one). If you are a sole proprietor, the IRS encourages you to use your Social Security number.

(4)	List first and circle the name of the legal trust, estate, or pension trust.

Note: If no name is circled when there is more than one name listed, the number will be considered to be that of the first name listed.

Back to Contents

GUIDELINES FOR CERTIFICATION OF TAXPAYER IDENTIFICATION
NUMBER ON SUBSTITUTE FORM W-9

Obtaining a Number

If you don’t have a taxpayer identification number or you don’t know your number, obtain Form SS-5, Application for a Social Security Number Card (for individuals), or Form SS-4, Application for Employer Identification Number (for business and all other entities) and apply for a number. These forms are available at the local office of the Social Security Administration or the Internal Revenue Service, on the internet at http://www.irs.gov, or by calling 1 (800) TAX-FORM.

Payees Exempt from Backup Withholding

Payees specifically exempt from backup withholding on ALL payments include the following:

•	An organization exempt from tax under Section 501(a) of the Internal Revenue Code of 1986, as amended (the “Code”), any individual retirement account, or a custodial account under Section 403(b)(7) of the Code if the account satisfies the requirements of Section 401(f)(2) of the Code.


•	The United States or any agency or instrumentality thereof.


•	A state, the District of Columbia, a possession of the United States, or any political subdivision or instrumentality thereof.


•	A foreign government, a political subdivision of a foreign government, or any agency or instrumentality thereof.


•	An international organization, or any agency or instrumentality thereof.

Payees that MAY BE EXEMPT from backup withholding include the following:

•	A corporation.


•	A foreign central bank of issue.


•	A dealer in securities or commodities required to register in the United States, the District of Columbia or a possession of the United States.


•	A futures commission merchant registered with the Commodity Futures Trading Commission.


•	A real estate investment trust.


•	An entity registered at all times during the tax year under the Investment Company Act of 1940.


•	A common trust fund operated by a bank under Section 584(a) of the Code.


•	A financial institution.


•	A middleman known in the investment community as a nominee or custodian.


•	A trust exempt from tax under Section 664 of the Code or described in Section 4947 of the Code.

Payments of dividends and patronage dividends not generally subject to backup withholding include the following:

•	Payments to nonresident aliens subject to withholding under Section 1441 of the Code.


•	Payments to partnerships not engaged in a trade or business in the United States and that have at least one nonresident alien partner.


•	Payments of patronage dividends where the amount received is not paid in money.


•	Payments made by certain foreign organizations.


•	Section 404(k) distributions made by an employee stock option plan.

Payments of interest not generally subject to backup withholding include the following:

•	Payments of interest on obligations issued by individuals. Note: You may be subject to backup withholding if this interest is $600 or more and is paid in the course of the payor’s trade or business and you have not provided your correct taxpayer identification number to the payor.


•	Payments of tax-exempt interest (including exempt-interest dividends under Section 852 of the Code).


•	Payments described in Section 6049(b)(5) of the Code to nonresident aliens.


•	Payments on tax-free covenant bonds under Section 1451 of the Code.


•	Payments made by certain foreign organizations.


•	Mortgage or student loan interest.

Exempt payees described above should file the Substitute Form W-9 to avoid possible erroneous backup withholding. IF YOU ARE AN EXEMPT PAYEE, FURNISH YOUR TAXPAYER IDENTIFICATION NUMBER ON THE FORM, CHECK THE BOX IN PART 3 OF THE FORM, SIGN AND DATE THE FORM AND RETURN IT TO THE PAYOR. IF YOU ARE A NONRESIDENT ALIEN OR A FOREIGN ENTITY NOT SUBJECT TO BACKUP WITHHOLDING, FILE WITH THE PAYOR THE APPROPRIATE COMPLETED IRS FORM W-8.

Certain payments other than interest, dividends and patronage dividends that are not subject to information reporting are also not subject to backup withholding. For details, see Sections 6041, 6041A, 6042, 6044, 6045, 6049, 6050A, and 6050N of the Code and the regulations promulgated thereunder.

Privacy Act Notice. Section 6109 of the Code requires most recipients of dividends, interest, or other payments to give taxpayer identification numbers to payors who must report the payments to the IRS. The IRS uses the numbers for identification purposes and to help verify the accuracy of your tax returns. The IRS may also provide this information to the Department of Justice for civil and criminal litigation, and to cities, states, the District of Columbia, and U.S. possessions to carry out their tax laws. The IRS may also disclose this information to other countries under a tax treaty, to federal and state agencies to enforce federal nontax criminal laws, or to federal law enforcement and intelligence agencies to combat terrorism. Payors must be given the numbers whether or not recipients are required to file tax returns. Payors must generally withhold a percentage (currently 28%) of taxable interest, dividends, and certain other payments to a payee who does not furnish a taxpayer identification number to a payor. Certain penalties may also apply.

Penalties. (1) Penalty for Failure to Furnish Taxpayer Identification Number. If you fail to furnish your correct taxpayer identification number to a payor, you are subject to a penalty of $50 for each such failure unless your failure is due to reasonable cause and not to willful neglect. (2) Civil Penalty for False Information with Respect to Withholding. If you make a false statement with no reasonable basis that results in no imposition of backup withholding, you are subject to a penalty of $500. (3) Criminal Penalty for Falsifying Information. Willfully falsifying certifications or affirmations may subject you to criminal penalties including fines and/or imprisonment. (4) Failure to Report Certain Dividend and Interest Payments. If you fail to include any portion of an includible payment for interest, dividends, or patronage dividends in gross income, such failure is strong evidence of negligence. If negligence is shown, you will be subject to a penalty of 20% on any portion of an underpayment attributable to that failure. (5) Misuse of Taxpayer Identification Numbers. If the requester discloses or uses taxpayer identification numbers in violation of federal law, the requester may be subject to civil and criminal penalties.

FOR ADDITIONAL INFORMATION CONTACT YOUR TAX ADVISOR OR THE INTERNAL REVENUE SERVICE.

Back to Contents

IMPORTANT: THIS LETTER OF TRANSMITTAL, TOGETHER WITH ANY REQUIRED SIGNATURE GUARANTEES, OR, IN THE CASE OF A BOOK-ENTRY TRANSFER, AN AGENT’S MESSAGE, AND ANY OTHER REQUIRED DOCUMENTS, MUST BE RECEIVED BY THE DEPOSITARY PRIOR TO THE EXPIRATION TIME AND EITHER CERTIFICATES FOR TENDERED SHARES MUST BE RECEIVED BY THE DEPOSITARY OR SHARES MUST BE DELIVERED PURSUANT TO THE PROCEDURES FOR BOOK-ENTRY TRANSFER, IN EACH CASE PRIOR TO THE EXPIRATION TIME, OR THE TENDERING STOCKHOLDER MUST COMPLY WITH THE PROCEDURES FOR GUARANTEED DELIVERY.

This Letter of Transmittal, certificates for shares and any other required documents should be sent or delivered by each stockholder of the Company or such stockholder’s bank, broker, dealer, trust company or other nominee to the Depositary at one of its addresses set forth below.

The Depositary for the Tender Offer is:

AMERICAN STOCK TRANSFER & TRUST COMPANY

By Mail:
American Stock Transfer
& Trust Company
Attention: Operations Center
59 Maiden Lane
New York, New York 10038

By Hand or Overnight Courier:
American Stock Transfer
& Trust Company
Attention: Operations Center
6201 15^th Avenue
Brooklyn, New York 11219

Delivery of this Letter of Transmittal to an address other than as set forth above will not constitute a valid delivery.

Questions and requests for assistance may be directed to the Information Agent at the address set forth below. Additional copies of the Offer to Purchase, this Letter of Transmittal and the Notice of Guaranteed Delivery may be obtained from the MacKenzie Partners, Inc, the Information Agent. You may also contact the Citigroup Global Markets Inc., the Dealer Manager, or your bank, broker, dealer, trust company or other nominee for assistance concerning the Tender Offer.

The Information Agent for the Tender Offer is:

105 Madison Avenue
New York, New York 10016
(212) 929-5500 (Call Collect)
E-mail: proxy@mackenziepartners.com
or
CALL TOLL-FREE (800) 322-2885

The Dealer Manager for the Tender Offer is:

Citigroup Global Markets Inc.
Special Equity Transactions Group
390 Greenwich Street, 5^th Floor
New York, New York 10013
(877) 531-8365 (toll free)
(212) 723-7236 (collect)

EX-99.A(1C) 9 b414446_exa1c.htm EXHIBIT (A)(1)(C) Prepared and filed by St Ives Burrups

Back to Contents

Exhibit (a)(1)(C)

Notice of Guaranteed Delivery
(Not to be used for Signature Guarantee)
for
Tender of Shares of Common Stock
(including the Associated Preferred Share Purchase Rights)
of
SAVIENT PHARMACEUTICALS, INC.

THE TENDER OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL
EXPIRE AT 9:00 A.M., NEW YORK CITY TIME, ON SEPTEMBER 12, 2006,
UNLESS THE TENDER OFFER IS EXTENDED

As set forth in Section 3 of the Offer to Purchase (as defined below) this form must be used to accept the Tender Offer (as defined below) if (1) certificates for your shares of common stock, par value $0.01 per share, including the associated preferred share purchase rights (the “rights”) issued under the Rights Agreement dated as of October 7, 1998, between Savient Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, as Rights Agent, as amended, are not immediately available, (2) the procedures for book-entry transfer cannot be completed on a timely basis or (3) time will not permit all required documents to reach the Depositary prior to the Expiration Time (as defined in Section 1 of the Offer to Purchase). This form may be delivered by hand or transmitted by facsimile transmission or mail to the Depositary. See Section 3 of the Offer to Purchase. Unless the context otherwise requires, all references to the shares shall refer to the common stock of the Company and shall include the rights, and unless the rights are redeemed prior to the Expiration Time, a tender of the shares will constitute a tender of the rights.

The Depositary for the Tender Offer is:

American Stock Transfer & Trust Company

By Mail:

American Stock Transfer & Trust Company
Attention: Operations Center
59 Maiden Lane
New York, New York 10038

By Facsimile Transmission:

For Eligible Institutions Only:
(718) 234-5001
For Confirmation Only Telephone:
(718) 921-8317

By Hand or Overnight Courier:

American Stock Transfer & Trust Company
Attention: Operations Center
6201 15th Avenue
Brooklyn, New York 11219

Delivery of this Notice of Guaranteed Delivery to an address, or transmission of instructions via a facsimile number, other than as set forth above will not constitute a valid delivery. For this Notice to be validly delivered, it must be received by the Depositary before the Expiration Time. Deliveries to the Company, the Dealer Manager, the Information Agent or the book-entry transfer facility (as defined in Section 3 of the Offer to Purchase) will not be forwarded to the Depositary and will not constitute a valid delivery.

This Notice is not to be used to guarantee signatures. If a signature on a Letter of Transmittal is required to be guaranteed by an eligible institution under the instructions in the Letter of Transmittal, the signature guarantee must appear in the applicable space provided in the signature box on the Letter of Transmittal.

Back to Contents

Ladies and Gentlemen:

The undersigned hereby tenders to Savient Pharmaceuticals, Inc., a Delaware corporation (the “Company”), at the price per share indicated in this Notice of Guaranteed Delivery, on the terms and subject to the conditions set forth in the Offer to Purchase dated August 14, 2006 (the “Offer to Purchase”), and the related Letter of Transmittal (which together, as they may be amended and supplemented from time to time, constitute the “Tender Offer”), receipt of which is hereby acknowledged, the number of shares set forth below, all pursuant to the guaranteed delivery procedures set forth in Section 3 of the Offer to Purchase. Unless the context otherwise requires, all references to shares shall refer to the common stock of the Company and shall include the rights, and unless the rights are redeemed prior to the Expiration Time, a tender of the shares will constitute a tender of the rights.

Number of shares to be tendered: __________ shares

Back to Contents

THE UNDERSIGNED IS TENDERING SHARES AS FOLLOWS (CHECK ONLY ONE BOX):

(1) SHARES TENDERED AT PRICE DETERMINED BY STOCKHOLDER (SEE INSTRUCTION 5 TO THE LETTER OF TRANSMITTAL)

By checking ONE of the following boxes below INSTEAD OF THE BOX UNDER “Shares Tendered at Price Determined in the Tender Offer,” the undersigned hereby tenders shares at the price checked. This action could result in none of the shares being purchased if the purchase price determined by the Company for the shares is less than the price checked below. A STOCKHOLDER WHO DESIRES TO TENDER SHARES AT MORE THAN ONE PRICE MUST COMPLETE A SEPARATE NOTICE OF GUARANTEED DELIVERY AND/OR LETTER OF TRANSMITTAL FOR EACH PRICE AT WHICH SHARES ARE TENDERED. The same shares cannot be tendered, unless previously properly withdrawn as provided in Section 4 of the Offer to Purchase, at more than one price.

PRICE (IN DOLLARS) PER SHARE AT WHICH SHARES ARE BEING TENDERED

$5.80	$6.20	$6.60
$5.90	$6.30	$6.70
$6.00	$6.40	$6.80
$6.10	$6.50

(2) SHARES TENDERED AT PRICE DETERMINED IN THE TENDER OFFER (SEE INSTRUCTION 5 TO THE LETTER OF TRANSMITTAL)

The undersigned wants to maximize the chance of having the Company purchase all of the shares the undersigned is tendering (subject to the possibility of proration). Accordingly, by checking this box instead of one of the price boxes above, the undersigned hereby tenders shares at, and is willing to accept, the purchase price determined in the Tender Offer. For purposes of determining the purchase price, those shares that are tendered by the undersigned agreeing to accept the purchase price determined in the Tender Offer will be deemed to be tendered at the minimum price. THE UNDERSIGNED UNDERSTANDS THAT THIS ELECTION MAY LOWER THE PURCHASE PRICE PAID FOR ALL SHARES IN THE TENDER OFFER AND COULD RESULT IN THE TENDERED SHARES BEING PURCHASED AT THE MINIMUM PRICE OF $5.80 PER SHARE.

CHECK ONLY ONE BOX ABOVE. IF MORE THAN ONE BOX IS CHECKED ABOVE, OR IF NO BOX IS CHECKED, THERE IS NO VALID TENDER OF SHARES.

Back to Contents

ODD LOTS
(See Instruction 14 to the Letter of Transmittal)

To be completed only if shares are being tendered by or on behalf of a person owning beneficially or of record fewer than 100 shares in the aggregate. The undersigned either (check one box):

is the beneficial or record owner of fewer than 100 shares in the aggregate, all of which are being tendered; or

is a broker, dealer, commercial bank, trust company, or other nominee that (a) is tendering for the beneficial owner(s), shares with respect to which it is the record holder, and (b) believes, based upon representations made to it by the beneficial owner(s), that each such person is the beneficial owner of an aggregate of fewer than 100 shares and is tendering all of the shares.

In addition, the undersigned is tendering either (check one box):

at the price per share indicated above in the section captioned “Shares Tendered at Price Determined by Stockholders”; or

at the purchase price, as the same will be determined by the Company in accordance with the terms of the Tender Offer (persons checking this box need not indicate the price per share above).

CONDITIONAL TENDER
(See Instruction 13 to the Letter of Transmittal)

The minimum number of shares that must be purchased from the undersigned, if any are purchased from the undersigned, is: ___________ shares.

If, because of proration, the minimum number of shares designated will not be purchased, the Company may accept conditional tenders by random lot, if necessary. However, to be eligible for purchase by random lot, the tendering stockholder must have tendered all of his, her or its shares and checked this box:

The tendered shares represent all shares held by the undersigned.

Back to Contents

SIGNATURE

Certificate No(s). (if available):

Name(s) of Record Holder(s):

	(Please Type or Print)

Address(es):

Zip Code:

Daytime Area Code and Telephone Number:

Signature(s):

Dated:

If shares will be tendered by book-entry transfer, check this box and provide the following information:

Name of Tendering Institution:

Account Number at Book-Entry Transfer Facility:

THE GUARANTEE SET FORTH BELOW MUST BE COMPLETED.

Back to Contents

GUARANTEE
(Not To Be Used For Signature Guarantee)

The undersigned, a firm that is a member in good standing of a recognized Medallion Program approved by the Securities Transfer Association, Inc., including the Securities Transfer Agents Medallion Program, the New York Stock Exchange, Inc. Medallion Signature Program or the Stock Exchange Medallion Program, or is otherwise an “eligible guarantor institution,” as that term is defined in Rule 17Ad-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), hereby guarantees (1) that the above named person(s) “own(s)” the shares tendered hereby within the meaning of Rule 14e-4 under the Exchange Act, (2) that such tender of shares complies with Rule 14e-4 under the Exchange Act and (3) to deliver to the Depositary either the certificates representing the shares tendered hereby, in proper form for transfer, or a book-entry confirmation (as defined in the Offer to Purchase) with respect to such shares, in any such case together with a properly completed and duly executed Letter of Transmittal, with any required signature guarantees, or an agent’s message (as defined in the Offer to Purchase) in the case of a book-entry delivery, and any other required documents, within three business days (as defined in the Offer to Purchase) after the date hereof.

The eligible institution that completes this form must communicate the guarantee to the Depositary and must deliver the Letter of Transmittal and certificates for shares to the Depositary within the time period shown herein. Failure to do so could result in financial loss to such eligible institution.

Name of Firm:

Authorized Signature:

Name:

	(Please Type or Print)

Title:

Address:

Zip Code:

Area Code and Telephone Number:

Dated:

Note: Do not send certificates for shares with this Notice.
Certificates for shares should be sent with your Letter of Transmittal.

EX-99.A(1D) 10 b414446_exa1d.htm EXHIBIT (A)(1)(D) Prepared and filed by St Ives Burrups

Back to Contents

Exhibit (a)(1)(D)

Offer to Purchase for Cash
by
SAVIENT PHARMACEUTICALS, INC.
of
Up to 10,000,000 Shares of its Common Stock
(including the Associated Preferred Share Purchase Rights)
at a Purchase Price Not Greater Than $6.80 nor Less Than $5.80 Per Share

THE TENDER OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL
EXPIRE AT 9:00 A.M., NEW YORK CITY TIME, ON SEPTEMBER 12, 2006,
UNLESS THE TENDER OFFER IS EXTENDED

August 14, 2006

To Brokers, Dealers, Commercial Banks,
Trust Companies and Other Nominees:

Enclosed for your consideration is an Offer to Purchase dated August 14, 2006 (the “Offer to Purchase”) relating to an offer by Savient Pharmaceuticals, Inc., a Delaware corporation (the “Company”), to purchase for cash up to 10,000,000 shares of its common stock, par value $0.01 per share, including the associated preferred share purchase rights (the “rights”) issued under the Rights Agreement dated as of October 7, 1998, between the Company and American Stock Transfer & Trust Company, as Rights Agent, as amended, at a price not greater than $6.80 nor less than $5.80 per share, net to the seller in cash, less any applicable withholding taxes and without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase and the related Letter of Transmittal (which together, as they may be amended and supplemented from time to time, constitute the “Tender Offer”). Please furnish copies of the enclosed materials to those of your clients for whom you hold shares registered in your name or in the name of your nominee. Unless the context otherwise requires, all references to the shares shall refer to the common stock of the Company and shall include the rights, and unless the rights are redeemed prior to the expiration of the Tender Offer, a tender of the shares will constitute a tender of the rights.

Enclosed with this letter are copies of the following documents:

Offer to Purchase dated August 14, 2006;


	2.	Letter of Transmittal, for your use in accepting the Tender Offer and tendering shares and for the information of your clients, including the Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9;


	3.	Notice of Guaranteed Delivery with respect to shares, to be used to accept the Tender Offer in the event you are unable to deliver the share certificates, together with all other required documents, to the Depositary before the Tender Offer expires, or if the procedure for book-entry transfer cannot be completed before the Tender Offer expires;


	4.	Form of letter that may be sent to your clients for whose accounts you hold shares registered in your name or in the name of your nominee, with an Instruction Form provided for obtaining such clients’ instructions with regard to the Tender Offer; and

Return envelope addressed to American Stock Transfer & Trust Company, the Depositary for the Tender Offer.

Back to Contents

The Tender Offer is not conditioned upon any minimum number of shares being tendered. The Tender Offer is, however, subject to certain conditions, which are described in Section 7 of the Offer to Purchase.

We urge you to contact your clients promptly. Please note that the Tender Offer, proration period and withdrawal rights will expire at 9:00 a.m., New York City time, on September 12, 2006, unless the Tender Offer is extended.

Under no circumstances will interest be paid on the purchase price, including but not limited to, by reason of any delay in making payment.

The Company will not pay any fees or commissions to brokers, dealers or other persons (other than fees to the Dealer Manager and the Information Agent as described in the Offer to Purchase) for soliciting tenders of shares in the Tender Offer. The Company will, however, upon request, reimburse brokers, dealers and commercial banks for customary mailing and handling expenses incurred by them in forwarding the Tender Offer and related materials to the beneficial owners of shares held by them as a nominee or in a fiduciary capacity. No broker, dealer, commercial bank or trust company has been authorized to act as the Company’s agent or the agent of the Dealer Manager, the Information Agent or the Depositary for purposes of the Tender Offer. The Company will pay or cause to be paid all stock transfer taxes, if any, on its purchase of shares, except as otherwise provided in Instruction 7 in the Letter of Transmittal.

Questions and requests for assistance may be directed to the Information Agent or to the Dealer Manager, at their respective addresses and telephone numbers set forth on the back cover of the Offer to Purchase. Requests for additional copies of the Offer to Purchase, the Letter of Transmittal or the Notice of Guaranteed Delivery should be directed to the Information Agent.

Very truly yours,

Citigroup Global Markets Inc.

Nothing contained in this letter or in the enclosed documents shall render you or any other
person the agent of the Company, the Depositary, the Dealer Manager, the Information
Agent or any affiliate of any of them or authorize you or any other person to give any
information or use any document or make any statement on behalf of any of them with
respect to the Tender Offer other than the enclosed documents and the statements
contained therein.

EX-99.A(1E) 11 b414446_exa1e.htm EXHIBIT (A)(1)(E) Prepared and filed by St Ives Burrups

Back to Contents

Exhibit (a)(1)(E)

Offer to Purchase for Cash
by
SAVIENT PHARMACEUTICALS, INC.
of
Up to 10,000,000 Shares of Its Common Stock
(including the Associated Preferred Share Purchase Rights)
at a Purchase Price Not Greater Than $6.80 nor Less Than $5.80 Per Share

THE TENDER OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL
EXPIRE AT 9:00 A.M., NEW YORK CITY TIME, ON SEPTEMBER 12, 2006,
UNLESS THE TENDER OFFER IS EXTENDED

To Our Clients:

Enclosed for your consideration are the Offer to Purchase dated August 14, 2006 (the “Offer to Purchase”) and the related Letter of Transmittal (which together, as they may be amended and supplemented from time to time, constitute the “Tender Offer”), in connection with the offer by Savient Pharmaceuticals, Inc., a Delaware corporation (the “Company”), to purchase for cash up to 10,000,000 shares of its common stock, par value $0.01 per share, including the associated preferred share purchase rights (the “rights”) issued under the Rights Agreement dated as of October 7, 1998, between the Company and American Stock Transfer & Trust Company, as Rights Agent, as amended, at a price not greater than $6.80 nor less than $5.80 per share, net to the seller in cash, less any applicable withholding taxes and without interest, upon the terms and subject to the conditions of the Tender Offer. Unless the context otherwise requires, all references to the shares shall refer to the common stock of the Company and shall include the rights, and unless the rights are redeemed prior to the expiration of the Tender Offer, a tender of the shares will constitute a tender of the rights.

On the terms and subject to the conditions of the Tender Offer, the Company will determine a single per share price, not greater than $6.80 nor less than $5.80 per share, net to the seller in cash, less any applicable withholding taxes and without interest, that it will pay for shares properly tendered and not properly withdrawn in the Tender Offer, taking into account the total number of shares tendered and the prices specified by tendering stockholders. After the Tender Offer expires, the Company will look at the prices chosen by stockholders for all of the shares properly tendered and not properly withdrawn. The Company will then select the lowest purchase price (in multiples of $0.10) within the price range specified above that will allow it to buy 10,000,000 shares, subject to its right to increase the total number of shares purchased to the extent permitted by applicable law. If fewer shares are properly tendered and not properly withdrawn, the Company will select the lowest price that will allow it to buy all the shares that are properly tendered and not properly withdrawn. All shares acquired by the Company in the Tender Offer will be acquired at the same purchase price regardless of whether the stockholder tendered at a lower price. The Company will purchase only shares properly tendered at prices at or below the purchase price it determines. However, because of the “odd lot” priority, proration and conditional tender provisions described in the Offer to Purchase, the Company may not purchase all of the shares tendered, even if stockholders tendered at or below the purchase price, if more than the number of shares the Company seeks are properly tendered and not properly withdrawn. The Company will return shares tendered at prices in excess of the purchase price that it determines and shares that it does not purchase because of the “odd lot” priority, proration and conditional tender provisions to the tendering stockholders at its expense promptly after the Tender Offer expires. See Sections 1 and 3 of the Offer to Purchase.

If the number of shares properly tendered at or below the purchase price determined in the Tender Offer and not properly withdrawn prior to the Expiration Time (as defined in Section 1 of the Offer to Purchase) is less than or equal to 10,000,000 shares, or such greater number of shares as the Company may elect to accept for payment, the Company will, subject to applicable law and upon the terms and subject to the conditions of the Tender Offer, purchase all shares so tendered at the purchase price determined by the Company.

Back to Contents

Upon the terms and subject to the conditions of the Tender Offer, if more than 10,000,000 shares, or such greater number of shares as the Company may elect to accept for payment, have been properly tendered at prices at or below the purchase price determined by the Company and not properly withdrawn prior to the Expiration Time, the Company will, subject to applicable law, purchase properly tendered shares on the basis described as follows: First, the Company will purchase all shares tendered by any stockholder who owns beneficially or of records an aggregate of fewer than 100 shares (an “Odd Lot Holder”) who tenders all shares owned beneficially and of record by the Odd Lot Holder at a price at or below the purchase price determined in the Tender Offer (tenders of less than all of the shares owned by an Odd Lot Holder will not qualify for this priority), and completes the section entitled “Odd Lots” in the Letter of Transmittal and, if applicable, in the Notice of Guaranteed Delivery. Second, subject to the conditional tender provisions described in Section 6 of the Offer to Purchase, the Company will purchase all other shares tendered at prices at or below the purchase price determined by the Company on a pro rata basis with appropriate adjustments to avoid purchases of fractional shares, as described in Section 6 of the Offer to Purchase. Third, if necessary to permit the Company to purchase 10,000,000 shares (or such greater number of shares as the Company may elect to accept for payment), shares conditionally tendered (for which the condition requiring the Company to purchase a specified number of shares was not initially satisfied) at or below the purchase price determined by the Company and not properly withdrawn, will, to the extent feasible, be selected for purchase by random lot. To be eligible for purchase by random lot, stockholders whose shares are conditionally tendered must have tendered all of their shares. See Sections 1, 3 and 6 of the Offer to Purchase.

We are the owner of record of shares held for your account. As such, we are the only ones who can tender your shares, and then only pursuant to your instructions. We are sending you the Letter of Transmittal for your information only; you cannot use it to tender shares we hold for your account.

Please instruct us as to whether you wish us to tender any or all of the shares we hold for your account on the terms and subject to the conditions of the Tender Offer.

Please note the following:

1. You may tender your shares at prices not greater than $6.80 nor less than $5.80 per share, as indicated in the attached Instruction Form, net to you in cash, less any applicable withholding taxes and without interest.

2. You should consult with your tax and investment advisors on the possibility of designating the priority in which your shares will be purchased in the event of proration.

3. The Tender Offer is not conditioned on any minimum number of shares being tendered. The Company’s obligation to accept, and pay for, shares validly tendered pursuant to the Tender Offer is conditioned upon satisfaction or waiver of the conditions described in Section 7 of the Offer to Purchase.

4. The Tender Offer, proration period and withdrawal rights will expire at 9:00 a.m., New York City time, on September 12, 2006, unless the Company extends the Tender Offer.

5. As of August 9, 2006, there were approximately 61,870,000 shares of the Company’s common stock issued and outstanding. The Tender Offer is for 10,000,000 shares, constituting approximately 16.2% of the total number of issued and outstanding shares of the Company’s common stock as of August 9, 2006.

6. If you wish to tender portions of your shares at different prices, you must complete a separate Instruction Form for each price at which you wish to tender each such portion of your shares. We must submit separate Letters of Transmittal on your behalf for each price you will accept for each portion tendered.

7. If you are an Odd Lot Holder and you instruct us before the expiration of the Tender Offer to tender on your behalf all of the shares that you own at or below the purchase price the Company determines and check the box captioned “Odd Lots” on the attached Instruction Form, the Company, on the terms and subject to the conditions of the Tender Offer, will accept all such shares for purchase before proration, if any, of the purchase of other shares properly tendered at or below the purchase price the Company determines and not properly withdrawn.

8. If you wish to condition your tender upon the purchase of all shares tendered or upon the Company’s purchase of a specified minimum number of the shares which you tender, you may elect to do so and thereby avoid possible proration of your tender. The Company’s purchase of shares from all tenders

Back to Contents

which are so conditioned, to the extent necessary, will be determined by random lot. To elect such a condition, complete the section captioned “Conditional Tender” in the attached Instruction Form.

If you wish to have us tender any or all of your shares, please so instruct us by completing, executing, detaching and returning to us the attached Instruction Form. If you authorize us to tender your shares, we will tender all your shares unless you specify otherwise on the attached Instruction Form.

Your prompt action is requested. Your Instruction Form should be forwarded to us in ample time to permit us to submit a tender on your behalf before the Expiration Time of the Tender Offer. Please note that the Tender Offer, proration period and withdrawal rights will expire at 9:00 a.m., New York City time, on September 12, 2006, unless the Tender Offer is extended.

The Tender Offer is being made solely under the Offer to Purchase and the Letter of Transmittal and is being made to all holders of shares of the Company’s common stock. The Tender Offer is not being made to, nor will tenders be accepted from or on behalf of, holders of shares residing in any jurisdiction in which the making of the Tender Offer or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction.

The Company’s Board of Directors has approved the Tender Offer. However, neither the Company nor its Board of Directors nor the Dealer Manager, the Depositary nor the Information Agent are making any recommendation to you as to whether to tender or refrain from tendering your shares or as to the price or prices at which you may choose to tender your shares. You must decide as to whether to tender your shares and, if so, how many shares to tender and the price or prices at which you will tender them. In doing so, you should read carefully the information in the Offer to Purchase and in the related Letter of Transmittal, and should consult your own tax and investment advisors.

Back to Contents

INSTRUCTION FORM WITH RESPECT TO
Offer to Purchase for Cash
by
SAVIENT PHARMACEUTICALS, INC.
of
Up to 10,000,000 Shares of its Common Stock
(including the Associated Preferred Share Purchase Rights)
at a Purchase Price Not Greater Than $6.80 nor Less Than $5.80 Per Share

The undersigned acknowledges receipt of your letter and the enclosed Offer to Purchase dated August 14, 2006 (the “Offer to Purchase”) and the related Letter of Transmittal (which together, as they may be amended and supplemented from time to time, constitute the “Tender Offer”), in connection with the offer by Savient Pharmaceuticals, Inc., a Delaware corporation (the “Company”), to purchase for cash up to 10,000,000 shares of its common stock, par value $0.01 per share, including the associated preferred share purchase rights (the “rights”) issued under the Rights Agreement dated as of October 7, 1998, between the Company and American Stock Transfer & Trust Company, as Rights Agent, as amended, at a price not greater than $6.80 nor less than $5.80 per share, net to the seller in cash, less any applicable withholding tax and without interest, upon the terms and subject to the conditions of the Tender Offer. Unless the context otherwise requires, all references to the shares shall refer to the common stock of the Company and shall include the rights, and unless the rights are redeemed prior to the Expiration Time, a tender of the shares will constitute a tender of the rights.

The undersigned hereby instructs you to tender to the Company the number of shares indicated below or, if no number is indicated, all shares you hold for the account of the undersigned, at the price per share indicated below, on the terms and subject to the conditions of the Tender Offer.

The undersigned understands that it is a violation of Rule 14e-4 promulgated under the Exchange Act for a person acting alone or in concert with others, directly or indirectly, to tender shares for such person’s own account unless at the time of tender and at the Expiration Time such person has a “net long position” in (1) a number of shares that is equal to or greater than the amount tendered and will deliver or cause to be delivered such shares for the purpose of tendering to the Company within the period specified in the Tender Offer or (2) other securities immediately convertible into, exercisable for or exchangeable into a number of shares (“Equivalent Securities”) that is equal to or greater than the number of shares tendered and, upon the acceptance of such tender, will acquire such shares by conversion, exchange or exercise of such Equivalent Securities to the extent required by the terms of the Tender Offer and will deliver or cause to be delivered such shares so acquired for the purpose of tender to the Company within the period specified in the Tender Offer. The undersigned understands that Rule 14e-4 also provides a similar restriction applicable to the tender or guarantee of a tender on behalf of another person. The undersigned understands that this Instruction Form constitutes the undersigned’s acceptance of the terms and conditions of the Tender Offer, as well as the undersigned’s representation and warranty to the Company that (1) the undersigned has a “net long position” in a number of shares or Equivalent Securities at least equal to the shares being tendered within the meaning of Rule 14e-4, and (2) such tender of shares complies with Rule 14e-4. The undersigned understands that the Company’s acceptance for payment of shares tendered pursuant to the Tender Offer will constitute a binding agreement between the undersigned and the Company upon the terms and subject to the conditions of the Tender Offer.

Number of shares to be tendered by you for the account of the undersigned ________ shares*

*Unless otherwise indicated it will be assumed that all shares held by us for your account are to be tendered.

Back to Contents

THE UNDERSIGNED IS TENDERING SHARES AS FOLLOWS (CHECK ONLY ONE BOX):

(1) SHARES TENDERED AT PRICE DETERMINED BY STOCKHOLDER (SEE INSTRUCTION 5 TO THE LETTER OF TRANSMITTAL)

By checking ONE of the following boxes below INSTEAD OF THE BOX UNDER “Shares Tendered at Price Determined in the Tender Offer,” the undersigned hereby tenders shares at the price checked. This action could result in none of the shares being purchased if the purchase price determined by the Company for the shares is less than the price checked below. A STOCKHOLDER WHO DESIRES TO TENDER SHARES AT MORE THAN ONE PRICE MUST COMPLETE A SEPARATE INSTRUCTION FORM FOR EACH PRICE AT WHICH SHARES ARE TENDERED. The same shares cannot be tendered, unless previously properly withdrawn as provided in Section 4 of the Offer to Purchase, at more than one price.

PRICE (IN DOLLARS) PER SHARE AT WHICH SHARES
ARE BEING TENDERED

$5.80	$6.20	$6.60
$5.90	$6.30	$6.70
$6.00	$6.40	$6.80
$6.10	$6.50

(2) SHARES TENDERED AT PRICE DETERMINED IN THE TENDER OFFER (SEE INSTRUCTION 5 TO THE LETTER OF TRANSMITTAL)

CHECK ONLY ONE BOX ABOVE. IF MORE THAN ONE BOX IS CHECKED ABOVE, OR IF NO BOX IS CHECKED, THERE IS NO VALID TENDER OF SHARES.

Back to Contents

ODD LOTS
(See Instruction 14 to the Letter of Transmittal)

To be completed only if shares are being tendered by or on behalf of a person owning beneficially or of record fewer than 100 shares in the aggregate.

By checking this box, the undersigned represents that the undersigned owns beneficially or of record
fewer than 100 shares in the aggregate and is tendering all of those shares.


	In addition, the undersigned is tendering shares either (check one box):


	at the price per share indicated above in the section captioned “Shares Tendered at Price Determined by Stockholder;” or


	at the purchase price, as the same will be determined by the Company in accordance with the terms of the Tender Offer (persons checking this box need not indicate the price per share above).

CONDITIONAL TENDER
(See Instruction 13 to the Letter of Transmittal)

A tendering stockholder may condition his, her or its tender of shares upon the Company purchasing a specified minimum number of the shares tendered, all as described in Section 6 of the Offer to Purchase. Unless at least the minimum number of shares you indicate below is purchased by the Company pursuant to the terms of the Tender Offer, none of the shares tendered by you will be purchased. It is the tendering stockholder’s responsibility to calculate the minimum number of shares that must be purchased if any are purchased, and you are urged to consult your own tax and investment advisors before completing this section. Unless this box has been checked and a minimum specified, the tender will be deemed unconditional.

The minimum number of shares that must be purchased from the undersigned, if any are purchased from the undersigned, is: _________________ shares.

The tendered shares represent all shares owned beneficially or of record by the undersigned.

SIGNATURE

Signature(s):

Name(s):

	(Please Print)

Taxpayer Identification Number:

Address(es):

	(Including Zip Code)

Area Code/Phone Number:

Date:

The method of delivery of this document is at the election and risk of the tendering stockholder. If delivery is by mail, then registered mail with return receipt requested, properly insured, is recommended. In all cases, sufficient time should be allowed to ensure timely delivery.

EX-99.A(1F) 12 b414446_exa1f.htm EXHIBIT (A)(1)(F) Prepared and filed by St Ives Burrups

Back to Contents

Exhibit (a)(1)(F)

Savient Pharmaceuticals Commences Offer to
Repurchase Up to 10 Million Shares
Represents Approximately 16.2% of Shares Outstanding

EAST BRUNSWICK, N.J., Aug 14, 2006 – Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) announced today that it has commenced an offer to repurchase up to 10 million shares of its common stock in a “modified Dutch Auction” tender offer at a price of not greater than $6.80 nor less than $5.80 per share. If Savient repurchases the full 10 million shares, the offer will result in the repurchase by Savient of approximately 16.2% of its currently outstanding shares. The tender offer will be financed from the Company’s existing cash position.

The tender offer, proration period and withdrawal rights will expire at 9:00 a.m., New York City time, on September 12, 2006, unless the tender offer is extended. Subject to applicable law, Savient reserves the right to accept for payment, according to the terms and conditions of the tender offer, up to an additional 2% of Savient’s outstanding shares (or approximately 1,200,000 shares).

Christopher Clement, President and Chief Executive Officer of Savient, said, “The Board believes that the recent trading price range of Savient’s shares is not fully reflective of the value of the Company’s business and future prospects. Consequently, the repurchase of Savient’s shares represents an attractive investment and an efficient means to provide value to our stockholders. In determining the size of the share repurchase plan, the Board of Directors carefully considered a broad range of factors including cash flow from operations and the estimated cost of completing the full clinical development for, and commercial launch of, our Puricase^® drug candidate currently in phase 3 clinical trials for treatment-failure gout, and the possible timing and effect of a generic version of Oxandrin^®.”

Mr. Clement continued, “The share repurchase represents yet another accomplishment toward meeting the goals of the strategic plan outlined for Savient several years ago. We are steadfast in our commitment to focus our efforts on achieving value for our stockholders.”

The Dealer Manager for the tender offer is Citigroup Global Markets Inc. The Information Agent for the tender offer is MacKenzie Partners, Inc.

This press release is neither an offer to purchase nor a solicitation of an offer to sell shares. The tender offer is made solely by the Offer to Purchase, dated August 14, 2006, and the related Letter of Transmittal, and any amendments or supplements thereto. Savient will be filing with the SEC on August 14, 2006 a Schedule TO that will include these documents and other materials as exhibits. Stockholders should carefully read the Schedule TO and its exhibits because they will contain important information, including the various terms and conditions of the tender offer. Stockholders will be able to obtain copies of these documents from the SEC’s website at http://www.sec.gov without charge when these documents become available. Stockholders may also request a copy of these documents from Savient at no cost, by writing or telephoning Savient at: Savient Pharmaceuticals, Inc., Attention: Investor Relations Department, One Tower Center, East Brunswick, New Jersey 08816, Telephone: (732) 418-9300. Stockholders should be sure to include their complete name and address in such requests. Stockholders can also find copies of these documents by visiting Savient’s website at http://www.savientpharma.com. Questions and requests for assistance may be directed to MacKenzie Partners, Inc., the Information Agent, at (800) 322-2885 (toll free) or (212) 929-5500 (collect), or Citigroup Global Markets Inc., the Dealer Manager, at (877) 531-8365 (toll free) or (212) 723-7236 (collect).

Back to Contents

FORWARD LOOKING LANGUAGE

This news release contains “forward-looking statements” which are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in the forward-looking statements. Such risks, trends and uncertainties are in some instances beyond the Savient’s control.

Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “will” and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about Savient’s business and the biopharmaceutical and specialty pharmaceutical industries in which Savient operates. Such risks and uncertainties include, but are not limited to, Savient’s stock price and market conditions, delay or failure in developing Puricase (PEG-uricase) and other product candidates, difficulties of expanding Savient’s product portfolio through in-licensing, introduction of generic competition for Oxandrin, fluctuations in buying patterns of wholesalers, potential future returns of Oxandrin or other products, Savient’s continuing to incur substantial net losses for the foreseeable future, difficulties in obtaining financing, potential development of alternative technologies or more effective products by competitors, reliance on third-parties to manufacture, market and distribute many of Savient’s products, economic, political and other risks associated with foreign operations, risks of maintaining protection for Savient’s intellectual property, risks of an adverse determination in on-going or future intellectual property litigation, and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries.

These risks and uncertainties include risks related to Savient’s businesses as well as the factors relating to the tender offer discussed in the Offer to Purchase. Savient may not actually achieve the plans, intentions or expectations disclosed in Savient’s forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Savient makes. Stockholders should not place undue reliance on the forward-looking statements, which speak only as to the date of this press release. Savient’s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that Savient may make. Except as required by law, Savient does not assume any obligation to update any forward-looking statements.

In addition, please refer to Savient’s Current Reports on Form 8-K filed on July 11, 2006 (two reports), August 10, 2006 and August 11, 2006, Savient’s Quarterly Reports on Form 10-Q for the quarterly periods ended June 30, 2006 and March 31, 2006, and Savient’s Annual Report on Form 10-K for the fiscal year ended December 31, 2005, in each case as filed with the SEC, for additional information on risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements or that may otherwise impact Savient and its business.

(SVNT-I)

CONTACTS:
Savient Pharmaceuticals, Inc.
Jack Domeischel, 732-565-4716
jdomeischel@savientpharma.com

EX-99.A(1G) 13 b414446_exa1g.htm EXHIBIT (A)(1)(G) Prepared and filed by St Ives Burrups

Back to Contents

Exhibit (a)(1)(G)

This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares. The Tender Offer (as defined below) is made solely by the Offer to Purchase, dated August 14, 2006, and the related Letter of Transmittal, and any amendments or supplements thereto. The Tender Offer is not being made to, nor will tenders be accepted from or on behalf of, holders of shares of common stock in any jurisdiction in which the making or acceptance of offers to sell shares would not be in compliance with the laws of that jurisdiction. In any jurisdiction where the securities, blue sky or other laws require the Tender Offer to be made by a licensed broker or dealer, the Tender Offer shall be deemed to be made on behalf of Savient Pharmaceuticals, Inc. by Citigroup Global Markets Inc., the Dealer Manager, or by one or more registered brokers or dealers registered under that jurisdiction’s laws.

Notice of Offer to Purchase for Cash
Up to 10,000,000 Shares of its Common Stock
(including the Associated Preferred Share Purchase Rights)
at a Purchase Price of Not Greater Than $6.80 nor Less Than $5.80 Per Share

Savient Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is offering to purchase for cash up to 10,000,000 shares of its common stock, par value $0.01 per share (the “common stock”), including the associated preferred share purchase rights (the “rights”) issued under the Rights Agreement dated as of October 7, 1998, between the Company and American Stock Transfer & Trust Company, as Rights Agent, as amended, at a price not greater than $6.80 nor less than $5.80 per share, net to the seller in cash, less any applicable withholding taxes and without interest, upon the terms and subject to the conditions described in the Offer to Purchase, dated August 14, 2006 (the “Offer to Purchase”), and the related Letter of Transmittal (the “Letter of Transmittal”) (which together, as they may be amended and supplemented from time to time, constitute the “Tender Offer”). Unless the context otherwise requires, all references to the shares shall refer to the common stock of the Company and shall include the rights, and unless the rights are redeemed prior to the expiration of the Tender Offer, a tender of the shares will constitute a tender of the rights.

THE TENDER OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS
WILL EXPIRE AT 9:00 A.M., NEW YORK CITY TIME, ON SEPTEMBER 12, 2006,
UNLESS THE TENDER OFFER IS EXTENDED

The Tender Offer is not conditioned upon any minimum number of shares being tendered. The Company’s obligation to accept, and pay for, shares validly tendered pursuant to the Tender Offer is conditioned upon satisfaction or waiver of the conditions described in Section 7 of the Offer to Purchase.

The Company’s Board of Directors has approved the Tender Offer. However, neither the Company nor its Board of Directors nor the Dealer Manager, the Depositary nor the Information Agent are making any recommendation to stockholders as to whether to tender or refrain from tendering their shares or as to the price or prices at which stockholders may choose to tender their shares. Stockholders must decide as to whether to tender their shares and, if so, how many shares to tender and the price or prices at which they will tender them. In doing so, stockholders should read carefully the information in the Offer to Purchase and in the related Letter of Transmittal, and should consult their own tax and investment advisors.

The Company’s directors and executive officers have each advised the Company that they do not intend to tender any of their shares in the Tender Offer.

As of August 9, 2006, there were approximately 61,870,000 shares of the Company’s common stock issued and outstanding. The 10,000,000 shares that the Company is offering to purchase represent

Back to Contents

approximately 16.2% of the Company’s issued and outstanding common stock as of August 9, 2006. The shares are listed and traded on The NASDAQ Global Market (“NASDAQ”) under the symbol “SVNT”. On August 11, 2006, the last full trading day before the Company commenced the Tender Offer, the closing price of the shares as reported on NASDAQ was $5.59 per share. Stockholders are urged to obtain current market quotations for the shares before deciding whether and at what price or prices to tender their shares.

The purpose of the Tender Offer is to repurchase a portion of the Company’s outstanding shares. The Company believes that the “modified Dutch Auction” tender offer described herein represents a mechanism to provide all of the Company’s stockholders with the opportunity to tender all or a portion of their shares and, thereby, receive a return of some or all of their investment if they so elect. The Tender Offer also provides stockholders (particularly those who, because of the size of their holdings, might not be able to sell their shares without potential disruption to the share price) with an opportunity to obtain liquidity with respect to all or a portion of their shares without potential disruption to the share price and the usual transaction costs associated with market sales. In addition, if the Company completes the Tender Offer, stockholders who do not participate in the Tender Offer will automatically increase their relative percentage ownership interest in the Company and its future operations at no additional cost to them. As a result, the Company’s Board of Directors believes that investing in the Company’s own shares in this manner is an attractive use of capital and an efficient means to provide value to the Company’s stockholders.

The Tender Offer also provides the Company’s stockholders with an efficient way to sell their shares without incurring brokers’ fees or commissions. Where shares are tendered by the registered owner of those shares directly to the Depositary, the sale of those shares in the Tender Offer will permit the seller to avoid the usual transaction costs associated with open market sales. Furthermore, Odd Lot Holders who hold shares registered in their names and tender their shares directly to the Depositary and whose shares are purchased in the Tender Offer will avoid any applicable odd lot discounts that might be payable on sales of their shares.

In accordance with the instructions to the Letter of Transmittal, stockholders desiring to tender shares must specify the price or prices, not in excess of $6.80 nor less than $5.80 per share, at which they are willing to sell their shares to the Company in the Tender Offer. Alternatively, stockholders desiring to tender shares can choose not to specify a price and, instead, can elect to tender their shares at the purchase price ultimately paid for shares properly tendered and not properly withdrawn in the Tender Offer, which could result in the tendering stockholder receiving the minimum price of $5.80 per share. Stockholders must follow the procedures set forth in Section 3 of the Offer to Purchase and in the Letter of Transmittal.

The Company is offering to purchase up to 10,000,000 shares in the Tender Offer. On the terms and subject to the conditions of the Tender Offer, the Company will determine a single per share price, not greater than $6.80 nor less than $5.80 per share, net to the seller in cash, less any applicable withholding taxes and without interest, that the Company will pay for shares properly tendered and not properly withdrawn in the Tender Offer, taking into account the total number of shares tendered and the prices specified by tendering stockholders. After the Expiration Time, the Company will look at the prices chosen by stockholders for all of the shares properly tendered and not properly withdrawn. The Company will then select the lowest purchase price (in multiples of $0.10) within the price range specified above that will allow the Company to buy 10,000,000 shares, subject to its right to increase the total number of shares purchased to the extent permitted by applicable law. If fewer shares are properly tendered and not properly withdrawn, the Company will select the lowest price that will allow the Company to buy all the shares that are properly tendered and not properly withdrawn. All shares the Company acquires in the Tender Offer will be acquired at the same purchase price regardless of whether the stockholder tendered at a lower price. The Company will purchase only shares properly tendered at prices at or below the purchase price the Company determines. However, because of the “odd lot” priority, proration and conditional tender provisions described in the Offer to Purchase, the Company may not purchase all of the shares tendered, even if stockholders tendered at or below the purchase price, if more than the number of shares the Company seeks are properly tendered and not properly withdrawn. The Company will return shares tendered at prices in excess of the purchase price that the Company determines and shares that the Company does not purchase because of “odd lot” priority, proration and conditional tender provisions to the tendering stockholders at the Company’s expense promptly after the Expiration Time. Subject to applicable law, the Company reserves the right to accept for payment,

Back to Contents

according to the terms and conditions of the Tender Offer, up to an additional 2% of the Company’s outstanding shares (or approximately 1,200,000 shares).

The term “Expiration Time” means 9:00 a.m., New York City time, on September 12, 2006, unless the Company, in its sole discretion, shall have extended the period of time during which the Tender Offer will remain open, in which event the term “Expiration Time” shall refer to the latest time and date at which the Tender Offer, as so extended by the Company, shall expire.

For purposes of the Tender Offer, the Company will be deemed to have accepted for payment (and therefore purchased), subject to the “odd lot” priority, proration and conditional tender provisions of the Tender Offer, shares that are properly tendered at or below the purchase price determined by the Company and not properly withdrawn only when, as and if the Company gives oral or written notice to the Depositary of the Company’s acceptance of the shares for payment pursuant to the Tender Offer.

Upon the terms and subject to the conditions of the Tender Offer, the Company will accept for payment and pay the per share purchase price for all of the shares accepted for payment pursuant to the Tender Offer promptly after the Expiration Time. In all cases, payment for shares tendered and accepted for payment pursuant to the Tender Offer will be made promptly, subject to possible delay in the event of proration, but only after timely receipt by the Depositary of: certificates for shares, or a timely book-entry confirmation of the deposit of shares into the Depositary’s account at the book-entry transfer facility (as defined in the Offer to Purchase); a properly completed and duly executed Letter of Transmittal, or, in the case of a book-entry transfer, an agent’s message (as defined in the Offer to Purchase); and any other required documents.

If more than 10,000,000 shares (or such greater number of shares as the Company may elect to accept for payment, subject to applicable law) are properly tendered at or below the purchase price the Company determines and not properly withdrawn prior to the Expiration Time, the Company will purchase shares as follows: first, all “odd lots” of less than 100 shares from holders who properly tender all of their shares at or below the purchase price determined in the Tender Offer and do not properly withdraw them before the Expiration Time; second, from all other stockholders who properly tender shares at or below the purchase price determined in the Tender Offer and who do not properly withdraw them before the Expiration Time, on a pro rata basis (except for stockholders who tendered shares conditionally for which the condition was not initially satisfied); and third, only if necessary to permit the Company to purchase 10,000,000 shares (or such greater number of shares as the Company may elect to accept for payment, subject to applicable law), from holders who have tendered shares at or below the purchase price determined in the Tender Offer conditionally (for which the condition was not initially satisfied) by random lot, to the extent feasible. To be eligible for purchase by random lot, stockholders whose shares are conditionally tendered must have tendered all of their shares.

The Company will return shares tendered at prices in excess of the purchase price that the Company determines and shares that the Company does not purchase because of the “odd lot” priority, proration or conditional tender provisions to the tendering stockholders at the Company’s expense promptly after the Expiration Time.

The Company expressly reserves the right, in its sole discretion, at any time and from time to time, to extend the period of time during which the Tender Offer is open and thereby delay acceptance for payment of, and payment for, any shares by giving oral or written notice of such extension to the Depositary and making a public announcement of such extension.

Tenders of shares are irrevocable, except that such shares may be withdrawn at any time prior to the Expiration Time and, unless such shares have been accepted for payment as provided in the Tender Offer, stockholders may also withdraw their previously tendered shares at any time after October 10, 2006. For a withdrawal to be effective, a written notice of withdrawal must be received in a timely manner by the Depositary at one of its addresses as set forth on the back cover of the Offer to Purchase. Any such notice of withdrawal must specify the name of the person having tendered the shares to be withdrawn, the number of shares to be withdrawn and the name of the registered holder of the shares to be withdrawn, if different from the name of the person who tendered the shares. If certificates for shares have been delivered or otherwise identified to the Depositary, then, prior to the physical release of those certificates, the serial numbers shown

Back to Contents

on those certificates must be submitted to the Depositary and, unless an eligible institution has tendered those shares, an eligible institution must guarantee the signatures on the notice of withdrawal. If a stockholder has used more than one Letter of Transmittal or has otherwise tendered shares in more than one group of shares, the stockholder may withdraw shares using either separate notices of withdrawal or a combined notice of withdrawal, so long as the information specified above is included. If shares have been delivered in accordance with the procedures for book-entry transfer described in the Offer to Purchase, any notice of withdrawal must also specify the name and number of the account at the book-entry transfer facility to be credited with the withdrawn shares and otherwise comply with the book-entry transfer facility’s procedures.

The Company will decide, in its sole discretion, all questions as to the form, validity and eligibility, including time of receipt, of notices of withdrawal, and each such decision will be final and binding on all parties. The Company also reserves the absolute right to waive any defect or irregularity in the withdrawal of shares by any stockholder, whether or not the Company waives similar defects or irregularities in the case of any other stockholder. None of the Company, the Dealer Manager, the Depositary, the Information Agent or any other person will be under any duty to give notification of any defects or irregularities in any notice of withdrawal or incur any liability for failure to give any such notification.

Generally, a U.S. stockholder will be subject to United States federal income taxation when the stockholder receives cash from the Company in exchange for shares the stockholder tenders in the Tender Offer. Depending on the stockholder’s particular circumstances, the stockholder will be treated as either (1) recognizing capital gain or loss from the disposition of shares or (2) receiving a dividend distribution from the Company. A foreign stockholder may be subject to withholding at a rate of 30% on payments received pursuant to the Tender Offer. A foreign stockholder may also be subject to tax in other jurisdictions on the disposal of shares. The Company recommends that stockholders consult with their tax advisors with respect to their particular situations.

The information required to be disclosed by Rule 13e-4(d)(1) under the Securities Exchange Act of 1934, as amended, is contained in the Offer to Purchase and is incorporated herein by reference.

The Offer to Purchase and the related Letter of Transmittal contain important information that stockholders should read carefully before they make any decision with respect to the Tender Offer. The Company is mailing promptly the Offer to Purchase and the related Letter of Transmittal to record holders of shares whose names appear on the Company’s stockholder list and will furnish the Offer to Purchase and the related Letter of Transmittal to brokers, dealers, commercial banks, trust companies and similar persons whose names, or the names of whose nominees, appear on the stockholder list or, if applicable, who are listed as participants in a clearing agency’s security position listing for subsequent transmittal to beneficial owners of shares.

Questions and requests for assistance may be directed to MacKenzie Partners, Inc., the Information Agent, or to Citigroup Global Markets Inc., the Dealer Manager, at their respective addresses and telephone numbers set forth below. Requests for additional copies of the Offer to Purchase, the related Letter of Transmittal or the Notice of Guaranteed Delivery should be directed to the Information Agent.

Back to Contents

The Information Agent for the Tender Offer is:

105 Madison Avenue
New York, New York 10016
(212) 929-5500 (Call Collect)
E-mail: proxy@mackenziepartners.com
or
CALL TOLL-FREE (800) 322-2885

The Dealer Manager for the Tender Offer is:

Citigroup Global Markets Inc.
Special Equity Transactions Group
390 Greenwich Street, 5^th Floor
New York, New York 10013
(877) 531-8365 (toll free)
(212) 723-7236 (collect)

August 14, 2006

-----END PRIVACY-ENHANCED MESSAGE-----